{
    "1": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with metastatic cholangiocarcinoma is evaluated for hyponatremia. His cholangiocarcinoma was diagnosed 1 year ago, and he has completed 5 cycles of cisplatin and gemcitabine; most recent administration was 1 month ago. His disease has progressed, and he is currently hospitalized with obstructive jaundice and inability to eat. He is currently receiving 300 mL of free water flushes every 8 hours through a nasogastric tube, but tube feeds have been held because of intolerance. </p>\n<p>On examination, BP is 100/60 mm Hg, and heart rate is 102/min. He has anasarca, with diminished basilar breath sounds in his lungs. Abdomen is soft, distended, and dull to percussion. The remainder of the examination is unremarkable. Urine output is 1 L/24 h.</p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:25%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:25%;\"><strong>1 Week Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:25%;\"><strong>Current</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">Serum</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">133 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">125</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">2.2 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Osmolality</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">265 mOsm/kg H<sub>2</sub>O</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">275–295 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">Urine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">&lt;20 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">40 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">   Osmolality</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">97 mOsm/kg H<sub>2</sub>O</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width:;;\">38–1400</td>\n</tr>\n</tbody>\n</table>\n<p>Thyroid-stimulating hormone and 8:00 AM cortisol levels are both normal.</p>\n<p><strong>Which ONE of the following is the MOST likely etiology of this patient’s hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Low solute intake"
            },
            {
                "label": "B.",
                "text": "Syndrome of inappropriate antidiuretic hormone secretion"
            },
            {
                "label": "C.",
                "text": "Salt-losing nephropathy"
            },
            {
                "label": "D.",
                "text": "Lipoprotein X accumulation"
            },
            {
                "label": "E.",
                "text": "Hypovolemia"
            }
        ],
        "correct_answer": "Low solute intake",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The etiology of this patient’s hyponatremia is most likely low solute intake.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has numerous possible reasons for hyponatremia. The first step in understanding the etiology of hyponatremia is to assess the serum osmolality. True hyponatremia, or water excess, will present with low serum effective osmolality. Importantly, the serum osmolality must be corrected for urea, an ineffective osmole, to yield the correct effective osmolality. Pseudohyponatremia may be seen in obstructive jaundice because of high levels of total cholesterol and/or lipoprotein X, which is not measured in a routine lipid panel. However, pseudohyponatremia would present with a normal serum osmolality.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step in assessing true hyponatremia is to examine the renal response, which should be water excretion, manifested as low urine osmolality and adequate urine sodium. This patient’s urine osmolality is low (&lt;100 mOsm/kg H<sub>2</sub>O), suggesting appropriate urinary free water excretion in the setting of hyponatremia. However, his urine sodium is also low, and in conjunction with hypotonic urine, suggests low solute intake. This hypothesis is corroborated by the history of poor oral nutrient intake. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His total daily osmolal excretion can be estimated by as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">osm excreted (mOsm/d) = Uosm (mOsm/kg H<sub>2</sub>O) × urine output (L/d) </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> = 97 mOsm/kg H<sub>2</sub>O × 1 L/d = 97 mOsm/d</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This value is below normal (600–800 mOsm/d) and is consistent with low solute intake. The treatment is to increase solute intake, either PO or IV, while avoiding correcting hyponatremia faster than approximately 6 mEq/d to mitigate the risk of osmotic demyelination syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is common in patients with malignancy, occurring in up to 15% of patients with small cell lung cancer and 3% of those with head and neck cancer. Certain chemotherapeutic agents may cause SIADH, including cyclophosphamide and vincristine. This patient’s findings are inconsistent with SIADH, which would demonstrate high urine osmolality.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cisplatin may cause hyponatremia via renal salt wasting, which usually presents with polyuria, volume depletion, and elevated urinary sodium. The mechanism is not well understood, but is likely attributable to direct proximal tubule cell damage and/or inhibition of the basolateral Na/K-ATPase and the distal tubule epithelial sodium channel. The low urine sodium here is inconsistent with salt-losing nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypovolemic hyponatremia is seen in patients with antidiuretic hormone release in response to low mean arterial pressure. Although the history and low urine sodium suggest hypovolemia, patients with hypovolemic hyponatremia will present with high urine osmolality. </p>\n<p>Hyponatremia is common in patients with cancer, occurring in up to 76% of patients with small cell lung cancer, 37% of those with non-small cell lung cancer, 37% of those with breast cancer, 64% of those with colorectal cancer, and 60% of those with lymphoma. Hyponatremia is independently associated with higher mortality and increased risk of falls.</p>\n</div>",
        "references": [
            "McGreal K, Budhiraja P, Jain N, Yu ASL: Current challenges in the evaluation and management of hyponatremia.Kidney Dis (Basel)2(2): 56–63, 2016",
            "Castillo JJ. Vincent M, Justice E: Diagnosis and management of hyponatremia in cancer patients.Oncologist12(6): 756-765, 2012",
            "Soares AG, Mironova E, Archer CR, Contreras J, Stockand JD, Abd El-Aziz TM: Cisplatin decreases ENaC activity contributing to renal salt wasting syndrome.Cancers (Basel)12(8): 2140, 2020",
            "Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.Kidney Int73(9): 994–1007, 2008",
            "Castillo JJ, Glezerman IG, Boklage SH, et al: The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients.BMC Cancer16: 564, 2016",
            "Renneboog B, Musch W, Vandemergel X, et al: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.Am J Med119(1): e1–8, 2006"
        ]
    },
    "2": {
        "question": "<div class=\"qtext\"><p>A 31-year-old woman presents to nephrology clinic for evaluation of newly diagnosed ADPKD. Her past medical history includes hypertension diagnosed 5 years ago. Her family history is notable for multiple members with polycystic kidneys, including a maternal grandfather requiring dialysis at age 53 and her mother requiring dialysis at age 59. Her only medication is lisinopril. </p>\n<p>The physical examination is unremarkable, with normal vital signs. Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>eGFR</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>69 mL/min/1.73 m<sup>2</sup></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≥60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>19 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alkaline phosphatase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>54 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30–120</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–1.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Beta-human chorionic gonadotropin (β-HCG)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Female, premenopausal nonpregnant: ˂1.0</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>A recent abdominal MRI reveals numerous, diffusely distributed, bilateral kidney cysts with a height-adjusted total kidney volume (htTKV) of 546 mL, corresponding to Mayo class 1C risk category. Genetic testing reveals a truncating mutation in the <em>PKD1</em> gene. She has a healthy 3-year-old child and does not plan on having more children.</p>\n<p><strong>Which ONE of the following patient characteristics MOST supports initiation of tolvaptan?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "PKD1truncating mutation"
            },
            {
                "label": "B.",
                "text": "Mayo class 1C risk category"
            },
            {
                "label": "C.",
                "text": "eGFR >60 mL/min/1.73 m2"
            },
            {
                "label": "D.",
                "text": "Two family members requiring dialysis"
            },
            {
                "label": "E.",
                "text": "Hypertension onset < 35 years of age"
            }
        ],
        "correct_answer": "Mayo class 1C risk category",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is at high risk of progression based on her Mayo class 1C score and that would be the strongest argument in favor of prescribing tolvaptan. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ADPKD is diagnosed by imaging. The next step is to assess the risk for rapid disease progression. The Mayo imaging classification tool uses htKTV and age to identify patients with typical (diffuse, bilateral, cystic kidney disease) ADPKD at a high risk for disease progression. This tool is particularly valuable for stratifying patients with normal kidney function at the time of evaluation. Patients with typical disease are stratified into 5 classes (1A–1E), with classes 1C–1E predicting rapid progression with likely benefit from tolvaptan. Mayo imaging classification has become the preferred method for determining risk for rapid progression given its validation in predicting eGFR decline and its relative simplicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients at high risk for disease progression should be considered for tolvaptan. Tolvaptan, a vasopressin V2 receptor inverse agonist (inhibitor), is approved for the treatment of rapidly progressive ADPKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Another method for assessing risk of progression is the predicting renal outcomes in polycystic kidney disease (PROPKD) score, which incorporates sex, the clinical criteria of hypertension or a urologic event before the age of 35, and genotype to categorize patients into low, intermediate, or high risk of progression. These categories correspond to median ages of ESRD onset of 70.6, 56.9, and 49 years, respectively. Although a truncating <em>PKD1</em> mutation and hypertension diagnosed before age 35 give this patient a high-intermediate PROPKD score, each of these clinical characteristics has limitations if used in isolation. eGFR can be used when indexed for age, but it struggles to predict rapid progression in young patients and in those with higher eGFR (&gt;60 mL/min/1.73 m<sup>2</sup>). Although the presence of several relatively young family members requiring dialysis is concerning, it does not have a widespread role in predicting rapid disease progression. </p>\n</div>",
        "references": [
            "Gordon CE, Miskulin DC, Perrone RD: Assessing risk of progression in ADPKD.Clin J Am Soc Nephrol17(1): 134–136, 2022",
            "Chebib FT, Perrone RD, Chapman AB, et al: A practical guide for treatment of rapidly progressive ADPKD with tolvaptan.J Am Soc Nephrol29(10): 2458–2470, 2018",
            "Cornec-Le Gall E, Audrezet M-P, Rousseau A, et al: The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease.J Am Soc Nephrol27(3): 942–951, 2016"
        ]
    },
    "3": {
        "question": "<div class=\"qtext\"><p>A 35-year-old man presents to clinic for evaluation of CKD. His past medical history is notable only for gout. He had his first attack at age 24 and has had a flare every 2–3 years since. Family history is significant for several family members with ESRD, including his father and brother at ages 45 and 41, respectively. His sister, aged 35, has CKD of unknown cause. He does not take any medications besides low-dose ibuprofen during gout attacks.</p>\n<p>Physical examination is unremarkable, with normal vital signs.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.9 mg/dL (2 years ago, 1.6)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Uric acid</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–7.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>120 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>39 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Antinuclear antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1:40</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Specific gravity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.010</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.002–1.030</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Blood</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>The urine sediment is bland, without hematuria, leukocyturia, or casts. Ultrasound shows kidney lengths of 8.5 and 8.8 cm, with mildly increased echogenicity and no obstruction.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Genetic testing"
            },
            {
                "label": "B.",
                "text": "Kidney biopsy"
            },
            {
                "label": "C.",
                "text": "Glucose-6-phosphate dehydrogenase assay"
            },
            {
                "label": "D.",
                "text": "Serum anti-phospholipase A2 receptor antibody titer"
            },
            {
                "label": "E.",
                "text": "Whole blood lead level"
            }
        ],
        "correct_answer": "Genetic testing",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with gout, a family history of ESRD, and CKD should have genetic testing as the next step in diagnostic testing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Depending on patient cohort, genetic etiologies are identified in 10%–40% of adults with CKD of unknown etiology. Whole exome sequencing (WES) in adult patients with CKD yielded a genetic diagnosis in 9.3%, and 15.2% of patients with a positive family history of kidney disease. In addition to potentially changing management, genetic testing provides the advantage of being noninvasive and may provide closure to patients who have otherwise had an unknown explanation for their kidney disease. Furthermore, it may aid in family planning and allow for screening of related family members who may be potential related living kidney donors. Unfortunately, medical insurance does not always cover the costs of genetic testing, even in patients who may benefit from it, although newer renal gene panels are lower cost. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Autosomal dominant tubulointerstitial kidney disease (ADTKD), previously called medullary cystic kidney disease, is caused by mutations in at least 5 different genes (<em>UMOD, MUC1, REN, HNF1B, </em>and <em>SEC61A1</em>). Identifying which gene is implicated can impact management and prognosis; for example, ADTKD-<em>UMOD </em>patients may benefit from treatment of hyperuricemia, and ADTKD-<em>REN </em>patients may benefit from fludrocortisone. Except for HNF1B, ADTKD is caused by the accumulation of misfolded proteins leading to inflammatory infiltration and interstitial fibrosis. In patients with CKD undergoing genetic testing, <em>UMOD</em> mutations were the most common after <em>PKD1, PKD2,</em> and <em>COL4A3–5</em>. Although this disease was previously called medullary cystic disease, cysts may or may not be present and are not required for diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has no proteinuria or concerning findings on urine microscopy to suggest a glomerular etiology to warrant a kidney biopsy or further serologic testing. G6PD testing is required before initiation of uric acid-lowering drugs such as rasburicase. However, first line therapy for gout with hyperuricemia is allopurinol, which does not require G6PD testing prior to initiation. Rasburicase is not FDA-approved for gout treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lead nephropathy is caused by chronic lead exposure and may manifest as progressive CKD with proximal tubulopathy, peripheral neuropathy, microcytic anemia, hypertension, and gout. Although this patient has a history of gout, none of the other signs or symptoms is present. Additionally, although a random whole blood lead level may establish the diagnosis, the sensitivity of this test is low if lead exposure has recently decreased, and a chelation protocol with urinary measurement may be required.</p>\n</div>",
        "references": [
            "Hays T, Groopman EE, Gharavi AG.: Genetic testing for kidney disease of unknown etiology.Kidney Int98(3): 590–600, 2020",
            "Groopman EE, Marasa M, Cameron-Christie S, et al: Diagnostic utility of exome sequencing for kidney disease.N Engl J Med380(2): 142–151, 2019",
            "Devuyst O, Olinger E, Weber S, et al: Autosomal dominant tubulointerstitial kidney disease.Nat Rev Dis Primers5(1): 60, 2019",
            "Moskowitz JL, Piret SE, Lhotta K, et al: Association between genotype and phenotype in uromodulin-associated kidney disease.Clin J Am Soc Nephrol8(8): 1349–1357, 2013",
            "Dahl NK, Bloom MS, Cherub FT, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease. J Am Soc Nephron 34(12): 2039-2050, 2023"
        ]
    },
    "4": {
        "question": "<div class=\"qtext\"><p>A 53-year-old man with ESRD attributed to hypertension presents to the emergency department with abrupt-onset, sharp, severe, lower chest pain radiating to the back. The pain began when he was straining to change a flat tire. The pain is associated with nausea and diaphoresis. His antihypertensive medications include amlodipine, fosinopril, and carvedilol, but he is nonadherent to therapy. He smokes one pack per day of cigarettes and does not consume drugs or misuse alcohol.</p>\n<p>The patient appears anxious and uncomfortable. BP is 190/120 mm Hg in the right arm, and the heart rate is 104/min and regular. Oxygen saturation is 94% while breathing room air. A left arm arteriovenous fistula is present, with thrill and bruit. The examination is notable for normal jugular venous pressure and carotid upstrokes, scattered rhonchi, and normal heart sounds. Abdominal and bilateral femoral bruits are present. The arms and legs are well perfused with intact distal pulses. </p>\n<p>EKG shows left ventricular hypertrophy and nonspecific ST-T wave changes. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14-18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN<p></p></td><td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">58 mg/dL</td><td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td></tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Troponin I, cardiac, serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.45 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤0.04</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>In addition to managing pain and controlling BP, which of the following is the next BEST step in diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cardiac catheterization"
            },
            {
                "label": "B.",
                "text": "Magnetic resonance angiography (MRA)"
            },
            {
                "label": "C.",
                "text": "CT angiography (CTA)"
            },
            {
                "label": "D.",
                "text": "Transesophageal echocardiogram (TEE)"
            },
            {
                "label": "E.",
                "text": "Chest x-ray"
            }
        ],
        "correct_answer": "CT angiography (CTA)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presenting with risk factors for aortic dissection (AD) and symptoms compatible with this diagnosis should undergo CTA as soon as possible.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Risk factors for AD include hypertension, age &gt;40 years, atherosclerosis, bicuspid aortic valve, and underlying vascular conditions such as Marfan syndrome. Severe pain is prominent in 90% of cases, but location, character, and end-organ damage are variable and depend on the location and extent of the dissection. AD has been reported in patients with ESRD and may be missed because of more common competing diagnoses such as acute coronary syndrome (ACS). AD is classified as type A if it involves the ascending aorta and is managed surgically. AD is classified as type B if the ascending aorta is not involved and is managed medically, with a goal of lowering systolic BP to 100–120 mm Hg and controlling heart rate to reduce aortic shear stress. AD requires rapid diagnosis and treatment because of the risk of severe organ damage and death. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CTA is the imaging modality of choice for AD because of its rapidity and accuracy. CTA for type A dissection is 80% and 94% sensitive for subacute and acute dissection, respectively, whereas CTA for type B dissection is 93% and 100% sensitive for subacute and acute dissection, respectively. There is no contraindication to use IV contrast in patients with ESRD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Compared with CTA, MRA has similar sensitivity and specificity but is time-consuming and not suitable for a critically ill patient requiring rapid titration of antihypertensive medications. MRA is not as widely available as CTA and is contraindicated in the presence of many implantable metal devices.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TEE has a high sensitivity for AD (up to 97%) but a slightly lower specificity (85%). Although TEE has the advantage of avoiding radiation exposure and IV contrast administration, it requires sedation and expertise that may not be immediately available, especially in the emergency setting. TEE has been proposed as an adjunct to CTA in cases of unclear diagnosis or during surgical repair of type A AD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chest x-ray has a relatively low sensitivity of 67% and specificity of 70% for type A AD, and the findings of a “widened mediastinum” are often missed, making chest x-ray an unreliable imaging modality, although this test is often the first to be obtained routinely in the emergency department. Chest x-ray has no proven value in the diagnosis of type B AD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has risk factors for ACS, the presentation is much more consistent with AD. Nonetheless, given the common occurrence of ACS, initial evaluation with troponin and EKG are essential, although not consistent with ACS in this patient. A slightly elevated troponin is frequently measured in patients with AD. Patients with ESRD may also have stable troponin I elevations, usually &lt;0.5 ng/mL. Thus, cardiac catheterization to evaluate the patency of the coronary arteries, without evidence of ischemia by troponin or EKG, is not appropriate and will likely delay diagnosis of AD.</p>\n</div>",
        "references": [
            "Braverman, AC: Aortic dissection: prompt diagnosis and emergent treatment are critical.Cleveland Clin J Med78(10): 685–696, 2011",
            "Gologorsky E, Karras R, Gologorsky A, Ricci M, Salerno TA: Transesophageal echocardiography after contrast-enhanced CT angiography in the diagnosis of type A aortic dissection.J Card Surg26(5): 495–500, 2011",
            "Urbania TH, Hope MD, Huffaker SD, Reddy GP: Role of computed tomography in the evaluation of acute chest pain.J Cardiovasc Comput Tomogr3(1 Suppl): S13–S22, 2009",
            "von Kodolitsch Y, Nienaber CA, Dieckmann C, et al: Chest radiography for the diagnosis of acute aortic syndrome.Am J Med116(2): 73–77, 2004",
            "Hiratzka, LF, Bakris, GL, Beckman, JA: 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease.Circulation121(13): e266–e369, 2010",
            "Perkins AM, Liteplo A, Noble VE: Ultrasound diagnosis of type A aortic dissection.J Emerg Med38(4): 490–493, 2010",
            "Kicska GA, Hurwitz Koweek LM, Ghoshhajra BB et al: ACR appropriateness criteria suspected acute aortic syndrome.J Am Coll Radiol18(11S): S474–481, 2021"
        ]
    },
    "5": {
        "question": "<div class=\"qtext\"><p>A 79-year-old woman presents for evaluation of chronic hyponatremia. Past medical history is notable for hypertension, a 40-pack-year history of tobacco use, chronic obstructive pulmonary disease (COPD), mild cognitive impairment, osteoarthritis, nonalcoholic steatohepatitis, and 3 falls in the last 6 months, one of which resulted in a distal radius fracture. Her medications include verapamil, tiotropium, albuterol as needed, calcium and vitamin D supplementation, and occasional acetaminophen. </p>\n<p>She has been unable to adhere to a prescribed 1 L/day fluid restriction because of dry mouth. She has been encouraged to eat a high protein diet by her primary care physician but has not been able to do so because her wrist fracture makes cooking difficult. She otherwise feels well.</p>\n<p>On physical examination, her BP is 155/74 mm Hg with a heart rate of 72/min. Cardiac and lung examinations are unremarkable. There is 1+ peripheral edema to her ankles. She has an abnormal gait. </p>\n<p>Serum sodium concentration was 127 mEq/L 3 years ago and 129 mEq/L 2 years ago. More recent laboratory data are as follows:</p>\n<table>\n</table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                126 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum osmolality \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                272 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                314 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–1400\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                71 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                31 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate management of this patient’s hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe urea"
            },
            {
                "label": "B.",
                "text": "Prescribe tolvaptan"
            },
            {
                "label": "C.",
                "text": "Prescribe sodium chloride PO"
            },
            {
                "label": "D.",
                "text": "No additional management"
            },
            {
                "label": "E.",
                "text": "Prescribe isotonic saline IV"
            }
        ],
        "correct_answer": "Prescribe urea",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with hyponatremia likely attributable to the syndrome of inappropriate antidiuretic hormone (SIADH), the most appropriate management is to prescribe urea.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has chronic, hypotonic hyponatremia. Based on the inappropriately elevated urine osmolality with relatively high urine sodium and potassium, the most likely diagnosis is SIADH, possibly from COPD. Urea induces an osmotic diuresis. Small, retrospective studies have shown that urea is effective in increasing the serum sodium concentration and is well tolerated in patients with hyponatremia. Additionally, a small clinical trial found that urea was as effective as tolvaptan in normalizing the serum sodium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although at first glance this patient’s hyponatremia is asymptomatic, closer scrutiny suggests adverse effects associated with her chronic hyponatremia. A meta-analysis of 15 studies found that hyponatremia was associated with an increased risk of falls, possibly due to gait abnormalities and attention deficit. Chronic hyponatremia has also been associated with an increased risk of fractures, and hyponatremia directly stimulates osteoclasts and promotes resorptive osteoporosis. Thus, no additional management of hyponatremia would not be the best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although tolvaptan is effective in increasing serum sodium, this medication is not the best choice in a patient with steatohepatitis, as tolvaptan has been found to increase serum liver transaminase levels. Although not a contraindication to concomitant use, moderate cytochrome P450 3A4 (CYP3A4) inhibitors such as verapamil can increase the serum concentration of tolvaptan. Lastly, the US Food and Drug Administration limits the use of tolvaptan to 1 month for treatment of hyponatremia, which would be ineffective to manage chronic hyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium chloride PO may raise the serum sodium slightly but could exacerbate volume overload and hypertension, which are already present in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isotonic saline IV may worsen hyponatremia from SIADH by desalination and would be difficult to administer in the outpatient setting.</p>\n</div>",
        "references": [
            "Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G: Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.Clin J Am Soc Nephrol7(5): 742–747, 2012",
            "Corona G, Norello D, Parenti G, Sforza A, Maggi M, Peri A: Hyponatremia, falls and bone fractures: A systematic review and meta-analysis.Clin Endocrinol89(4): 505–513, 2018",
            "Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.Am J Med119(1): 71.e1–e8, 2006",
            "Rondon-Berrios H, Tandukar S, Mor MK, et al: Urea for the treatment of hyponatremia.Clin J Am Soc Nephrol13(11): 1627–1632, 2018",
            "Barsony J, Sugimura Y, Verbalis JG: Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss.J Biol Chem286(12): 10864–10875, 2011"
        ]
    },
    "6": {
        "question": "<div class=\"qtext\"><p>A 55-year-old man with ESRD attributed to diabetes and cirrhosis caused by hepatitis C is brought to the emergency department with confusion, fatigue, nausea, and vomiting. The patient is unable to provide any history, but his wife reports he was in his usual state of health the previous day. He has complained of significant constipation, for which he has been taking laxatives. His last dialysis treatment was 2 days ago. His medications include lisinopril, insulin, sevelamer, metoprolol, and furosemide. </p>\n<p>On arrival, he is lethargic but following simple commands. His BP is 110/74 mm Hg, and heart rate is 60/min. His lungs are clear, and cardiovascular examination shows bradycardia. Abdomen distended with a fluid wave and shifting dullness but is nontender. He has diminished deep tendon reflexes. He has a right brachiocephalic arteriovenous fistula with a strong bruit and thrill. </p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                133 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                99 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                270 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Lactulose"
            },
            {
                "label": "B.",
                "text": "Hemodialysis"
            },
            {
                "label": "C.",
                "text": "Isotonic saline"
            },
            {
                "label": "D.",
                "text": "Insulin"
            },
            {
                "label": "E.",
                "text": "Patiromer"
            }
        ],
        "correct_answer": "Hemodialysis",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should undergo urgent HD for symptomatic hypermagnesemia because of use of magnesium-containing laxatives. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is rare for patients with normal kidney function to develop hypermagnesemia, because the kidneys efficiently respond to increased magnesium intake. However, symptomatic hypermagnesemia may occur in the setting of impaired kidney function or after large, rapid magnesium loads, such as magnesium sulfate IV used to treat preeclampsia. In patients with ESRD, magnesium toxicity may develop quickly with standard doses of magnesium-based laxatives or antacids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypermagnesemia blocks calcium channels affecting cardiac conduction and neuromuscular and central nervous system function. Moderate hypermagnesemia may inhibit PTH secretion, leading to hypocalcemia. Clinical manifestations of magnesium toxicity vary depending on severity, ranging from nausea, vomiting, headache, and diminished deep tendon reflexes to hypotension, bradycardia, and somnolence. Muscle paralysis leading to respiratory failure, complete heart block, and cardiac arrest may occur with severe hypermagnesemia. Renal clearance leads to rapid improvement of magnesium levels if the source of magnesium is discontinued. However, urinary excretion is limited with moderately decreased kidney function, and urgent dialysis is indicated in this patient with severely symptomatic hypermagnesemia. HD provides the most rapid reduction to nontoxic magnesium levels, typically within 2–4 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcium IV should be given immediately to reverse the neuromuscular and cardiac toxicity of hypermagnesemia while awaiting HD initiation. Although calcium may mitigate the effects of hypermagnesemia, dialysis is ultimately necessary for magnesium removal. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although IV isotonic fluids may improve hypotension, they will not improve hypermagnesemia in patients with negligible kidney function such as this one. Lactulose may be effective in treating hepatic encephalopathy, which can develop in patients with cirrhosis and constipation, but this patient has another more likely reason for his symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient does not have evidence of diabetic ketoacidosis or hyperosmolar nonketotic hyperglycemia, so although insulin may be required, it would not be the next best step in therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patiromer is a nonabsorbable organic polymer that contains a calcium-sorbitol counter-ion and binds enteric potassium, resulting in potassium removal. It also binds magnesium in the colon and has been reported to cause hypomagnesemia. Although patiromer may lower magnesium, the effect may be delayed and insufficient to correct severe hypermagnesemia in a patient with ESRD. In addition, patiromer should be avoided in patients with severe constipation and/or bowel obstruction.</p>\n</div>",
        "references": [
            "Alaini A, Roldan CA, Servilla K, Colombo ES: Near death by milk of magnesia.BMJ Case Rep2017:bcr2016218260.",
            "Bakris GL, Pitts B, Weir MR, et al: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial.JAMA314(2): 151–161, 2015"
        ]
    },
    "7": {
        "question": "<div class=\"qtext\"><p>A 17-year-old man presents to clinic for evaluation of nephrolithiasis. Two weeks ago, he presented to the emergency department with right-sided flank pain. A CT scan of the abdomen and pelvis demonstrated a 4-mm stone in the right distal ureter with mild hydronephrosis and a 1.2-cm staghorn calculus in the left kidney. He was treated with tamsulosin and discharged for a trial of passage. He reports that he passed a stone 3 days ago, which he brings with him today. He currently denies fevers, chills, dysuria, visible hematuria, or abdominal or flank pain. He reports a family history of kidney stones in his paternal grandfather. </p>\n<p>The kidney stone measures 3.5 mm in length and is yellow in appearance. </p>\n<p>Laboratory data are as follows:</p>\n<table>\n</table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis demonstrates a pH of 6.0, specific gravity 1.010, 2+ blood, and negative protein, leukocyte esterase, and nitrite. </p>\n<p><strong>In addition to sending the stone for analysis, which ONE of the following would BEST establish a diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ash leaf spots and facial angiofibromas on skin exam"
            },
            {
                "label": "B.",
                "text": "Crystalline deposits in the cornea on eye exam"
            },
            {
                "label": "C.",
                "text": "Anhidrosis and periumbilical angiokeratomas on skin exam"
            },
            {
                "label": "D.",
                "text": "Low serum ceruloplasmin on laboratory testing"
            },
            {
                "label": "E.",
                "text": "Hexagonal crystals on urine microscopy"
            }
        ],
        "correct_answer": "Hexagonal crystals on urine microscopy",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The presence of pathognomonic hexagonal crystals on urine microscopy will confirm the diagnosis of cystinuria. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The development of bilateral stones and a staghorn calculus in the second decade of life with a positive family history should prompt an evaluation for cystinuria. Cystinuria is an autosomal recessive disorder caused by a mutation in the dibasic amino acid transporter in the proximal tubule, causing a failure to reabsorb cystine, ornithine, lysine, and arginine. Although the other amino acids are relatively soluble, cystine is not at physiologic urine pH, and increased urinary cystine excretion causes cystine supersaturation and subsequent stone formation. Cystinuria is the most common genetic cause of nephrolithiasis in children. The average age of presentation with stone disease is 12–13 years, and about 75% of patients have bilateral stones on initial diagnosis. Stones are yellow-brown in appearance, and the presence of characteristic hexagonal crystals on urine microscopy confirms the diagnosis of cystinuria. If crystals are not visible, urine can be combined with cyanide-nitroprusside; the presence of cystine will cause the urine to turn purple. Stone composition analysis and measurement of 24-hour urinary cystine excretion may also be used to diagnose cystinuria. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ash leaf spots and facial angiofibromas are characteristic of tuberous sclerosis complex (TSC). TSC is a systemic disorder characterized by the development of benign tumors in multiple organs. In the kidney, the most common finding is kidney angiomyolipomas.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cystine crystals deposit in the cornea and conjunctiva of patients with cystinosis. Cystinosis is a rare, autosomal recessive lysosomal storage disease characterized by intracellular accumulation of cystine in different tissues and organs. Cystine accumulation in the kidneys is associated with impaired proximal tubule function and progressive CKD. Cystine deposits in the eyes may be seen in patients as young as 1 year old on slit-lamp examination and are associated with photophobia, blepharospasm, and visual loss. The most common kidney manifestation is proteinuria and CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Angiokeratomas are a common dermatological manifestation of Fabry disease, seen in 36%–66% of patients, and occur in the groin, hip, and periumbilical regions. Anhidrosis or hypohidrosis, lack of or decreased sweating, is found in 28%–53%. Corneal opacities can be seen in almost all affected male patients. Although Fabry disease is associated with early onset CKD, nephrolithiasis is typically not present. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Wilson disease is a rare, autosomal recessive disease characterized by impaired biliary copper excretion and a low serum ceruloplasmin level. Copper accumulates in the liver, brain, and cornea, with almost all patients exhibiting dysarthria. Renal manifestations of Wilson disease include proximal and distal renal tubular acidosis (RTA). Distal RTA may lead to nephrocalcinosis and nephrolithiasis caused by hypercalciuria, hypocitraturia, and persistently high urine pH, favoring precipitation of calcium phosphate stones. The absence of metabolic acidosis and liver disease makes Wilson disease an unlikely etiology for nephrolithiasis in this patient.</p>\n</div>",
        "references": [
            "D’Ambrosio V, Capolongo G, Goldfarb D, Gambaro G, Ferraro PM: Cystinuria: an update on pathophysiology, genetics, and clinical management.Pediatr Nephrol2021 Nov 23. doi: 10.1007/s00467-021-05342-y [online ahead of print]",
            "Howles SA, Thakker RV: Genetics of kidney stone disease.Urology17(7): 407–421, 2020",
            "Servais A, Morinière V, Grünfeld JP, et al: Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping.Clin J Am Soc Nephrol3(1): 27–35, 2008",
            "Stechman MJ, Loh NY, Thakker RV: Genetic causes of hypercalciuric nephrolithiasis.Pediatr Nephrol24(12): 2321–2332, 2009"
        ]
    },
    "8": {
        "question": "<div class=\"qtext\"><p>A 75-year-old man with a long-standing history of type 2 diabetes and mantle cell lymphoma is evaluated for new-onset proteinuria. Diabetes has been well controlled, with no retinopathy reported on his most recent eye examination. His lymphoma was diagnosed 3 years ago. He initially underwent pre-autologous stem cell transplant (SCT) conditioning with cyclophosphamide, fludarabine, and total body irradiation. The autologous SCT was unsuccessful and was followed by allogeneic SCT. Graft-versus-host disease (GVHD) prophylaxis included tacrolimus, sirolimus, and methotrexate, which was discontinued by 7 months after SCT. He developed skin GVHD 8 months after SCT, which was managed with a course of prednisone. </p>\n<p>He is now 13 months status post allogeneic SCT. He feels well but notes new edema of his lower extremities and foamy urine. He reports no NSAID or over-the-counter medication use. </p>\n<p>On examination, BP is 165/96 mm Hg, and heart rate is 76/min. He has periorbital edema and 3+ edema of the lower extremities to the thighs bilaterally.</p>\n<p>Laboratory data are as follows: </p>\n<table>\n</table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                43,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                177,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                243 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                240 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Haptoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                53 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40–240\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      BK virus, plasma\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2000/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis: specific gravity 1.027, protein 4+; microscopy: 7 RBC/hpf, 2 WBC/hpf</p>\n<p>24-hour urine protein: 11 g (reference range, &lt;100 mg/24 hr)</p>\n<p><strong>Which ONE of the following is the MOST likely cause of proteinuria in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "B.",
                "text": "BK virus nephropathy"
            },
            {
                "label": "C.",
                "text": "Membranous nephropathy"
            },
            {
                "label": "D.",
                "text": "Engraftment syndrome"
            },
            {
                "label": "E.",
                "text": "Diabetic nephropathy"
            }
        ],
        "correct_answer": "Membranous nephropathy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with nephrotic syndrome 13 months after SCT most likely has membranous nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nephrotic syndrome is a rare complication of SCT that typically presents more than 6 months after SCT. This is thought to occur as a result of tapering immunosuppression for GVHD, leading to immune cell dysregulation. This phenomenon is postulated to be the renal manifestation of GVHD. Kidney biopsy is consistent with membranous nephropathy in the majority of cases, with minimal change disease as the second most common cause. Recognition of this phenomenon is important and can be initially detected with routine urinalysis testing in patients who have undergone SCT. New-onset proteinuria should prompt kidney biopsy and potentially reinitiating immunosuppression. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transplant-associated thrombotic microangiopathy (TMA) has been reported with calcineurin inhibitors and occurs more often when tacrolimus is given in combination with sirolimus. Although these medications were discontinued 4 months ago, TMA may not respond to immunosuppression withdrawal. However, this patient does not meet clinical criteria for TMA, which include thrombocytopenia and microangiopathic hemolytic anemia (decreased haptoglobin, elevated lactate dehydrogenase, and schistocytes on peripheral blood smear). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BK virus nephropathy can occur as a complication of SCT because of BK virus reactivation from immunosuppression. Plasma BK virus levels &gt;10,000 copies/mL tend to correlate better with kidney injury than elevated urine BK levels. Patients with BK virus nephropathy often present with AKI and varying degrees of dysuria and hematuria, including hemorrhagic cystitis. BK viremia by itself does not cause nephrotic syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Engraftment syndrome is an early complication of SCT and typically occurs within the first few weeks. It is a proinflammatory state characterized by fever, rash, and noncardiogenic pulmonary edema. This patient presents 13 months after SCT, well after engraftment has already taken place.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has a history of long-standing diabetes, the adequate glycemic control and absence of retinopathy suggest that diabetic nephropathy is not the most likely diagnosis.</p>\n</div>",
        "references": [
            "Hingorani S: Renal complications of hematopoietic-cell transplantation.N Engl J Med374(23): 2256–2267, 2016",
            "Miura K, Sekine T, Takamizawa M, et al: Early occurrence of nephrotic syndrome associated with cord blood stem cell transplantation.Clin Exp Nephrol16(1): 180–182, 2012",
            "Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B: Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?Clin J Am Soc Nephrol1(4): 685–694, 2006",
            "Beyar-Katz O, Davila EK, Zuckerman T, et al: Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy.Biol Blood Marrow Transplant22(6): 975–981, 2016",
            "Haines HL, Laskin BL, Goebel J, et al: Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation.Biol Blood Marrow Transplant17(10): 1512–159, 2011",
            "Spitzer TR: Engraftment syndrome: double-edged sword of hematopoietic cell transplants.Bone Marrow Transplant50(4):469–475, 2015",
            "Shayani S, Palmer J, Stiller T, et al: Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.Biol Blood Marrow Transplant19(2): 298–304, 2013",
            "Li A, Wu Q, Davis C, et al: Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal.Biol Blood Marrow Transplant25(3): 570–576, 2019"
        ]
    },
    "9": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with CKD stage G3a/A1, hypertension, and rheumatoid arthritis presents to nephrology clinic for follow-up. He has a history of rheumatoid arthritis that has progressed despite treatment with methotrexate, so infliximab was added to his regimen 6 months ago. Over the last 3 weeks, he has noted increased hair loss, photosensitivity, and joint pains, for which he started taking ibuprofen. His other medications include amlodipine, lisinopril, chlorthalidone, and methotrexate.</p>\n<p>On examination, his BP is 160/80 mm Hg with a heart rate of 80/min. He is in no acute distress and appears his stated age. There is no evidence of a cardiac murmur or rub. He has trace peripheral edema. </p>\n<p>His serum creatinine is 3.0 mg/dL (reference range, 0.7–1.3), increased from his baseline of 1.7 mg/dL. His urinalysis shows microscopic hematuria with a urine protein-to-creatinine (UPC) ratio of 3.5 mg/mg (reference range, &lt;0.2; his last urinalysis was bland with a UPC ratio of 0.5 mg/mg). RBC casts are noted on urine microscopy.</p>\n<p>Kidney biopsy reveals diffuse, proliferative glomerulonephritis. Immunofluorescence shows a “full house” staining pattern for complement components C3, C4, and C1q and immunoglobulins A, G, and M.</p>\n<p> </p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s clinical presentation and biopsy findings?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Infliximab"
            },
            {
                "label": "B.",
                "text": "Hypertension"
            },
            {
                "label": "C.",
                "text": "Ibuprofen"
            },
            {
                "label": "D.",
                "text": "Rheumatoid arthritis"
            },
            {
                "label": "E.",
                "text": "Methotrexate"
            }
        ],
        "correct_answer": "Infliximab",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely explanation for this patient’s presentation with nephritic syndrome and biopsy findings consistent with lupus nephritis is infliximab. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Therapy with tumor necrosis factor (TNF)-α inhibitors such infliximab, etanercept, and adalimumab have been shown to result in a drug-induced lupus syndrome. Skin involvement is predominant in these patients (malar rash and photosensitivity) with findings of positive ANA, anti–double-stranded DNA antibodies, and hypocomplementemia. Kidney manifestations are rare, but proliferative lupus nephritis has been described with these agents. Although the exact pathogenesis is not known, it has been proposed that TNF-α–induced cytokine imbalance along with the induction of apoptosis in inflammatory cells drives autoantibody formation. Lupus symptoms can develop on average about 6 months after the drug is initiated. Rarely, ANCA-associated vasculitis has been associated with TNF-α inhibitors.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Severe or malignant hypertension could cause AKI but is typically associated with microangiopathic hemolytic anemia and presents with microthrombi on kidney biopsy. Ibuprofen and other NSAIDs have been associated with acute interstitial nephritis and membranous nephropathy but would not be expected to cause proliferative glomerulonephritis. The glomerulopathy most often associated with rheumatoid arthritis is also membranous nephropathy, not lupus nephritis. Methotrexate can cause AKI by crystal deposition in tubules and by acute interstitial nephritis. </p>\n</div>",
        "references": [
            "Hogan J, Markowitz GS, Radhakrishnan J: Drug-induced glomerular disease: immune-mediated injury.Clin J Am Soc Nephrol10(7): 1300–1310, 2015",
            "De Bandt M, Sibilia J, Le Loet X, et al: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.Arthritis Res Ther7(3): R545–R551, 2005"
        ]
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 64-year-old man with ESRD receiving CCPD, type 2 diabetes, and heart failure with preserved ejection fraction presents to his outpatient PD center with diarrhea, muscle weakness, and cramping. His dialysis regimen consists of 5 × 2-L exchanges of 2.5% dextrose. He reports unchanged urine output and appetite. His medications include insulin, lisinopril, metoprolol, torsemide, and spironolactone. </p>\n<p>On examination, he is a well-appearing man in no distress. BP is 150/82 mm Hg, and heart rate is 66/min. Heart and lung examinations are normal, and the abdomen is soft and nontender. His PD catheter exit site is without erythema, exudate, or tenderness. Lower extremities have 1+ edema bilaterally to the mid-shin. Strength is 5/5 in all extremities.</p>\n<p>Laboratory data are as follows:</p>\n<table></table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.1 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">99 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">28 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">54 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.7 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.2 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Magnesium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.8 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.6–2.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Phosphorus</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.8 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–4.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total Kt/V (weekly)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.1</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≥1.7</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Dialysate Kt/V urea (weekly)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.3</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Renal Kt/V urea (weekly)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.8</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong> </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Add potassium chloride 4 mEq/L to the dialysate"
            },
            {
                "label": "B.",
                "text": "Prescribe potassium chloride 40 mEq IV"
            },
            {
                "label": "C.",
                "text": "Prescribe potassium citrate 30 mEq PO twice daily"
            },
            {
                "label": "D.",
                "text": "Prescribe potassium chloride 40 mEq PO twice daily"
            },
            {
                "label": "E.",
                "text": "Discontinue torsemide"
            }
        ],
        "correct_answer": "Prescribe potassium chloride 40 mEq PO twice daily",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This outpatient receiving CCPD with hypokalemia is best managed with PO potassium chloride. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Peritoneal dialysate, in contrast to HD dialysate, contains no potassium (K), so patients receiving PD are at risk of developing hypokalemia. Patients with additional sources of K loss, such as gastrointestinal as in this case, are especially vulnerable to hypokalemia. Hypokalemia is associated with peritonitis and increased mortality. In most cases of mild hypokalemia, K may be administered PO over days to weeks, although many patients require ongoing supplementation to offset peritoneal losses.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PO potassium is typically administered as KCl, K citrate, or K phosphate. KCl is most commonly used for patients with chloride depletion, either from gastrointestinal or renal losses. K citrate is useful for patients with concurrent metabolic acidosis and K phosphate for those with hypophosphatemia, often attributed to malnutrition. This patient, with no evidence of metabolic acidosis or hypophosphatemia, does not require K citrate or K phosphate, respectively, which may be more expensive than KCl and are sometimes not covered by health insurance. The relatively high total CO<sub>2</sub> in this patient is likely attributable to lactate administration during PD, with subsequent hepatic conversion to bicarbonate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium supplementation PO is usually preferred to IV or intraperitoneal (IP) replacement, as these modalities have been associated with risk of hyperkalemia. IP K replacement has also been associated with an increased risk of peritonitis during K spiking of the dialysate bags, and IV supplementation is inconvenient and often unnecessary in the outpatient setting. Lastly, the rate of IV KCl administration is usually recommended to be ≤20 mEq/h given the caustic nature of the infusion, especially if extravasation were to occur. Therefore, IV or IP replacement would not be the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although torsemide may contribute to hypokalemia given this patient’s residual kidney function, he has a history of heart failure, with hypertension and volume overload on examination. Discontinuing torsemide may improve serum potassium but could worsen volume overload and hypertension, so would not be the next best step in management. </p>\n</div>",
        "references": [
            "Lee S, Kang E, Yoo KD, et al: Lower serum potassium associated with increased mortality in dialysis patients: a nationwide prospective observational cohort study in Korea.PLoS ONE12(3): e0171842, 2017",
            "Unwin RJ, Luft FC, Shirley DG: Pathophysiology and management of hypokalemia: a clinical perspective.Nat Rev Nephrol7(2): 75–84, 2011",
            "Weir MR, Espaillat R: Clinical perspectives on the rationale for potassium supplementation.Postgrad Med127(5): 539–548, 2015",
            "Kim GH, Han JS: Therapeutic approach to hypokalemia.Nephron92(Suppl 1): 28–32, 2002",
            "Khan AN, Bernardini J, Johnston JR, Piraino B: Hypokalemia in peritoneal dialysis patients.Perit Dial Int16(6): 652, 1996"
        ]
    },
    "11": {
        "question": "<div class=\"qtext\"><p>A 55-year-old man is evaluated on hospital day 14 for AKI. He was admitted 2 weeks ago to the ICU with community-acquired pneumonia. His past medical history included only diabetes mellitus managed with glipizide. </p>\n<p>On admission, he was febrile, hypotensive, tachycardic, and hypoxemic. An examination and chest x-ray demonstrated a left lower lobe pneumonia. Laboratory data were notable for leukocytosis, a serum creatinine of 1.1 mg/dL (reference range, 0.7–1.3), and a normal urinalysis. </p>\n<p>He was treated with mechanical ventilation, fentanyl, midazolam, norepinephrine, insulin, omeprazole, and a 10-day course of levofloxacin, which was completed on day 11. Blood and tracheal aspirate cultures were negative. His respiratory status and BP improved over the first week such that mechanical ventilation and norepinephrine were discontinued. Between hospital days 7 and 14, serum creatinine increased, and he became oliguric. </p>\n<p>On hospital day 14, he is now afebrile and stable without inotropic or ventilatory support. There are coarse breath sounds bilaterally and 2+ lower extremity edema. There are no rashes. </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\"><strong>Admission</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\"><strong>Hospital </strong></p>\n<p style=\"text-align: center;\"><strong style=\"font-size: inherit; font-style: normal;\"><strong>Day 4</strong></strong></p>\n<p style=\"text-align: center;\"></p>\n<p style=\"text-align: center;\"></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\"><strong>Hospital </strong></p>\n<p style=\"text-align: center;\"><strong style=\"font-size: inherit; font-style: normal;\"><strong>Day 7</strong></strong></p>\n<p style=\"text-align: center;\"></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\"><strong>Hospital </strong></p>\n<p style=\"text-align: center;\"><strong style=\"font-size: inherit; font-style: normal;\"><strong><strong><strong>Day </strong></strong>10</strong></strong></p>\n<p style=\"text-align: center;\"></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\"><strong>Hospital</strong></p>\n<p style=\"text-align: center;\"><strong><strong><strong><strong>Day </strong></strong>14</strong></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">Serum creatinine (mg/dL)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">1.1</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">1.0</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">1.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">1.8</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p style=\"text-align: center;\">2.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>The urinalysis demonstrates 1+ blood and 2+ protein. Microscopy demonstrates 3–6 RBC/hpf, 4–10 WBC/hpf, and occasional granular casts. The urine protein-to-creatinine ratio is 1.2 mg/mg (reference range, &lt;0.2). The fractional excretion of sodium is 2%. A urine culture from day 12 grew 1000 colony forming units/mL of gram-positive bacteria. Ultrasonography of the kidneys is normal.</p>\n<p><strong>Which of the following is the MOST appropriate next step in the management of this patient’s acute kidney injury?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Supportive care"
            },
            {
                "label": "B.",
                "text": "Methylprednisolone"
            },
            {
                "label": "C.",
                "text": "Ultrasound-guided kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Vancomycin"
            },
            {
                "label": "E.",
                "text": "Urine eosinophil stain"
            }
        ],
        "correct_answer": "Ultrasound-guided kidney biopsy",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in the evaluation of this patient’s AKI is an ultrasound-guided kidney biopsy. This man with community-acquired pneumonia and sepsis has developed severe AKI without improvement despite discontinuation of his antibiotics 4 days ago. In addition, he has an abnormal urinalysis that is notable for hematuria, pyuria, and proteinuria. In this case, the differential diagnosis includes ischemic or toxic acute tubular necrosis (ATN), acute interstitial nephritis (AIN), and infection-associated glomerulonephritis. Neither the physical examination nor routine blood and urine studies are able to identify the cause of AKI with adequate certainty to guide therapy when multiple potential factors may contribute. Although ischemic ATN is possible given the recent period of hypotension, the patient is at risk for both infectious causes of AIN (such as <em>Legionella</em>) and drug-induced AIN (related to the quinolone or the proton-pump inhibitor). Kidney biopsy is indicated to distinguish among these possibilities and guide therapy. The data on glucocorticoid use in AIN is challenging to interpret, as there are no prospective randomized controlled trials (RCTs). However, retrospective data suggest that glucocorticoids are associated with improved outcomes in AIN when initiated early and in patients with &lt;50% interstitial fibrosis on kidney biopsy. Thus, early biopsy is indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine eosinophil stain is neither sensitive nor specific for the diagnosis of AIN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the urine culture did grow a small number of gram-positive organisms, the patient did not have other features to suggest urinary tract infection. Bacteriuria, which is common in catheterized patients, would not explain the AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Corticosteroids would be indicated if AIN or a steroid-responsive glomerulonephritis is identified on biopsy, but empiric therapy is not justified in this patient who has experienced recent serious infection and is at risk for side effects, including worsened glycemic control. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ongoing supportive care would be appropriate if there were evidence of kidney function recovery, such as an improvement in urine output or a decreased rate of rise in the serum creatinine. A patient who is oliguric may benefit from early diagnosis of treatable causes of AKI, because earlier treatment may improve the likelihood and degree of eventual recovery. </p>\n</div>",
        "references": [
            "Raghavan R, Eknoyan G: Acute interstitial nephritis – a reappraisal and update.ClinNephrol82(3):149–162, 2014",
            "Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, Quintana L: Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis.Clin J Am Soc13(12):1851–1858, 2018",
            "Muriithi AK, Nasr SH, Leung N: Utility of urine eosinophils in the diagnosis of acute interstitial nephritis.Clin J Am Soc Nephrol8(11): 1857–1862, 2013",
            "Perazella MA, Bomback AS: Urinary eosinophils in AIN: Farewell to an old biomarker?Clin J Am Soc Nephrol8: 1841–1843, 2013",
            "Blank M, Parkin L, Paul C, Herbison P: A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use.Kidney Int86: 837–844, 2014",
            "Moledina DG, Perazella MA: Drug-induced acute interstitial nephritis.Clin J Am Soc Nephrol. 12(12): 2046–2049, 2017"
        ]
    },
    "12": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman with a history of ADPKD and hypertension returns for a follow-up visit at 6 weeks postpartum. She discontinued lisinopril when she learned that she was pregnant and did not require antihypertensive therapy during pregnancy. The pregnancy was uncomplicated, and she had a spontaneous vaginal delivery at 38 weeks. Currently, she is breastfeeding and hopes to do so for at least 6 months. She also has a history of depression but has not required pharmacologic therapy for a few years. During pregnancy, she gained 16 kg and is now 5 kg over her baseline weight.</p>\n<p>Her BP is 150/95 mm Hg, and her heart rate is 88/min. She has palpable kidneys and no edema. </p>\n<p>Her serum creatinine is 1.0 mg/dL (reference range, 0.5–1.1) and her potassium is 4.2 mEq/L (reference range, 3.5–5.0). Her urine protein-to-creatinine ratio is 0.3 mg/mg (reference range, &lt;0.2).</p>\n<p></p>\n<p><strong>In addition to encouraging exercise and a healthy diet, which of the following is the BEST agent to manage this patient’s hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Chlorthalidone"
            },
            {
                "label": "B.",
                "text": "Methyldopa"
            },
            {
                "label": "C.",
                "text": "Labetalol"
            },
            {
                "label": "D.",
                "text": "Lisinopril"
            },
            {
                "label": "E.",
                "text": "Furosemide"
            }
        ],
        "correct_answer": "Labetalol",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Labetalol is the best option for treatment of hypertension in this postpartum patient who is lactating. Labetalol is considered a first-line agent for management of hypertension during pregnancy and in the postpartum period. Only low levels of labetalol have been found in breastmilk.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The centrally acting agent, methyldopa, is also recommended as a first-line agent for patients both during pregnancy and in the postpartum period with lactation; however, methyldopa may be associated with depression. Because the postpartum period is a time when women are particularly susceptible to clinical depression, this agent is best avoided during this time.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ACEIs have a low molecular weight, so transfer to breast milk is possible. Levels are unlikely to be clinically relevant, but hypotension in the infant is possible, and preterm babies may be at particular risk. The available safety data for lisinopril is limited, in contrast to reassuring data for α- and β-adrenergic blockers and nifedipine. If there is a compelling reason to use an ACEI during lactation, captopril and enalapril are preferred because there are more data available with regard to the safety of these short-acting agents. Thus, lisinopril would not be the next best step in hypertension management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thiazides and loop diuretics are usually discouraged for women who are breastfeeding or expressing milk because these agents may decrease breast milk production. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When prescribing medication to lactating women, it is useful to consult the LactMed database. This database contains information regarding medication levels in breast milk and potential adverse effects to the nursing infant, and it is updated monthly. The baby’s pediatrician may also be a useful resource. If an antihypertensive agent is initiated during lactation, the baby’s well-being should be reassessed within several days and after any dose adjustments. </p>\n</div>",
        "references": [
            "National Institute of Health and US National Library of Medicine: The LactMed database. Available at:https://www.ncbi.nlm.nih.gov/sites/books/NBK501922/. Accessed August 5, 2022.",
            "National Collaborating Centre for Women's and Children's Health (UK): Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. NICE Clinical Guidelines 107, 2010"
        ]
    },
    "13": {
        "question": "<div class=\"qtext\"><p>A pregnant 31-year-old woman is evaluated for proteinuria. She is gravida 2 para 1 and currently at 32 weeks gestation. She reports a history of mild preeclampsia during her first pregnancy 7 years ago, and received nephrology care postpartum and treatment for hypertension for approximately 2 years, but then did not follow up. Her BP has been satisfactory, but urinalyses throughout this pregnancy have been notable for 2+ blood and 2+ protein. Her medications are a prenatal vitamin and low dose aspirin. </p>\n<p>Earlier today, at a routine visit, BP was 165/95 mm Hg. She was subsequently admitted. With bed rest, the BP was 138/84 mm Hg, and a repeated measurement 4 hours later is 140/82 mm Hg. She appears well and in no distress. Her lungs are clear, and there are a gravid uterus and trace lower extremity edema. </p>\n<p>Her serum creatinine is 1.1 mg/dL (reference range, 0.5–1.1), and uric acid is 6 mg/dL (reference range, 3.0–7.0). A urinalysis is notable for 2+ blood and 3+ protein. Microscopy shows 3–8 RBC/hpf and many are dysmorphic. The urine protein-to-creatinine ratio is 1.1 mg/mg (reference range, &lt;0.2).</p>\n<p><strong>Which of the following is MOST appropriate recommendation at this time? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Delivery"
            },
            {
                "label": "B.",
                "text": "Observation"
            },
            {
                "label": "C.",
                "text": "Lisinopril"
            },
            {
                "label": "D.",
                "text": "Labetalol"
            },
            {
                "label": "E.",
                "text": "Magnesium"
            }
        ],
        "correct_answer": "Observation",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate recommendation at this time is ongoing observation. This patient has a history of hypertension, and data suggest underlying kidney disease given her persistent proteinuria and dysmorphic hematuria. In addition, she has a serum creatinine that is high for a woman at 32 weeks gestation. The diagnosis of preeclampsia can be challenging in the setting of underlying kidney disease because hypertension and proteinuria are features of both. In addition, hypertension, decreased kidney function, and proteinuria also increase the risk of preeclampsia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The definition of preeclampsia, according to the American College of Obstetrics and Gynecologists (ACOG), is an elevation of BP (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg on 2 measurements at bed rest, 4 hours apart) in a patient with previously normal BP after 20 weeks of gestation, plus proteinuria or any features of severe preeclampsia. Features of severe preeclampsia include stage 2 hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg on 2 measurements at bed rest, 4 hours apart), thrombocytopenia, abnormal liver function tests, AKI, pulmonary edema, or new-onset cerebral or visual disturbances. This patient has high BP, but readings improved with bed rest. She has proteinuria, but this finding appears to be chronic. There is no acute indication for delivery, but the patient requires vigilant observation. Current ACOG guidelines state that patients without severe features of gestational hypertension should be managed expectantly until 37 weeks. She also has decreased kidney function, and efforts should be made to determine the level of kidney function prior to and during pregnancy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is promise that biomarkers will soon be available to differentiate preeclampsia from CKD. Increased levels of soluble fms-like tyrosine kinase-1 (sFLT-1), decreased levels of placental growth factor (PlGF), and an increased ratio of sFLT-1 to PlGF may soon be used to discriminate between these 2 diagnoses. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Magnesium is recommended in all patients with preeclampsia as seizure prophylaxis. This patient does not clearly have evidence of preeclampsia. Lisinopril may be appropriate after delivery, but this agent is contraindicated during pregnancy and during breastfeeding. Labetalol is considered a first-line agent for management of hypertension during pregnancy, but because this patient’s BP improved with bed rest, no pharmacologic therapy is indicated at this time. Current recommendations from ACOG suggest treatment for chronic hypertension if the systolic BP is ≥160 mm Hg or the diastolic BP is ≥110 mm Hg.</p>\n</div>",
        "references": [
            "Williams D, Davison J: Chronic kidney disease in pregnancy. BMJ 336: 211–215, 2008",
            "Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, Ferraresi M, Todros T, Piccoli GB: Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 83: 177–181, 2013",
            "Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.Obstet Gynecol. 135(6):e237-e260, 2020."
        ]
    },
    "14": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man with ESRD status post kidney transplantation is evaluated for severe allograft dysfunction. Past medical history includes immunoglobulin A (IgA) nephropathy, diabetes, and hypertension. He received a deceased donor kidney transplant 3 months ago with antithymocyte globulin (ATG) induction therapy and immunosuppression with tacrolimus, prednisone, and mycophenolate mofetil (MMF). His postoperative course was complicated by delayed graft function. Allograft biopsy 2 weeks after transplantation revealed antibody- and cell-mediated rejection. Management consisted of plasmapheresis, IV immunoglobulin, and a 10-day course of ATG. Kidney function improved enough to discontinue dialysis, and his creatinine improved to 3.0 mg/dL (reference range, 0.7–1.3) 1 month ago. The patient’s creatinine is now 6.3 mg/dL, and urine output has declined.</p>\n<p>Current medications include tacrolimus, MMF, prednisone, trimethoprim/sulfamethoxazole, amlodipine, famotidine, and insulin.</p>\n<p>On examination, there is tenderness over the allograft in the right lower quadrant. Cardiovascular and pulmonary examinations are within normal limits. There is a right-sided brachiocephalic fistula with a bruit and a thrill.</p>\n<p>Repeat allograft biopsy reveals diffuse inflammatory cell infiltration of the interstitial space with severe tubulitis and severe arteritis. Both simian virus (SV)-40 and C4d immunohistochemistry stains are negative.</p>\n<p><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform transplant nephrectomy"
            },
            {
                "label": "B.",
                "text": "Administer ATG"
            },
            {
                "label": "C.",
                "text": "Administer rituximab"
            },
            {
                "label": "D.",
                "text": "Administer cidofovir"
            },
            {
                "label": "E.",
                "text": "Switch tacrolimus to belatacept"
            }
        ],
        "correct_answer": "Perform transplant nephrectomy",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with histologic evidence of severe and intractable rejection should undergo transplant nephrectomy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The role of allograft nephrectomy for a failed kidney transplant remains a subject of investigation. There appears to be a survival benefit associated with allograft nephrectomy for those patients returning to dialysis. However, the success of subsequent retransplantation may suffer, perhaps because of increased alloimmunization at the time of nephrectomy. Alternatively, the withdrawal of all immunosuppression that may follow nephrectomy may result in a more robust immune response to any retained donor antigen. Patients who retain a nonfunctional allograft are often treated indefinitely with low-intensity immunosuppression to minimize the risk for symptomatic rejection, which may continue to suppress the immune response.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is general agreement that transplant nephrectomy is indicated in patients with refractory, symptomatic rejection, particularly if it occurs within 3 months of implantation. This patient has severe, symptomatic rejection and advanced CKD despite 2 prior courses of ATG and ongoing triple immunosuppression.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Additional ATG would not be advisable in this patient, given the failure to respond to prior therapy and increasing risk of post-transplant lymphoproliferative disorder (PTLD) and opportunistic infections that would be posed by further ATG exposure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rituximab may be considered in cases of refractory antibody-mediated rejection but likely has limited utility in cell-mediated rejection, which is considered to be largely T cell-mediated. Cidofovir is an antiviral medication that has been used in cases of BK virus nephropathy, although 2019 guidelines do not recommend the use of this agent. The negative SV-40 stain argues against a diagnosis of BK virus nephropathy. Switching a calcineurin inhibitor (CNI) to belatacept should be considered when there is evidence of CNI nephrotoxicity, which is not present here. It should be noted that belatacept is associated with an increased risk of post-transplant lymphoproliferative disorder and is contraindicated in EBV-naïve patients.</p>\n</div>",
        "references": [
            "Aung NN, Irish A, Swaminathan R, Burrows S, et al: Graft nephrectomy for people with a failed kidney transplant.Cochrane Database Syst Rev[Internet] 2016 Available from:https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012377/full[Accessed Aug 5, 2022]",
            "Akoh JA: Transplant nephrectomy.World J Transplant1: 4–12, 2011",
            "Ayus JC, Achinger SG, Lee S, Sayegh MH, Go AS: Transplant nephrectomy improves survival following a failed renal allograft.J Am Soc Nephrol21(2): 374–380, 2010",
            "Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice: BK polyomavirus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.Clin Transplant33(9): e13528, 2019"
        ]
    },
    "15": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man with ESRD is evaluated for dyspnea. He receives HD 3 times per week via a left upper arm brachiocephalic arteriovenous fistula (AVF).  </p>\n<p>Several months ago, he underwent a cardiac catheterization as part of an evaluation for dyspnea with exertion. A coronary artery stent was placed in the right circumflex artery. Despite this intervention, he has continued to experience dyspnea with normal activity. Attempts to decrease his dry weight have resulted in hypotension. His hemoglobin has been 11 g/dL (reference range, 14–18), and he has met his target Kt/V.</p>\n<p>On examination, he appears comfortable at rest. His BP is 160/70 mm Hg. There is jugular venous distention and a transmitted heart murmur from the AV fistula, as well as a prominent second heart sound. Lungs are clear to auscultation and the left brachiocephalic AVF has a vigorous bruit and palpable thrill. There is 1+ lower extremity edema.</p>\n<p>Catheterization report:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Right ventricular pressure/Right ventricular end-diastolic pressure</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">58/4 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">15–30/2–6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Pulmonary artery pressure</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">58/18 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">15–30/6–12</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Mean pulmonary artery pressure</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">31 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9–19</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Mean pulmonary artery occlusion pressure</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6–12</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Left ventricular pressure/ Left ventricular end-diastolic pressure</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Normal</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n</tbody>\n</table>\n<p>Pulmonary studies including spirometry, diffusion capacity, and estimated lung volumes are within normal limits, and a radionucleotide ventilation-perfusion scan is normal. An echocardiogram shows no evidence of intracardiac shunting; there is left ventricular hypertrophy, both the right and left ventricular chambers are dilated, the ejection fraction is 40–45%, and the pulmonary artery pressure is 56 mm Hg. There are no new wall motion abnormalities. </p>\n<p><strong>Which of the following is the MOST likely to IMPROVE this patient’s symptoms? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Admission for IV inotrope therapy"
            },
            {
                "label": "B.",
                "text": "Ligation of the AVF and placement of a tunneled dialysis catheter"
            },
            {
                "label": "C.",
                "text": "Initiation of pulmonary vasodilator therapy"
            },
            {
                "label": "D.",
                "text": "Placement of a right forearm AVF"
            },
            {
                "label": "E.",
                "text": "Distal revascularization with interval ligation (DRIL)"
            }
        ],
        "correct_answer": "Ligation of the AVF and placement of a tunneled dialysis catheter",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ligation of the upper arm fistula is the intervention most likely to reverse this patient’s symptoms in the setting of symptomatic pulmonary hypertension. This patient has evidence of pulmonary hypertension based on the elevated pulmonary artery pressures on cardiac catheterization. Normally, filling pressures in the right heart are considerably lower than the left heart. Here, there is evidence of elevated right ventricular pressures and pulmonary artery pressures without evidence of elevated left ventricular end-diastolic pressures (LVEDP); high LVEDP would suggest left ventricular dysfunction. In addition, there is no evidence of pulmonary disease or intracardiac shunting to explain the elevated right-sided cardiac pressures. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The pathophysiology of pulmonary hypertension (PH) is complex and often multifactorial, which has prompted the World Health Organization to classify causes into groups (1–5) rather than simply primary and secondary PH. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The left-to-right shunting that occurs with a surgically created AVF may result in hemodynamic changes analogous to the changes seen with congenital atrial or ventricular septal defects, which result in an increase in the pulmonary artery flow that is several times normal. PH caused by an AVF such as in this case would fit best into group 5, which includes miscellaneous mechanisms not included in groups 1–4.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">Group 1</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 70%;\">Primary or genetic </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Group 2</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Left heart disease (most common)</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Group 3</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Lung disease, such as chronic obstructive pulmonary disease</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Group 4</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chronic thromboembolic disease</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Group 5</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Multifactorial or uncertain </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The incidence of PH from AVFs is unknown but appears to be more common with upper arm AVFs. Treatment of PH from a hyperfunctioning AVF requires a decrease in the flow of the AVF. This decrease can sometimes be achieved by banding the AVF with a prosthetic graft segment. However, banding may not decrease the flow sufficiently to improve signs and symptoms, or banding may limit flow excessively and result in decreased function or thrombosis of the access. Furthermore, this procedure often results in dilation either before or after the segment and recurrence of the high flow state. Creation of a distal AVF and ligation of the proximal AVF could obviate high flow problems but would require suitable distal vessels, which are often lacking (if suitable forearm vessels existed, the patient likely would not have required an upper arm AVF). Thus, definitive treatment of this patient’s symptoms requires surgical ligation of the AVF. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Group 1 PH may respond to pulmonary vasodilator therapy, but these medications would not be indicated in this case. Inotropic therapy is used for patients with acute or chronic severe systolic dysfunction not manageable by other means, but would not be indicated for this patient with only mildly reduced ejection fraction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The distal revascularization with interval ligation (DRIL) procedure is used for the treatment of vascular access steal syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with ligation of the hyperfunctioning access will need an alternative HD access or conversion to PD, but placement of a new HD access or initiation of PD would not improve symptoms related to the hyperfunctioning AVF. </p>\n</div>",
        "references": [
            "Sise ME, Courtwright AM, channick RM: Pulmonary hypertension in patients with chronic and end stage renal disease.Kidney Int84(4): 682–692, 2013",
            "Chemla ES, Morsy M, Anderson L, Whitemore A: Inflow reduction by distalization of anastomosis treats efficiently high-inflow high-cardiac output vascular access for hemodialysis.Semin Dial20: 68–72, 2007",
            "Yigla M, Abassi Z, Reisner SA, Nakhoul F: Pulmonary hypertension in hemodialysis patients: An unrecognized threat.Semin Dial19: 353–357, 2006",
            "Clarkson MR, Gilbil L, Little D, Donohoe J: Reversal of pulmonary hypertension after ligation of brachiocephalic arteriovenous fistula.Am J Kidney Dis40: 1–4, 2002",
            "Taichman D, Omelas J, Chung L, Klinger J, et al: Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146: 449–475, 2014",
            "Goldhaber J, Hamilton M: Role of inotropic agents in the treatment of heart failure.Circulation121: 1655–1660, 2010"
        ]
    },
    "16": {
        "question": "<div class=\"qtext\"><p>A 54-year-old woman with ESRD is evaluated during HD. She has ESRD attributed to hypertension and has been dialyzing thrice weekly for the past 5 years. Recently, her interdialytic weight gain (IDWG) has been 4–5 kg above her estimated dry weight (EDW). She is adherent to prescribed medications, including antihypertensives, but notes constant thirst and dry mouth. Medications include lisinopril, nifedipine, hydralazine, and labetalol. </p>\n<p>The HD prescription is as follows: time 3.5 h, blood flow rate 450–500 mL/min, dialysate flow rate 500 mL/min; dialysate sodium 140 mEq/L, potassium 3 mEq/L, calcium 2.5 mEq/L, and bicarbonate 35 mEq/L.</p>\n<p>On exam, she has 2+ bilateral leg edema. The EDW is 84 kg, and pre-dialysis weight today is 89 kg. BP is 174/96 mm Hg pre-dialysis and 128/76 mm Hg post-dialysis. </p>\n<p><strong>Which of the following is the NEXT best step in managing hypertension and IDWG?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Isolated ultrafiltration before dialysis"
            },
            {
                "label": "B.",
                "text": "Encourage fluid restriction"
            },
            {
                "label": "C.",
                "text": "Increase dialysis time"
            },
            {
                "label": "D.",
                "text": "Decrease estimated dry weight"
            },
            {
                "label": "E.",
                "text": "Decrease dialysate sodium concentration"
            }
        ],
        "correct_answer": "Decrease dialysate sodium concentration",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A decrease in the dialysate sodium concentration is the next best step in managing this patient’s hypertension and large IDWG.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although higher dialysate sodium concentrations can ameliorate cramping and hypotension during HD, patients who receive dialysis with higher sodium baths have less plasma volume removal than those dialyzed with lower sodium baths, even when ultrafiltration volumes are matched. In addition, patients with higher dialysate sodium concentrations have more thirst, attributed to cellular dehydration of central thirst sensors (as in hypernatremia) and subsequently more interdialytic fluid intake. Thus, prior practices using high sodium baths, sodium “modeling” (high sodium concentration baths at the onset, which decreased over the course of the treatment), and hypertonic saline have been largely abandoned. Indeed, a modest reduction in dialysate sodium has been associated with decreased pre- and post-dialysis BP, as well as decreased ultrafiltration requirements and fewer episodes of symptomatic intradialytic hypotension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">One strategy to identify the optimal dialysate sodium is to aim for a sodium level that is 0–2 mEq/L less than the patient’s serum sodium level prior to dialysis, provided that the serum sodium is ≥136 mEq/L. If the patient has a low serum sodium level prior to dialysis, other strategies are needed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The optimal BP target for patients with ESRD is not known, and a recent KDIGO Controversies Conference concluded that evidence is currently insufficient to make specific recommendations. Older guidelines from the National Kidney Foundation KDOQI guidelines recommend pre-dialysis BP &lt;140/90 mm Hg and post-dialysis BP &lt;130/80 mm Hg. Because this patient’s post-dialysis BP is acceptable, a decrease in the EDW is not indicated and could lead to hypotension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isolated ultrafiltration followed by diffusional clearance has been touted as a well-tolerated strategy to remove plasma volume and limit symptomatic hypotension. This strategy was more useful when acetate-based instead of bicarbonate-based dialysate was more common, as acetate may cause hemodynamic instability, but is rarely indicated in modern practice. Isolated ultrafiltration followed by HD is rarely used as a regular component of the dialysis prescription because it would require longer treatment periods to achieve the same clearance if a component of each treatment is only comprised of ultrafiltration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An increase in dialysis treatment time would help this patient tolerate the requisite fluid removal to achieve her EDW; however, it would not address the large IDWG.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">All patients should be encouraged to limit sodium and fluid intake, but counseling alone is unlikely to help resolve the current problem.  </p>\n</div>",
        "references": [
            "National Kidney Foundation: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.Am J Kidney Dis45(suppl 3): 16–153, 2005",
            "Munoz Mendoza J, Aramreddy R, Schller B: Dialysate Sodium: Choosing the Optimal Hemodialysis Bath.Am J Kidney Dis66(4):710–720, 2015",
            "Shah A, Davenport A: Does a reduction in dialysate sodium improve blood pressure control in hemodialysis patients?Nephrology (Carlton) 17: 358–363, 2012",
            "Santos SF, Peixoto AJ: Sodium balance in maintenance hemodialysis.Semin Dial23: 549–555, 2010",
            "Flythe JE, Chang TI, Gallagher MP et al: Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int97(5): 861‒876, 2020"
        ]
    },
    "17": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man with a history of CKD stage G4/A2 attributed to chronic glomerulonephritis presents to establish nephrology care after a recent move. Past medical history includes hypertension, hypothyroidism, and benign prostatic hypertrophy. He feels well and walks 1‒2 miles 5 times per week. He does not smoke cigarettes or take NSAIDs or herbal supplements. Medications include lisinopril, empagliflozin, chlorthalidone, tamsulosin, and levothyroxine.</p>\n<p>On exam, BP is 126/84 mm Hg and heart rate is 78/min. His heart rhythm is regular without murmurs or rub. Lungs are clear. He has no carotid, abdominal, or femoral bruits. There is no peripheral edema.</p>\n<p>Laboratory data include:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Result</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Cholesterol, total<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">172 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Desirable, &lt;200<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Low-density lipoprotein (LDL)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">69 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Optimal, &lt;100<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">High-density lipoprotein (HDL)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">39 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Low, &gt;40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Triglycerides, fasting<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">163 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Normal, &lt;150 <br/>Optimal, &lt;100<br/></td>\n</tr>\n</tbody>\n</table><strong><p><strong>Which one of the following is the MOST appropriate next step in management?</strong></p></strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Colesevelam"
            },
            {
                "label": "B.",
                "text": "Fenofibrate"
            },
            {
                "label": "C.",
                "text": "No change"
            },
            {
                "label": "D.",
                "text": "Ezetimibe"
            },
            {
                "label": "E.",
                "text": "Atorvastatin"
            }
        ],
        "correct_answer": "Atorvastatin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with CKD stage G4 should be prescribed a statin to prevent major adverse cardiovascular events (MACE).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">KDIGO 2013 guidelines recommend prescribing a statin or statin plus ezetimibe to any patient ≥50 years old with CKD stage G3‒G5 (not receiving dialysis). This recommendation is largely derived from data obtained from post hoc analysis of large clinical trials and the Study of Heart and Renal Protection (SHARP) trial.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Data from the Alberta Kidney Disease cohort found that patients with advanced CKD, defined as eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, and who are over the age of 50 were found to have a rate of coronary heart disease or fatal myocardial infarction of &gt;10 per 1000 person-years, regardless of other comorbidities. Thus, these 2 risk factors of age and advanced CKD alone bring patients into the high cardiovascular risk category, necessitating statin therapy regardless of baseline cholesterol levels. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The SHARP trial revealed that patients with CKD who took a combination of simvastatin plus ezetimibe had fewer MACE, notably stroke and need for coronary revascularization, compared with those who received placebo.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">These recommendations are in line with those from the American Heart Association and American College of Cardiology, which state that patients without evidence of cardiovascular disease who are 40–75 years old and have ≥7.5% risk of heart attack or stroke within 10 years should be treated with a statin regardless of lipid levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no evidence that monotherapy with non-statin agents provide cardiovascular risk reduction in patients with CKD. Ezetimibe is a cholesterol absorption inhibitor, which was used in combination with simvastatin, to reduce the incidence of MACE in patients with advanced CKD in the SHARP study. Fenofibrate is a fibric acid derivative, which is used to increase HDL levels and decrease triglyceride levels. There has been an association between increased serum creatinine and use of fenofibrate in patients with CKD, but the mechanism has not been elucidated, and it appears to be reversible. Nevertheless, studies using these agents have failed to show a mortality benefit, and fibrates in conjunction with statins increase the risk of rhabdomyolysis. Colesevelam is a bile acid sequestrant, which can be used to lower cholesterol, but its use is often limited by gastrointestinal side effects. In addition, colesevelam binds to and impairs absorption of many medications, including levothyroxine and diuretics. </p>\n</div>",
        "references": [
            "Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.Kidney Int Suppl3: 259–305, 2013",
            "Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF: Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis.Ann Intern Med157: 263–275, 2012",
            "Baigent C, Landray MJ, Reith C, Emberson J, et al: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial.Lancet377: 2181–2192, 2011",
            "Tonelli M: We don't prescribe statins to lower cholesterol: We prescribe statins to reduce vascular risk.J Am Soc Nephrol26(5): 1001–1003, 2015"
        ]
    },
    "18": {
        "question": "<div class=\"qtext\"><p>A 41-year-old woman with ESRD receiving PD is evaluated in the emergency department for dyspnea and a dry cough. She started PD 6 weeks ago and recently transitioned from CAPD to CCPD. Since starting PD, she has had a significant improvement in hypertension and edema. Past medical history is significant for hypertension, latent tuberculosis infection treated with 9 months of isoniazid, and diastolic heart failure. Current medications include bumetanide, losartan, carvedilol, nifedipine, and topical gentamicin cream.</p>\n<p>On physical examination, BP is 142/78 mm Hg, pulse is 64/min, and temperature is 37.4°C. There are dullness to percussion and absent breath sounds in the right lung fields. The jugular venous pressure is normal, and there is no peripheral edema. Abdominal examination reveals a PD catheter with no erythema, tenderness, or drainage.</p>\n<p>Chest x-ray confirms the presence of a large, right-sided pleural effusion.</p>\n<p><strong>Which of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CT of the chest after adding iodinated contrast to the dialysate"
            },
            {
                "label": "B.",
                "text": "Thoracentesis with measurement of glucose level in the pleural fluid"
            },
            {
                "label": "C.",
                "text": "Nuclear imaging after adding radioisotope to the dialysate"
            },
            {
                "label": "D.",
                "text": "Thoracentesis after adding methylene blue to the dialysate"
            }
        ],
        "correct_answer": "Thoracentesis with measurement of glucose level in the pleural fluid",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management in this patient with symptoms due to suspected PD-related hydrothorax is to perform a thoracentesis and measure the glucose level in the pleural fluid.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient appears to have developed PD-related hydrothorax, which occurs more commonly on the right side (80% of cases). The pathophysiology is thought to involve transudation of dialysate from the high-pressure peritoneum to the low-pressure thorax, similar to a hepatic hydrothorax in patients with cirrhosis and ascites. A PD-related effusion has characteristics of a transudate on pleural fluid analysis, although it differs from other causes of transudative effusions because of the high glucose level that would be similar to that of the dialysate and considerably higher than the patient’s blood glucose level. If the dialysate contains icodextrin instead of dextrose, the addition of iodine to the pleural fluid sample with a subsequent blue-black reaction (confirming the presence of the starch icodextrin from the peritoneal fluid) would be diagnostic. In addition to its utility as a diagnostic test, a thoracentesis is warranted for therapeutic purposes in this patient to treat her dyspnea. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Radioisotope testing is complex and often unreliable. Methylene blue can be added to the dialysate, although there have been reports of chemical peritonitis caused by this agent. CT peritoneography may be helpful, but is more cumbersome, and would be unnecessary if thoracentesis establishes the hydrothorax to be PD-related.</p>\n</div>",
        "references": [
            "Yaxley J, Twomey K: Peritoneal Dialysis Complicated by Pleuroperitoneal Communication and Hydrothorax.Ochsner J17:124–127, 2017",
            "Epstein DM, Kline LR, Albelda SM, Miller WT: Tuberculous pleural effusions.Chest91: 106–109, 1987"
        ]
    },
    "19": {
        "question": "<div class=\"qtext\"><p>A 32-year-old man presents to the emergency department with dyspnea, nausea, vomiting, malaise, and headache. One week ago, he developed watery diarrhea that persisted for several days. He has a history of stage 1 hypertension for the past 3 years but does not take any medications. There is no history of drug use, travel, or exposure to animals.</p>\n<p>On examination, his BP is 230/124 mm Hg and pulse is 80/min. Fundoscopy reveals no evidence of hypertensive retinopathy. An S4 gallop, bibasilar crackles, and 1+ lower extremity edema are present. His neurologic examination, including mentation, is normal. Chest x-ray reveals patchy opacities consistent with pulmonary edema. A peripheral blood smear reveals schistocytes. Ultrasound shows hyperechoic kidneys 10 cm in length with no evidence of obstruction.</p>\n<p>He receives IV furosemide and labetalol with resolution of his headache and hypertension within 48 hours. Follow-up laboratory data are obtained 5 days after admission.</p>\n<p>Laboratory results include the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Admission</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Hospital Day 5</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.2 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>60,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>49,000</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>64 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>72</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.7</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Lactate dehydrogenase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>850 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>820</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80–225</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Haptoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>33 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>83–267</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  ADAMTS13 activity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>33%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&gt;60%</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>95 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>86</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>20 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Prothrombin time, plasma</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13.5 s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11–13</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  International normalized ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Stool</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Polymerase chain reaction  (PCR) for <em>Escherichia coli</em> O157:H7</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Shiga toxin assay</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Complement-mediated hemolytic uremic syndrome"
            },
            {
                "label": "B.",
                "text": "Malignant hypertension"
            },
            {
                "label": "C.",
                "text": "Infection-associated thrombotic microangiopathy"
            },
            {
                "label": "D.",
                "text": "Disseminated intravascular coagulation"
            },
            {
                "label": "E.",
                "text": "Thrombotic thrombocytopenic purpura"
            }
        ],
        "correct_answer": "Complement-mediated hemolytic uremic syndrome",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Complement-mediated hemolytic uremic syndrome (HUS) is the most likely diagnosis in this man presenting with thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thrombotic microangiopathies (TMAs) are a group of disorders characterized by small-vessel thrombo-occlusive tissue damage, MAHA, and thrombocytopenia. TMAs were classically defined by clinical phenotype. Emerging knowledge of the pathophysiology and biochemical basis of these disorders has added diagnostic specificity and helped guide appropriate management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hemolytic uremic syndromes are TMAs clinically characterized by prominent kidney involvement. HUS can be precipitated by Shiga-toxin producing E. coli (STEC) infection, usually in the form of hemorrhagic enteritis due to serotype O157:H7. Occasionally, other serotypes of E. coli or Shigella cause this syndrome. Complement-mediated HUS (also known as atypical HUS, aHUS) is caused by disorders of the alternative pathway of complement, often due to an inherited or acquired deficiency of factor H. Depending on the nature of the defect in the alternative pathway, C3 may be normal or depressed. Infections, including gastroenteritis, are a common trigger for aHUS, making the distinction from Shiga-toxin mediated HUS challenging. In this case, the absence of hemorrhagic enteritis and the negative stool PCR and toxin assays all point to aHUS as the most likely diagnosis. Further investigation of the alternative complement pathway would be indicated. Because some of these cases relate to an acquired antibody to factor H (or other components), plasma exchange may be beneficial. Cases that do not respond to plasma exchange, or those due to a hereditary defect, can be treated with eculizumab, a C5 inhibitor that blocks the formation of the C5–9 membrane attack complex.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The presentation of thrombotic thrombocytopenia purpura (TTP) can overlap with that of HUS but typically has more prominent neurologic involvement and often lower platelet counts. TTP is caused by an inherited or acquired deficiency of ADAMTS-13, an enzyme that cleaves large von Willebrand multimers. A plasma ADAMTS-13 activity &gt;10% effectively excludes this diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Disseminated intravascular coagulation (DIC) can cause TMA with AKI but is excluded in this case by the normal coagulation studies.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Malignant hypertension can cause TMA in a minority of patients. The severe thrombocytopenia, ongoing hemolysis despite control of BP, and absence of hypertensive retinopathy argue against hypertension as the main underlying cause of TMA in this case. Recent studies have shown that some patients thought to have hypertension-induced TMA might have underlying genetic defects in genes regulating the alternative complement pathway.</p>\n</div>",
        "references": [
            "Brocklebank V, Wood KM, Kavanagh D: Thrombotic microangiopathy and the kidney.Clin J Am Soc Nephrol13(2): 300–317, 2018",
            "Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, et al: Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.Kidney Int91(16): 1420–1425, 2017",
            "Phillips EH, Westwood JP, Brocklebank V, Wong EK, et al: The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.J Thromb Haemost14: 175–185, 2016",
            "Scully M, Cataland S, Coppo P, de la Rubia J, et al: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.J Thromb Haemost15(2): 312–322, 2017",
            "Thind G, Kailasam K: Malignant hypertension as a rare cause of thrombotic microangiopathy.BMJ Case Reppii: bcr-2017–220457, 2017",
            "Shantsila A, Lip GYH: Malignant hypertension revisited: Does this still exist?Am J Hypertens30(6): 543–549, 2017"
        ]
    },
    "20": {
        "question": "<div class=\"qtext\"><p>A 46-year-old woman who receives in-center HD thrice weekly develops chest pain, dyspnea, nausea, and abdominal pain during dialysis. </p>\n<p>Her dialysis prescription includes heparin 1000 units IV bolus and 500 units/h during treatment, as well as erythropoietin 5000 units IV. She undergoes HD for 4 hours with dialysate sodium 138 mEq/L and potassium 3 mEq/L. Ultrafiltration is usually 2‒2.5 L with each treatment. This center does not reuse dialyzers. </p>\n<p>The treatment had been unremarkable with no venous or arterial pressure alarms, and the patient had stable vital signs until 2.5 hours had passed, at which time she developed the symptoms mentioned. The dialysis nurse promptly clamped the dialysis lines and did not return the patient’s blood. </p>\n<p>On physical examination, the patient appears acutely ill. Her BP is 145/78 mm Hg and heart rate is 105/min. She is afebrile, and the abdomen is soft and nontender. There is no lower extremity edema. </p>\n<p>Laboratory data include:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Haptoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                83–267\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2520 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Testing of the water supply shows normal levels of copper, chlorine, chloramine, nitrates, and trace elements and no appreciable levels of bacteria or endotoxin. The temperature of the dialysate was normal. </p>\n<p>Two patients at 2 other centers, remote from this dialysis unit, have also recently been evaluated for hemolysis. </p>\n<p><strong>Which of the following is the MOST likely cause of this patient’s clinical presentation? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Methemoglobinemia"
            },
            {
                "label": "B.",
                "text": "Faulty blood tubing sets"
            },
            {
                "label": "C.",
                "text": "Air embolism"
            },
            {
                "label": "D.",
                "text": "Hyperkalemia"
            },
            {
                "label": "E.",
                "text": "Citrate toxicity"
            }
        ],
        "correct_answer": "Faulty blood tubing sets",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of hemolysis in this patient is faulty blood tubing sets. Hemolysis is a rare but serious complication of HD and a reminder that HD requires vigilant attention to each component of the treatment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A malfunctioning component of the machinery or tubing should be considered when patients from disparate units are affected. This phenomenon occurred in 1998, when 30 patients in 7 facilities in 3 states developed hemolysis. Ultimately, the only feature in common with all cases was that these 30 patients all received dialysis with disposable blood tubing from the same manufacturer and the same lot number. Further investigation revealed that the tubing had a narrowing in the orifice that led to mechanical hemolysis during dialysis. A recall of the tubing from this lot avoided subsequent episodes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In contrast, when patients from the same unit develop symptoms, the water system should be investigated. Copper, chloramine, and chlorine are all contaminants of the public water supply that are usually removed by components of the water purification system including adsorption to the carbon beds. These agents can cause hemolysis if they escape into the product water used to generate dialysate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Methemoglobinemia develops when hemoglobin is oxidized and cannot bind oxygen efficiently. Patients present with dyspnea and cyanosis, and may occasionally be diagnosed by changes in the color of the blood in the dialysis lines. Methemoglobinemia can be caused by dialysate contamination from several agents, and hemolysis may follow. Hydrogen peroxide used for cleaning at the dialysis unit has also been implicated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Citrate toxicity is uncommon in routine HD, which uses heparin for anticoagulation, whereas this is an important concern in citrate-anticoagulated CRRT. Citrate toxicity manifests with a hypocalcemia, an elevated anion gap metabolic acidosis or a metabolic alkalosis, and an increased risk of bleeding.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Air embolism can cause dyspnea but would not explain the hematologic findings of severe hemolysis or the abnormalities in the other patients at remote units. </p>\n<p>Hyperkalemia can result from, but does not cause, hemolysis. </p>\n</div>",
        "references": [
            "Saha M, Allon M:  Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies.Clin J Am Soc Nephrol12(2): 357–369, 2017",
            "Duffy R, Tomashek K, Spangenberg M, Spry L: Multistate outbreak of hemolysis in hemodialysis patients traced to faulty blood tubing sets.Kidney Int57: 1668–1674, 2000",
            "Kasparek T, Rodriguez OE: What medical directors need to know about dialysis facility water management?Clin J Am Soc Nephrol10: 1061–1071, 2015"
        ]
    },
    "21": {
        "question": "<div class=\"qtext\"><p>A 78-year-old man presents for follow-up of CKD stage G4 attributed to long-standing hypertension. Three months ago, he read an article about limiting protein intake to delay the onset of ESRD and began eating a protein-restricted diet. He now consumes mainly vegetables as well as eggs for high biological value protein. He feels well except for mild fatigue. His weight is 70 kg. </p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   eGFR</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">19 mL/min/1.73 m<sup>2</sup></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≥60</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   C-reactive protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.8 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≤0.8</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Protein-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.3 mg/mg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Urea nitrogen</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3 g/24 h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12‒20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.2 g/24 h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">15–25 mg/kg</td>\n</tr>\n</tbody>\n</table>\n<p>(Note: assume that each g of nitrogen is derived from 6.25 g protein, and non-urea nitrogen excretion is relatively constant at 30 mg/kg/day.)</p>\n<p><strong>Which of the following is the BEST recommendation for this patient’s dietary protein intake?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Protein intake is sufficient"
            },
            {
                "label": "B.",
                "text": "Protein intake should be decreased"
            },
            {
                "label": "C.",
                "text": "Protein intake should be increased"
            },
            {
                "label": "D.",
                "text": "Protein intake cannot be estimated"
            }
        ],
        "correct_answer": "Protein intake should be increased",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s protein intake should be increased to meet a minimum level of at least 0.6 g/kg/day. Some guidelines suggest a range of 0.8‒1.0 g/kg/day in patients with CKD. His current intake is 32 g/day (only 0.45 g/kg, see below). Several clinical trials have found that moderate protein restriction to a level of 0.6–0.8 g/kg/day is associated with a slower decline in kidney function. This effect has been estimated to be in the range of 1 mL/min/year, thereby delaying the need for RRT slightly. Restriction of protein intake to lower levels has been associated with higher all-cause mortality and is therefore not recommended. In addition, patients with nephrotic syndrome were excluded from most studies evaluating protein restriction, so this strategy is not recommended for these patients.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Provided the patient is at steady state, a complete 24-hour urine collection and the patient’s weight can be used to calculate daily protein intake as follows (see also note in the stem above):</p>\n<p>Estimated protein intake = 6.25 × total urine nitrogen</p>\n<p>= 6.25 × (urine urea nitrogen + non-urea nitrogen)</p>\n<p>            = 6.25 × (3 g + [30 mg/kg × 70 kg])</p>\n<p>            = 6.25 × (3 + 2.1 g)</p>\n<p>            = 32 g</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 24-hour urine collection is cumbersome and has largely been replaced by random or spot urine samples to estimate proteinuria. The completeness of a 24-hour urine collection is generally estimated by the total creatinine excreted normalized for sex and body weight. Daily creatinine excretion for women and the elderly (due to decreased muscle mass) is expected to be 15–20 mg/kg/day. The lower limit of expected creatinine excretion in a 70-kg older man would be (15 mg/kg/day ´ 70 kg =) 1.05 g. In this case, therefore, the 1.2 g/day urine creatinine excretion indicates a complete collection, so this patient’s protein intake can be reasonably inferred.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although serum albumin is one marker used to evaluate nutrition, the serum albumin also varies with inflammation and volume status, falling in the setting of active inflammation, but rising in the setting of volume contraction. Thus, the albumin level may remain normal even if protein intake is inadequate and might be low when protein intake is sufficient.</p>\n</div>",
        "references": [
            "Tynkevich E, Flamant M, Haymann J-P, Metzger M, et al: Decrease in Urinary Creatinine Excretion in Early Stage Chronic Kidney Disease.PLoS One9(11): e111949, 2014",
            "Rodby R: Timed Urine Collections for Albumin and Protein: “The King Is Dead, Long Live the King!”Am J Kidney Dis68(6):836–838, 2016",
            "Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure.Kidney Int27: 58–65, 1985",
            "KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.Kidney IntSuppl 3.5, 2013",
            "Menon V, Kopple JD, Wang X, Beck GJ, et al: Effect of a low protein diet on outcomes: Long-term follow up of the Modification of Diet in Renal Disease (MDRD) Study.Am J Kidney Dis53: 208–217, 2009",
            "Bellizzi V, Signoriello S, Minutolo R et al: No additional benefit of prescribing a very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a pragmatic, randomized, controlled trial.Am J Clin Nutr115(5):1404-1417, 2022",
            "Wright M, Southcott E, MacLaughlin H, Wineberg S: Clinical practice guideline on undernutrition in chronic kidney disease.BMC Nephrol20: 370, 2019"
        ]
    },
    "22": {
        "question": "<div class=\"qtext\"><p>A 22-year-old woman is referred to the nephrology clinic for 2 episodes of gross hematuria over the last 2 weeks. She has no significant past medical history and no family history of hematuria or kidney disease. </p>\n<p>On examination, her BP is 160/95 mm Hg. She has no murmurs. Lungs are clear to auscultation in all fields. Her abdomen is soft and nontender with normal bowel sounds. She has 1+ lower extremity edema. There is no rash.</p>\n<p>Her serum creatinine is 1.8 mg/dL (reference range, 0.5–1.1) and is 2.1 when repeated 1 week later. Her urine protein-to-creatinine ratio is 1.3 mg/mg (reference range, &lt;0.2). Urinalysis with microscopy shows 15 dysmorphic RBCs/hpf and &gt;500 mg/dL albumin.</p>\n<p>Kidney biopsy shows mesangial expansion in all glomeruli. Crescents are present in 60% of glomeruli sampled with mild endocapillary proliferation. No significant interstitial fibrosis or tubular atrophy are present. Immunofluorescence microscopy shows 3+ IgA and 1+ C3 complement mesangial staining. Electron microscopy is significant for mesangial deposits with increased mesangial matrix and cellularity. </p>\n<p><strong>Along with initiation of glucocorticoids and renin-angiotensin-aldosterone blockade, which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe dapagliflozin"
            },
            {
                "label": "B.",
                "text": "Prescribe cyclophosphamide"
            },
            {
                "label": "C.",
                "text": "No additional management"
            },
            {
                "label": "D.",
                "text": "Refer for tonsillectomy"
            },
            {
                "label": "E.",
                "text": "Prescribe hydroxychloroquine"
            }
        ],
        "correct_answer": "Prescribe cyclophosphamide",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management for this patient with crescentic IgA nephropathy is to prescribe cyclophosphamide. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IgA nephropathy (IgAN) is an immune complex-mediated glomerulopathy. The optimal treatment for IgAN is unclear and the subject of much research, especially regarding corticosteroid initiation. Patients with rapidly progressive glomerulonephritis and crescents on kidney biopsy may benefit from more aggressive immunosuppression. This patient has additional risk factors for poor outcome, including hypertension and AKI on presentation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Small trials have shown improvement in crescentic IgAN with glucocorticoid and cyclophosphamide combination therapy. One such study examined the clinical course of 12 patients with crescentic IgAN and AKI.<sup> </sup>After 6 months of treatment<strong> </strong>with corticosteroids and cyclophosphamide, kidney function and proteinuria both improved. Repeat kidney biopsy was performed in all patients, and no crescents were observed after therapy. Consequently, KDIGO guidelines recommend treating patients with crescentic IgAN with glucocorticoids and cyclophosphamide. Of note, long-term outcomes from the Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial did not show any benefit of immunosuppression in progressive IgAN, although patients with crescents in &gt;50% of glomeruli were excluded.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In several studies from Japan, performing a tonsillectomy in patients with IgAN has been associated with improved kidney survival, but tonsillectomy is not currently the standard of care for patients with rapidly progressive disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A small randomized controlled trial has shown efficacy for hydroxychloroquine for reducing proteinuria in a group of Chinese patients. This drug has not been studied in patients with rapidly worsening kidney function. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to have favorable effects in reducing proteinuria and eGFR decline in patients with CKD, including those with IgAN, but SGLT2 inhibitors have not been studied in patients with rapidly progressive glomerulonephritis. </p>\n</div>",
        "references": [
            "Rauen T, Wied S, Fitzner C, et al: After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.Kidney Int98(4): 1044–1052, 2020",
            "Wheeler DC, Toto RD, Stefansson BV, et al: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.Kidney Int100(1): 215–224, 2021",
            "Tumlin JA, Lohavichan V, Hennigar R: Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.Nephrol Dial Transplant18(7): 1231–1239, 2003",
            "Rovin BH, Adler SG, Barratt J, et al: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.Kidney Int100(4 Suppl): S1–S276, 2021",
            "Pattrapornpisut P, Avila-Casado C, Reich HN: IgA Nephropathy: Core Curriculum 2021.Am J Kidney Dis78(3): 429–441, 2012",
            "Haas M, Verhave JC, Liu ZH, et al: A multicenter study of the predictive value of crescents in IgA nephropathy.J Am Soc Nephrol28: 691–701, 2017"
        ]
    },
    "23": {
        "question": "<div class=\"qtext\"><p>A 57-year-old woman with urothelial cancer is evaluated for a subacute rise in her serum creatinine. Six months ago, her creatinine was 1.1 mg/dL, and it has steadily risen to 1.8 mg/dL today. The patient does not have orthostatic or new urinary symptoms. </p>\n<p>Her urothelial cancer was diagnosed 2.5 years ago, and she was treated with cisplatin and gemcitabine before undergoing radical cystectomy with ileal conduit. Eleven months ago, she was prescribed nivolumab and ipilimumab (immune checkpoint inhibitors) for progressive disease. Her other medications include omeprazole, ondansetron, and folic acid. She does not use NSAIDs or other over-the-counter or herbal medications.  </p>\n<p>On examination, BP is 123/67 mm Hg, and heart rate is 76/min without postural changes. She is afebrile. She has a well-healed and pink ileal stoma in the right lower quadrant of her abdomen. The remainder of her examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table></table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">13,500/μL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10.2 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelets</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">302,000/μL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Serum</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">138 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.7 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">101 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98<span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>–</span>106          </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23<span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>–</span>28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.8 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">72 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">45 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Trace</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Blood</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Trace</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Ketones</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Leukocyte esterase</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3+</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Nitrite</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n</tbody>\n</table>\n<p>Urine microscopy shows 0–2 RBCs/HPF, 16–30 WBCs/HPF, and few bacteria.</p>\n<p>CT scan of the abdomen and pelvis with contrast shows mild bilateral hydroureter to the level of the urinary diversion, unchanged from 1 year ago.</p>\n<p><strong>Which of the following is the MOST likely cause of decreased kidney function?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Obstruction"
            },
            {
                "label": "B.",
                "text": "Nivolumab"
            },
            {
                "label": "C.",
                "text": "Hypovolemia"
            },
            {
                "label": "D.",
                "text": "Gemcitabine"
            },
            {
                "label": "E.",
                "text": "Urinary tract infection"
            }
        ],
        "correct_answer": "Nivolumab",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with slowly progressive kidney disease most likely has acute interstitial nephritis (AIN) because of exposure to immune checkpoint inhibitors (ICPIs).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ICPIs include anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies and programmed death-1 (PD-1) inhibitors, which reverse T-cell tolerance against tumors and prevents cancer from evading the immune response. These agents cause several immune-related adverse effects (IRAEs), including skin rash (41%), gastrointestinal disease (45%), various endocrinopathies (16%), and AIN (2%–5%).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ICPI-AIN has been found to develop within a prolonged time frame of 6–37 weeks after initiation of therapy rather than the 7–14 days seen after exposure to many other drugs.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Combination therapy with anti-CTLA-4 agents (ipilimumab) and PD-1 inhibitors (nivolumab) is associated with higher incidence of AIN and other IRAE. Patients with CKD and those taking proton-pump inhibitors, antibiotics, and NSAIDs are at relatively higher risk of developing CPI-AKI. Proteinuria occurs sporadically and is frequently sub-nephrotic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient’s CT scan shows evidence of chronic, mild hydronephrosis, related to either the urothelial cancer itself or sequelae of surgery, there has been no change in this finding to explain the intercurrent increase in creatinine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypovolemia may complicate the management of patients receiving chemotherapy, frequently attributed to vomiting and decreased PO intake, but this patient has no signs or symptoms of hypovolemia, and the relatively high urine sodium and fractional excretion of sodium do not suggest hypoperfusion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gemcitabine and cisplatin are both associated with decreased kidney function. Gemcitabine has been implicated in thrombotic microangiopathy, which manifests as microangiopathic hemolytic anemia with thrombocytopenia. Cisplatin has been associated with tubular injury and Fanconi syndrome. There is no evidence for either gemcitabine or cisplatin toxicity in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although WBCs and bacteria are present in the urine, these are frequently noted in the urinalysis of patients with ileal conduits, as the urine is in direct contact with the nonsterile bowel wall. There are no signs, symptoms, or other evidence of urinary tract infection in this patient.</p>\n</div>",
        "references": [
            "Cortazar FB, Kibbelaar ZA, Glezerman IG, et al: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study.J Am Soc Nephrol31(2): 435–446, 2020",
            "Hid Cadena R, Abdulahad WH, Hospers GAP, et al: Checks and balances in autoimmune vasculitis.Front Immunol9: 315, 2018",
            "Kumar V, Chaudhary N, Garg M, et al: Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy.Front Pharmacol8: 49, 2017"
        ]
    },
    "24": {
        "question": "<div class=\"qtext\"><p>A 20-year-old man is evaluated in nephrology clinic for resistant hypertension, diagnosed last year during a work physical. His current medications include carvedilol, amlodipine, lisinopril, chlorthalidone, and potassium chloride. His family history is notable for a father who has had hypertension since age 22 and a paternal grandfather who had a hemorrhagic stroke at age 36. He reports no symptoms, and review of systems is negative.</p>\n<p>On examination, BP is 165/95 mm Hg, heart rate is 65/min, and body mass index is 22 kg/m<sup>2</sup>. The remainder of examination is unremarkable except for a cardiac gallop. </p>\n<p>Laboratory data, done at 8:30 AM, are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Plasma renin activity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.3 ng/mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2–3.6, normal diet, upright\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Plasma aldosterone\n                concentration\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                31 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤10, supine or seated\n            </td>\n</tr>\n</tbody>\n</table>\n<p>His urinalysis is normal. </p>\n<p>A saline suppression test is done, with repeat plasma aldosterone concentration of 27 ng/dL. A CT scan of the adrenal glands is reported as normal.</p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Glucocorticoid-remediable aldosteronism"
            },
            {
                "label": "B.",
                "text": "Liddle syndrome"
            },
            {
                "label": "C.",
                "text": "Fibromuscular dysplasia"
            },
            {
                "label": "D.",
                "text": "Cushing syndrome"
            },
            {
                "label": "E.",
                "text": "11β-hydroxylase deficiency"
            }
        ],
        "correct_answer": "Glucocorticoid-remediable aldosteronism",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has glucocorticoid-remediable aldosteronism (GRA).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">GRA is an autosomal dominant condition, found almost exclusively in patients with European ancestry, characterized by hypertension and aldosterone excess regulated by adrenocorticotropin hormone (ACTH) rather than angiotensin II. GRA is caused by an unequal crossing over between the gene encoding 11β-hydroxylase (<em>CYP11B1</em>) and the gene encoding aldosterone synthase (<em>CYP11B2</em>). This abnormality results in ectopic expression of aldosterone synthase activity in the cortisol-producing zona fasciculata. Aldosterone production is regulated by ACTH but not by BP or potassium, and levels will not be suppressed by saline infusion. Renin levels are low because of negative feedback induced by chronic hypertension and volume overload.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with GRA generally present before the age of 21 with hypertension, usually severe, and have a strong family history of hypertension before the age of 21 and/or early-onset hemorrhagic stroke. The aldosterone excess caused by GRA and resulting hypokalemia follows the circadian rhythm of ACTH release, so it may not be discovered by routine laboratory testing. However, treatment with a thiazide diuretic may produce marked hypokalemia. Definitive treatment of GRA is physiologic-dose glucocorticoid supplementation to suppress ACTH and aldosterone production. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Liddle syndrome is a genetic disorder of the epithelial sodium channel in the collecting duct. Constitutive activity of this channel leads to manifestations of hyperaldosteronism, including hypokalemia and metabolic alkalosis, but plasma levels of renin and aldosterone will be low.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fibromuscular dysplasia of the renal arteries leads to renal artery stenosis and renovascular hypertension due to the activation of the renin-angiotensin-aldosterone axis in response to decreased perfusion pressure in the affected kidney. In this disorder, renin and aldosterone levels will be elevated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cushing syndrome often occurs when a pituitary or adrenal adenoma produces excess cortisol. Hypercortisolism may stimulate both glucocorticoid and mineralocorticoid receptor activity. Patients with Cushing syndrome would have evidence of hypercortisolism (hyperglycemia, fat redistribution) but low levels of renin and aldosterone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">11β-hydroxylase deficiency may be primary or acquired. Patients with this disorder are unable to convert 11-deoxycorticosterone (DOC) and 11-dexoxycortisol to corticosterone and cortisol. The accumulation of DOC, which is a mineralocorticoid, leads to symptoms of hyperaldosteronism. In this condition, again, both renin and aldosterone are suppressed.  </p>\n</div>",
        "references": [
            "Funder JW, Carey RM, Mantero F, et al: The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab101(5): 1889–18916, 2016",
            "Halperin F, Dluhy RG: Glucocorticoid-remediable aldosteronism.Endocrinol Metab Clin North Am40(2): 333–341, 2011",
            "Bulsari K, Falhammar H: Clinical perspectives in congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency.Endocrine55(1): 19–36, 2017",
            "Gornik HL, Persu A, Adlam D, et al: First International Consensus on the diagnosis and management of fibromuscular dysplasia.Vasc Med24(2): 164–189, 2019"
        ]
    },
    "25": {
        "question": "<div class=\"qtext\"><p>An 80-year-old man with ESRD due to type 2 diabetes and hepatitis C presents to the emergency department with 4 months of nausea, vomiting, abdominal pain, bloating, and weight loss. Ten years ago, he initiated CCPD using 1.5% and 2.5% dextrose solutions, along with a 7.5% icodextrin daytime dwell. He tolerated PD well, other than 2 episodes of culture-negative peritonitis and an umbilical hernia repair. Two years ago, his vision began to worsen, and he switched to HD. He has had several recent hospitalizations for small bowel obstruction. </p>\n<p>A CT scan of his abdomen and pelvis is shown below.  </p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b1q22.png\" width=\"75%\"/><br/>\n<figcaption><em>Image courtesy of Scott Liebman, MD, University of Rochester Medical Center</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is MOST closely associated with his current condition?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hepatitis C"
            },
            {
                "label": "B.",
                "text": "History of peritonitis"
            },
            {
                "label": "C.",
                "text": "Use of icodextrin"
            },
            {
                "label": "D.",
                "text": "Adhesions from hernia repair"
            },
            {
                "label": "E.",
                "text": "Duration of PD"
            }
        ],
        "correct_answer": "Duration of PD",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has classic symptoms and imaging consistent with encapsulating peritoneal sclerosis (EPS), which is most closely associated with prolonged PD (&gt;5 years).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">EPS is a rare complication of PD characterized by intraperitoneal inflammation and fibrosis. Patients often present with symptoms of recurrent bowel obstruction, and imaging often shows peritoneal calcification, bowel thickening, bowel tethering, and bowel dilation, although these need not be present nor are they pathognomonic of the diagnosis. EPS may present while on PD, after transitioning to HD, or even after successful kidney transplantation. A high degree of suspicion is needed to make the diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In multiple studies from different countries, the strongest and most consistent predictive risk factor for EPS is a long duration of PD, particularly ≥5 years (although the majority of patients receiving PD for many years do not develop EPS). There is some concern that multiple episodes of severe peritonitis may increase risk, although this is not conclusive. Mild peritonitis, such as the culture-negative episodes seen in this patient, does not seem to increase risk.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although there is controversy over whether those on PD with EPS should switch modalities to HD, there is no evidence suggesting that changing to HD itself is a risk factor. Although icodextrin and previous abdominal surgeries have been implicated as risk factors for EPS in a small number of studies, the International Society for Peritoneal Dialysis position paper considers the data “too imprecise and/or inconsistent” to reliably implicate these as EPS risk factors. This patient has a history of hepatitis C, which can cause cirrhosis and liver disease, but his CT scan showing calcification along the intestinal wall is consistent with EPS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">EPS is an ominous diagnosis, associated with significant morbidity and mortality. In one study, the median survival after diagnosis was 12–21 months, somewhat improved by tamoxifen treatment. Other treatment options include immunosuppression, parenteral nutrition, and lysis of adhesions.</p>\n</div>",
        "references": [
            "Brown EA, Bargman J, van Biesen W, et al: Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis–position paper for ISPD: 2017 update.Perit Dial Int37(4): 362–374, 2017",
            "Kawanishi H, Kawaguchi Y, Fukui H, et al: Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.Am J Kidney Dis44(4): 729–737, 2004",
            "Johnson DW, Cho Y, Livingston BE, et al: Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes.Kidney Int77(10): 904–912, 2010",
            "Brown MC, Simpson K, Kerssens JJ, Mactier RA; Scottish Renal Registry: Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.Clin J Am Soc Nephrol4(7): 1222–1229, 2009",
            "Balasubramaniam G, Brown EA, Davenport A, et al: The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis.Nephrol Dial Transplant24(10): 3209–3215, 2009"
        ]
    },
    "26": {
        "question": "<div class=\"qtext\"><p>A 62-year-old woman with a history of hypertension, poorly controlled type 2 diabetes, and alcohol use disorder presents to the emergency department with shortness of breath. She also reports a 9-kg weight loss over the last 2 months, 2 weeks of low-grade fevers, and abdominal distention. Her home medications include lisinopril, insulin, chlorthalidone, spironolactone, aspirin, and a multivitamin. </p>\n<p>BP is 124/82 mm Hg, heart rate is 94/min, respiratory rate is 22/min, and temperature is 37.2°C. There are no orthostatic changes in BP or heart rate. She is in mild respiratory distress and has temporal wasting. Her abdomen is slightly distended without rebound tenderness. The remainder of the examination is unremarkable.</p>\n<p>A CT scan of her abdomen and pelvis is remarkable for bulky lymphadenopathy in the pelvis and retroperitoneum.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10,800/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>141 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>104 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>26 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>165 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>308 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>275–295</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Lactate dehydrogenase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>677 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80–225</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Arterial pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.25</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Arterial pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42 (room air)</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for blood, protein, or ketones.</p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Diabetic ketoacidosis"
            },
            {
                "label": "B.",
                "text": "Salicylate toxicity"
            },
            {
                "label": "C.",
                "text": "Ethanol intoxication"
            },
            {
                "label": "D.",
                "text": "Lactic acidosis"
            },
            {
                "label": "E.",
                "text": "Renal tubular acidosis"
            }
        ],
        "correct_answer": "Lactic acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with high anion gap metabolic acidosis and possible lymphoma most likely has a type B lactic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient presents with a clinical history and data highly suggestive of a lymphoma, including constitutional (“B”) symptoms, an elevated lactate dehydrogenase (LDH) level, and imaging consistent with lymphoma. Lymphomas and other highly metabolically active tumors can convert glucose to lactate via anaerobic glycolysis, a phenomenon known as the Warburg effect. This condition is a subset of type B lactic acidosis, in which glucose bypasses the typical oxidative pathway (mitochondrial metabolism via the Krebs cycle), even in the presence of sufficient oxygen. The exact reason for cancer cells switching to anaerobic glycolysis is unclear; possible reasons include a more rapid production of ATP and enhancement of certain intracellular signaling pathways. Another possibility is that this pathway may be preferred in the setting of thiamine deficiency, a co-factor required for pyruvate entry into the Krebs cycle, and there are some reports that thiamine supplementation can help treat the Warburg effect. Usually, the excess lactic acid produced by the Warburg effect is converted back to glucose in the liver, but patients with extensive liver disease or metastases may accumulate lactic acid.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> Type A lactic acidosis is more commonly encountered and involves anaerobic production of lactic acid from pyruvic acid, usually because of a metabolic mismatch between oxygen needs of the tissues and insufficient oxygen delivery in the setting of sepsis or other severe illness. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has diabetes, there is no evidence of severe hyperglycemia or ketonuria, so diabetic ketoacidosis is unlikely.</p>\n<p>Ethanol intoxication could cause an anion gap metabolic acidosis but is frequently also associated with a serum osmolal gap, especially in the early stages before the neutral osmolyte ethanol is converted to acetaldehyde and acetic acid. The osmolal gap is calculated as follows:</p>\n<p> </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">measured (Sosm) – calculated osmolality = Sosm – (2 × Na + [BUN/2.8] + [glucose/18])</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> = 308 – (282 + 9 + 9) = 8 mOsm/kg H<sub>2</sub>O</p>\n<p> </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the absence of a significant osmolal gap, and the presence of a high LDH and new significant lymphadenopathy, ethanol intoxication is less likely than type B lactic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Salicylate toxicity would also cause high anion gap metabolic acidosis and may itself also cause type B lactic acidosis, but unique to salicylate toxicity is stimulation of the medullary respiratory center in some cases, which would cause a concurrent respiratory alkalosis. In this case, the pCO<sub>2</sub> is decreased to the level expected for compensation of a simple metabolic acidosis, so this disorder would not be the most likely diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although renal tubular acidosis (RTA) may complicate diabetic kidney disease and similar findings would be expected with spironolactone therapy, this patient has a pure anion gap metabolic acidosis, which would be inconsistent with a diagnosis of RTA.</p>\n</div>",
        "references": [
            "Brault C, Zerbib Y, Delette C, et al: The Warburg effect as a type B lactic acidosis in a patient with acute myeloid leukemia: a diagnostic challenge for clinicians.Front Oncol8: 232, 2018",
            "Friedenberg AS, Brandoff DE, Schiffman FJ: Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review.Medicine (Baltimore)86(4): 225–232, 2007",
            "Liberti MV, Locasale JW: The Warburg effect: how does it benefit cancer cells?Trends Biochem Sci41(3): 211–218, 2016",
            "He Y, Ong J, Ong S: Refractory lactic acidosis and an approach to its management–a case report.J Crit Care Med (Targu Mures)5(2): 60–65, 2019",
            "Kraut JA, Madias NE: Metabolic acidosis: pathophysiology, diagnosis and management.Nat Rev Nephrol6(5): 274–285, 2010"
        ]
    },
    "27": {
        "question": "<div class=\"qtext\"><p>A 43-year-old woman with no significant past medical history collapses shortly after finishing a marathon. On initial assessment, she is conscious but is unable to answer questions.</p>\n<p>Vital signs include BP of 100/62 mm Hg and heart rate of 126/min. Her lungs are clear to auscultation, but she begins to vomit upon further examination.</p>\n<p>A peripheral IV is inserted, and laboratory studies are drawn.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "0.9% saline"
            },
            {
                "label": "B.",
                "text": "3% saline"
            },
            {
                "label": "C.",
                "text": "Desmopressin (ddAVP)"
            },
            {
                "label": "D.",
                "text": "5% dextrose in water"
            },
            {
                "label": "E.",
                "text": "Epinephrine"
            }
        ],
        "correct_answer": "3% saline",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with history, signs, and symptoms consistent with severe exercise-associated hyponatremia (EAH) and should be administered a small bolus, typically 100 mL, of 3% saline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">EAH is an important endurance-related complication and is potentially fatal if improperly managed. Frequently, history of water intake during the marathon and measurement of serum sodium at the point of care are unavailable, so a high index of suspicion for EAH is required in this clinical scenario. The incidence of EAH may be as high as 18% of marathon runners and increases with more extreme events.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Symptoms of EAH vary from mild nausea and dizziness to severe cases, including seizures and encephalopathy. The pathophysiology is multifactorial: strenuous exercise leads to sodium loss, and thus volume depletion, through perspiration. The resultant decreased GFR impairs urinary dilution capabilities. Anti-diuretic hormone (ADH) is stimulated through exercise and activation of angiotensin II in the setting of decreased renal blood flow and tubular solute delivery, leading to water retention. Finally, hypotonic fluid replacement during the race further exacerbates the hyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Management of EAH depends on severity of symptoms. For those with severe symptoms of hyponatremia (seizures, encephalopathy), the recommendation for initial management is to immediately give 100 mL of hypertonic (3%) saline to reduce cerebral edema by raising serum sodium and osmolality. If neurologic symptoms do not improve, this regimen can be repeated 1–2 more times in 10-minute intervals.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Administration of 0.9% saline (with or without ddAVP) is incorrect. This patient has severe hyponatremia, and the serum osmolality should be raised quickly to alleviate cerebral edema. ddAVP administration is sometimes given simultaneously with hypertonic saline in hyponatremia to avoid overcorrection. In this scenario, 100 mL of 3% saline is a sodium load of only 51 mEq.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Epinephrine would be the appropriate choice for anaphylactic shock, which is not suspected in this patient. This patient most likely has severe hyponatremia, so giving 5% dextrose in water would not be appropriate.</p>\n</div>",
        "references": [
            "Rosner MH, Kirven J: Exercise-associated hyponatremia.Clin J Am Soc Nephrol2(1): 151–161, 2007",
            "Bennett BL, Hew-Butler T, Rosner MH, Myers T, Lipman GS: Wilderness Medical Society clinical practice guidelines for the management of exercise-associated hyponatremia: 2019 update.Wilderness Environ Med31(1): 50–62, 2020",
            "Almond CSD, Shin AY, Fortescue EB, et al: Hyponatremia among runners in the Boston Marathon.N Engl J Med352(15): 1550–1556, 2005",
            "Siegel AJ, Verbalis JG, Clement S et al: Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion.Am J Med120(5): e11–e17, 2007"
        ]
    },
    "28": {
        "question": "<div class=\"qtext\"><p>An 82-year-old man with CKD stage 4 due to hypertension and benign prostatic hypertrophy presents to the emergency department after a fall. He describes dizziness preceding the event but no loss of consciousness. His medications include lisinopril, metoprolol, and tamsulosin, and he reports mistakenly taking metoprolol instead of tamsulosin last night. He takes NSAIDs intermittently for back pain, most recently 2 days ago. </p>\n<p>On examination, BP is 98/66 mm Hg, heart rate is 48/min, and oxygen saturation is 96% while breathing room air. His neck veins are flat, cardiac examination is normal except for bradycardia, and lungs are clear. He has suprapubic fullness and tenderness and trace lower extremity edema. His neurologic exam is normal other than mild tremor. </p>\n<p>A urinary catheter is placed, and 500 mL of urine drains immediately.</p>\n<p>Laboratory data are as follows</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>138 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.4 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>102 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>86 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.6 mg/dL (baseline 2.4)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>112 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>EKG shows a junctional escape rhythm with heart rate 50/min.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s EKG changes?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hyperkalemia"
            },
            {
                "label": "B.",
                "text": "Metoprolol overdose"
            },
            {
                "label": "C.",
                "text": "Acute kidney injury"
            },
            {
                "label": "D.",
                "text": "Ischemic heart disease"
            },
            {
                "label": "E.",
                "text": "Hypocalcemia"
            }
        ],
        "correct_answer": "Hyperkalemia",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with symptomatic hyperkalemia with associated EKG changes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cardiac conduction abnormalities are a well-known complication of hyperkalemia. EKG changes do not always correlate with the level of hyperkalemia, but classically they begin with peaked T waves (defined as at least 60% of the QRS complex amplitude) and shortened QT interval. Conduction abnormalities include atrioventricular and bundle branch blocks, sinus bradycardia, junctional escape rhythms, ventricular arrhythmias, and asystole. Of note, there are some data suggesting that EKG manifestations of hyperkalemia are variable and unreliable for diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has several risk factors for hyperkalemia, including AKI, CKD, ACEI and β-blocker prescription, metabolic acidosis, and bladder outlet obstruction. Early recognition and management of symptomatic/severe hyperkalemia is essential. Relieving the obstruction with a urinary catheter should improve kidney function and promote potassium excretion, but stabilizing the cardiac membrane with IV calcium gluconate is the most important initial step in management. AKI itself would not explain the EKG findings in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metoprolol increases the risk of hyperkalemia by inhibiting β-adrenergic-mediated uptake of potassium into cells. However, this process is typically facilitated by β2-adrenergic receptors, so the risk of hyperkalemia is much lower with selective β1-receptor blockers such as metoprolol. Moreover, although metoprolol would cause sinus bradycardia, it would not produce a junctional escape rhythm. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypocalcemia is commonly seen in patients with advanced kidney disease. However, the most common EKG finding in hypocalcemia is prolongation of the QT interval and not junctional bradycardia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although it would be appropriate to rule out coronary ischemia, there are no data to suggest this diagnosis in this patient, and hyperkalemia is a much more likely cause of the EKG findings.</p>\n</div>",
        "references": [
            "Yamada S, Inaba M: Potassium metabolism and management in patients with CKD.Nutrients13(6): 1751, 2021",
            "Montague BT, Ouellette JR, Buller GK: Retrospective review of the frequency of ECG changes in hyperkalemia.Clin J Am Soc Nephrol3(2): 324–330, 2008",
            "Montford JR, Linas S: How dangerous is hyperkalemia?J Am Soc Nephrol28(11): 3155–3165, 2017"
        ]
    },
    "29": {
        "question": "<div class=\"qtext\"><p>A 52-year-old woman presents to clinic for evaluation of metabolic acidosis. She has a history of hypertension, type 2 diabetes, osteoarthritis, and class 3 obesity for which she had a jejunoileal bypass surgery performed 5 years ago. She reports intermittent episodes of confusion, ataxia, and slurred speech. She reports no changes to her appetite or oral intake but has been eating a higher carbohydrate diet while training for a half-marathon. Her medications include metformin, empagliflozin, telmisartan, and rosuvastatin. She does not drink alcohol or use recreational or over-the-counter medications. </p>\n<p>Her physical examination is unremarkable, without tremor or asterixis.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9,500/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>280,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>139 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5 .0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>104 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>18 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>94 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Lactic acid</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mmol/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–2.1 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Beta-hydroxybutyrate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.4 mg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.4</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Arterial blood gas pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Arterial blood gas pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine ketones</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Wernicke encephalopathy"
            },
            {
                "label": "B.",
                "text": "ᴅ-lactic acidosis"
            },
            {
                "label": "C.",
                "text": "Toluene intoxication"
            },
            {
                "label": "D.",
                "text": "Vitamin B12 deficiency"
            },
            {
                "label": "E.",
                "text": "Euglycemic diabetic ketoacidosis"
            }
        ],
        "correct_answer": "ᴅ-lactic acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely etiology of this patient’s symptoms and metabolic acidosis is ᴅ-lactic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ᴅ-Lactic acidosis is a rare form of lactic acidosis that primarily occurs in patients with short gut syndrome or jejunal-ileal bypass who consume a high carbohydrate diet. Colonic bacteria metabolize carbohydrates to ᴅ-lactic acid, which can accumulate and be absorbed into the bloodstream. The human form of lactate dehydrogenase does not convert ᴅ-lactate into its metabolic products, leading to its accumulation and the predominantly neurological symptoms described here. Patents with small bowel resection are at risk because there is less surface area for carbohydrate reabsorption, with resultant increased delivery of carbohydrates to the colon. Additionally, these patients tend to have gram-positive bacterial overgrowth in the intestines, which leads to production of more lactate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The serum test for lactate only assesses ʟ-lactate, and a high index of suspicion is necessary to diagnose ᴅ-lactic acidosis in patients with appropriate clinical risk factors. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Wernicke encephalopathy can cause ataxia and confusion but is not associated with acid-base disorders. Similarly, vitamin B12 deficiency can cause anemia and may be seen in patients with short gut syndrome but would not cause an anion-gap metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Toluene intoxication typically causes hyperchloremic metabolic acidosis associated with hypokalemia and would be suspected in a patient with a history of glue or solvent inhalation. Sodium-glucose cotransporter-2 (SGLT2) inhibitors act by causing glycosuria, which is expected and observed here, and is also associated with euglycemic diabetic ketoacidosis. However, serum or urine ketones will typically reveal ketones, which were absent in this case.</p>\n</div>",
        "references": [
            "Kraut JA, Madias NE: Serum anion gap: its uses and limitations in clinical medicine.ClinJ Am Soc Nephrol2(1):162–174, 2007",
            "Bianchetti DGAM, Amelio GS, Lava SAG, et al: D-lactic acidosis in humans: systematic literature review.Pediatr Nephrol33(4): 673–681, 2018",
            "Fenves AZ, Emmett M: Approach to patients with high anion gap metabolic acidosis: core curriculum 2021.Am J Kidney Dis78(4): 590–600, 2021"
        ]
    },
    "30": {
        "question": "<div class=\"qtext\"><p>A 58-year-old woman with ESRD due to IgA nephropathy status post deceased donor kidney transplant 2 years ago is seen in the emergency department following a seizure. Her medications include tacrolimus, mycophenolate mofetil, and metoprolol.</p>\n<p>Her care partner reports that the patient had a seizure while sitting outside on their porch. The patient recently started a new grapefruit juice-based diet and has otherwise been in her normal state of health.</p>\n<p>Vital signs include BP of 160/88 mm Hg, heart rate of 75/min, and respiratory rate of 16/min. She appears well. With the exception of a new resting tremor, her neurologic examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>127 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>105 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8 mg/dL (baseline, 1.3)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Magnesium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6–2.6</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Tacrolimus 12-hour trough level is pending. A CT scan of the head without contrast reveals no intracranial abnormalities.</p>\n<p><strong>Which ONE of the following is the MOST LIKELY cause of this patient’s seizures?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Tacrolimus"
            },
            {
                "label": "B.",
                "text": "Hypomagnesemia"
            },
            {
                "label": "C.",
                "text": "Hyponatremia"
            },
            {
                "label": "D.",
                "text": "Mycophenolate mofetil"
            },
            {
                "label": "E.",
                "text": "IgA nephropathy"
            }
        ],
        "correct_answer": "Tacrolimus",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tacrolimus toxicity is the most likely cause of this patient’s seizures.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Neurotoxicity is frequently seen in kidney transplant recipients who take tacrolimus. Mild symptoms are most common and include tremor, neuralgia, and peripheral nephropathy. More severe symptoms include seizures, vision loss, and leukoencephalopathy. These more severe symptoms are most commonly encountered with transient spikes in tacrolimus trough levels. Grapefruit is a potent inhibitor of the cytochrome P450 enzyme system, and inhibiting tacrolimus metabolism by gastrointestinal P450 can increase tacrolimus levels and cause toxicity. Her resting tremor also points toward tacrolimus toxicity, even in the absence of laboratory data confirming an elevated tacrolimus trough.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Severe and acute hyponatremia has been associated with seizures, with CT findings often demonstrating cerebral edema, which is absent in this case. Seizure is unlikely with relatively mild hyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypomagnesemia is a well-known side effect of tacrolimus via decreased expression of transient receptor potential melastatin-6 (TRPM6) in the distal tubule. However, hypomagnesemia has only rarely been shown to be associated with seizures and would not cause tremor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mycophenolate mofetil use and IgA nephropathy are not associated with seizures.</p>\n</div>",
        "references": [
            "Farouk SS, Rein JL: The many faces of calcineurin inhibitor toxicity—what the FK?Adv Chronic Kidney Dis27(1): 56‒66, 2020",
            "Bechstein WO: Neurotoxicity of calcineurin inhibitors: impact and clinical management.Transpl Int13(5): 313‒326, 2000",
            "Nijenhuis T, Hoenderop JGJ, Bindels RJM: Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.J Am Soc Nephrol15(3): 549‒557, 2004"
        ]
    },
    "31": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man without significant past medical history presented to urgent care with a sore throat and fever 3 months ago. At that time, BP was 160/90 mm Hg, and temperature was 38.5°C. His posterior pharynx was erythematous, and he had cervical lymphadenopathy. A urine dipstick revealed 2+ blood and 2+ protein, and a rapid antigen detection test was positive for group A <em>Streptococcus</em>. He was prescribed a 7-day course of penicillin with symptomatic improvement. </p>\n<p>He now presents for follow-up in the outpatient clinic. He is asymptomatic, and vital signs and examination are unremarkable other than BP 155/88 mm Hg. Urine microscopy shows numerous acanthocytes.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>3 months ago</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                50 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2500 mg/24 h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;100           </td>\n</tr>\n</tbody>\n</table>\n<p>A kidney biopsy reveals MPGN with immunofluorescence positive for dominant C3 staining (4+) in a granular pattern along the GBM, with all other immune reactants staining trace or negative. Repeat immunofluorescence on pronase-digested paraffin-embedded tissue shows identical findings.</p>\n<p><strong>Which ONE of the following laboratory tests is MOST likely to establish a diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Serum immunofixation"
            },
            {
                "label": "B.",
                "text": "Anti-streptolysin O antibodies"
            },
            {
                "label": "C.",
                "text": "C3 nephritic factor autoantibodies"
            },
            {
                "label": "D.",
                "text": "Anti-hepatitis C antibodies"
            },
            {
                "label": "E.",
                "text": "C3 genetic sequencing"
            }
        ],
        "correct_answer": "Serum immunofixation",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate laboratory test to establish a diagnosis in this patient with C3 glomerulopathy (C3G) is serum immunofixation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">C3G is a rare progressive chronic glomerulonephritis caused by dysregulation of the alternative complement pathway. C3G is diagnosed histologically and requires C3 staining on immunofluorescence to be greater than 2 orders of magnitude compared with the other immune reactants. Large case series have revealed that the majority of patients with C3 glomerulopathy ≥50 years of age have an underlying monoclonal gammopathy. These monoclonal immunoglobulins are believed to act as autoantibodies to the complement regulatory proteins, resulting in a prolonged half-life of factor H or C3 convertase, with unrestrained complement activation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Identifying a monoclonal gammopathy in a patient with newly diagnosed C3G is important, as emerging evidence suggests that treating the underlying gammopathy improves kidney outcomes. It is also important to note that failure to unmask monoclonal immune deposits after pronase digestion does not exclude monoclonal gammopathy-associated C3G. Thus, older patients with biopsy findings consistent with a C3 glomerulopathy should be evaluated for monoclonal gammopathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is important to exclude infection-related glomerulonephritis (IRG) when histology suggests a diagnosis of C3G, as IRG can also be C3 dominant. Elevated titers of extracellular streptococcal antigens would suggest recent group A <em>Streptococcus</em> (GAS) pharyngitis; however, persistent kidney dysfunction and urine abnormalities months after resolution of GAS pharyngitis is less consistent with IRG or post-streptococcal glomerulonephritis and is more consistent with persistent dysregulation of the alternative complement pathway. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">C3G can be caused by autoantibodies to the C3 convertase, designated C3 nephritic factor. However, given this patient’s age and the potential for resolution of C3G with prompt treatment of a monoclonal gammopathy, serum immunofixation would be the more appropriate test. Complement-associated genetic variants can be implicated in ~30% of cases of C3G, but this would be a less likely etiology of C3G in an elderly man.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hepatitis C often presents with MPGN on light microscopy, this pattern of injury is usually mediated by immune complexes, which were not found in this biopsy.</p>\n</div>",
        "references": [
            "Hou J, Markowitz GS, Bomback AS, et al: Toward a working definition of C3 glomerulopathy by immunofluorescence.Kidney Int85(2): 450–6, 2014",
            "Bomback AS, Santoriello D, Avasare RS, et al: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.Kidney Int 93(4): 977–985, 2018",
            "Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.Kidney Int94(1): 178–186, 2018",
            "Chauvet S, Fremeaux-Bacchi V, Petitprez F, et al: Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.Blood129(11): 1437–1447, 2017",
            "Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S: C3 glomerulopathy: ten year’s experience at Mayo Clinic.Mayo Clin Proc93(8): 991–1008, 2018",
            "Sethi S, Fervenza FC, Zhang Y, et al: Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.Kidney Int83(2): 293–299, 2013"
        ]
    },
    "32": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man is admitted to the hospital for 3 days of progressive shortness of breath and cough productive of small amounts of blood. His past medical history includes hypertension and chronic obstructive pulmonary disease. Medications include hydrochlorothiazide and albuterol as needed. He has a 30 pack-year history of smoking and drinks alcohol once per week. He recently started a new job as an auto mechanic.</p>\n<p>BP is 160/100 mm Hg, heart rate is 105/min, temperature is 37°C, and oxygen saturation is 92% while breathing room air. Coarse breath sounds in all lung fields are heard on auscultation, and he has trace bilateral lower extremity edema. The remainder of his examination is unremarkable, other than tachycardia. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>4500/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>10.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>12‒16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>160,000/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>3.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>0.5‒1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Antinuclear antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Anti-myeloperoxidase antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>&lt;1.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Anti-proteinase 3 antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Anti-GBM antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>Positive</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>135 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 30.3705%;\">\n<p>38 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.665%;\">\n<p>14–48</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals pH 5.5, specific gravity 1.015, 1+ protein, and 2+ blood. Microscopy reveals 8–10 dysmorphic RBC/HPF and 6–8 WBC/HPF.</p>\n<p>Chest x-ray shows bilateral ground glass opacities in all lung fields.</p>\n<p><strong>Which ONE of the following is the BEST NEXT STEP in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Furosemide"
            },
            {
                "label": "B.",
                "text": "Cyclophosphamide"
            },
            {
                "label": "C.",
                "text": "Plasmapheresis"
            },
            {
                "label": "D.",
                "text": "Rituximab"
            },
            {
                "label": "E.",
                "text": "Kidney biopsy"
            }
        ],
        "correct_answer": "Plasmapheresis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with AKI and anti-GBM antibodies should undergo plasmapheresis. Other components of therapy would include immunosuppression with both corticosteroids and cyclophosphamide, and possibly dialysis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anti-GBM disease is a small vessel vasculitis affecting glomerular capillaries; when accompanied by pulmonary hemorrhage, it is referred to as Goodpasture syndrome. This disease is characterized by production of autoantibodies against the noncollagenous-1 domain of the α-3 chain of type IV collagen present in pulmonary and glomerular basement membranes, leading to alveolar hemorrhage and crescentic glomerulonephritis, respectively. Cigarette smoking and inhalation of hydrocarbons have been implicated as triggers causing injury to basement membranes leading to the exposure of previously sequestered antigens, which may explain why patients exposed to these toxins are at greater risk of pulmonary hemorrhage with anti-GBM disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the renal prognosis for anti-GBM disease is frequently grim, in patients who present early and without significant comorbidity, plasmapheresis is recommended as the initial treatment strategy to remove pathogenic autoantibodies in patients presenting with alveolar hemorrhage and AKI not requiring dialysis, particularly when serum creatinine is &lt;6.8 mg/dL. Immunosuppressive agents such as cyclophosphamide and corticosteroids should also be initiated to inhibit further autoantibody formation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Furosemide may be useful in patients with AKI who have volume overload, including pulmonary edema, but would not be the next best step in therapy to address the AKI itself. Additionally, the lung findings on examination and chest x-ray may indicate pulmonary hemorrhage rather than edema, in which case furosemide would not be helpful.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Neither cyclophosphamide nor rituximab alone has been studied for the initial treatment of anti-GBM disease, although rituximab monotherapy has been used successfully in some patients who have failed to respond to conventional treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy would be useful for further diagnosis and prognosis of AKI, but in this patient with severe symptoms and positive anti-GBM serology, preventing further lung and kidney injury with plasmapheresis should take priority. In cases of renal-limited disease, if kidney biopsy shows 100% crescents or &gt;50% global glomerulosclerosis, immunosuppression may be discontinued, as the likelihood of renal recovery is low.</p>\n</div>",
        "references": [
            "Rovin BH, Adler SG, Barratt J, et al: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.Kidney Int100: 753–779, 2021",
            "McAdoo SP, Pusey CD: Anti-glomerular basement membrane disease.Clin J Am Soc Nephrol12(7): 1162–1172, 2017",
            "Clark WF, Huang SS, Walsh MW: Plasmapheresis for the treatment of kidney diseases.Kidney Int90(5): 974–984, 2016"
        ]
    },
    "33": {
        "question": "<div class=\"qtext\"><p>A 59-year-old man with ESRD due to hypertensive nephrosclerosis is evaluated for kidney transplant candidacy. He was initiated on in-center HD 4 months ago and received the seasonal flu and pneumococcal conjugate vaccine (PCV13) upon admission to the facility and a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later. He is up to date with vaccination against COVID-19, and his last tetanus-diphtheria booster was given 2 years ago at the time of a workplace injury, but he cannot recall prior hepatitis B vaccination.</p>\n<p>On examination, his BP is 154/92 mm Hg, heart rate is 71/min and regular, and temperature is normal. Other than mild pedal edema and a right internal jugular tunneled dialysis catheter, the rest of the examination is unremarkable. Laboratory studies done as a part of transplant evaluation are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range </strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hepatitis B surface antigen</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hepatitis B surface antibody</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">86 mIU/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Positive, &gt;10 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hepatitis B core antibody </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hepatitis C antibody</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varicella IgG</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Positive </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varicella IgM</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer hepatitis B vaccine"
            },
            {
                "label": "B.",
                "text": "Administer tetanus-diphtheria (Td) vaccine"
            },
            {
                "label": "C.",
                "text": "Administer pneumococcal polysaccharide (PPSV23) vaccine"
            },
            {
                "label": "D.",
                "text": "Administer recombinant zoster vaccine"
            },
            {
                "label": "E.",
                "text": "No further vaccination needed"
            }
        ],
        "correct_answer": "Administer recombinant zoster vaccine",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with ESRD should receive the zoster vaccine prior to kidney transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Infections caused by herpes zoster are of significant concern in patients with ESRD due to their immunocompromised status. The risk of developing herpes zoster reactivation is about 2-fold higher in patients receiving HD compared with age- and sex-matched controls. Moreover, the risk of mortality associated with zoster appears higher in patients with ESRD compared with the general population. Therefore, prevention of zoster in patients receiving dialysis is of significant importance. In a matched cohort study, zoster vaccination in patients with ESRD reduced the risk of developing zoster compared with a matched unvaccinated cohort. The Centers for Disease Control recommends vaccination of patients with ESRD who meet age requirements, unless contraindicated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Furthermore, this patient is now undergoing evaluation for kidney transplantation. The US Advisory Committee on Immunization Practices and American Society of Transplantation recommend vaccination against zoster for solid organ transplant recipients ≥50 years old. This recommendation is based on evidence that immunocompromised patients are at substantial risk of zoster infection and that immunization against zoster is effective in reducing the incidence of, and complications from, zoster. Although either recombinant zoster vaccine (RZV, given in 2 doses, 2–6 months apart) or the live attenuated zoster vaccine (ZVL, given as 1 dose) can be used before transplantation, use of ZVL is contraindicated after transplantation. An interval of 4 weeks between live vaccine administration and transplantation is generally recommended. A positive varicella IgG in the presence of negative IgM suggests immunity against chickenpox due to prior infection or vaccination but does not protect against zoster.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is immune to hepatitis B, as indicated by his high surface antibody titers, so vaccination is not indicated. The Td booster is indicated every 10 years, so revaccination is not necessary at this time. It is recommended that patients with ESRD receive the PCV13 vaccine followed by the first dose of PPSV23 at least 8 weeks apart. Subsequent dosing of PPSV23 is recommended after 5 years and therefore is not needed at this time.</p>\n</div>",
        "references": [
            "Kuo CC, Lee CT, Lee IM, et al: Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study.Am J Kidney Dis59(3): 428–433, 2012",
            "Ahn JN, Waller JL, Baer SL, et al: Mortality risk after herpes zoster infection in end-stage renal disease patients.Clin Kidney J12(1): 101–105, 2019",
            "Dooling K L, Guo A, Patel M, et al: Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines.MMWR Morb Mortal Wkly Rep67(3): 103–108, 2018",
            "Tseng HF, Luo Y, Shi J, et al: Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease.Clin Infect Dis62(4): 462–467, 2016",
            "Danziger-Isakov L, Kumar D, AST ID Community of Practice: Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation infectious diseases community of practice. Clin Transplant 33(9): e13563, 2019"
        ]
    },
    "34": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman presents to the nephrology clinic for follow-up of lupus nephritis. Her past medical history includes SLE diagnosed at age 20 and class IV lupus nephritis diagnosed at age 24 years. She reports that she was married 6 months ago and is planning for conception. She has no facial rash, photosensitivity, or joint pains. She has had scanty menstrual periods every 35 days for the last year. Her medications include mycophenolate mofetil, prednisone, furosemide, hydroxychloroquine, and an oral contraceptive.</p>\n<p>On examination, her BP is 140/80 mm Hg, heart rate is 95/min, and body mass index (BMI) is 28 kg/m<sup>2</sup>. Heart, lung, and abdominal examinations are unremarkable. She has bilateral trace lower extremity edema. There are no malar rash, oral ulcers, joint swelling, or skin lesions.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5‒1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Antinuclear antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1:240</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Anti-double-stranded DNA antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10 IU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0‒7 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Anti-Smith antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8 IU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows pH 5.5, specific gravity 1.015, 1+ protein, and no blood. Urine microscopy shows 1‒2 RBC/HPF and 1‒2 WBC/HPF. Urine protein-to-creatinine ratio has decreased from 2 to 1 mg/mg over the last year (reference range, &lt;0.2).</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Continue current medications"
            },
            {
                "label": "B.",
                "text": "Continue prednisone only"
            },
            {
                "label": "C.",
                "text": "Counsel patient to wait to conceive until proteinuria resolves"
            },
            {
                "label": "D.",
                "text": "Change mycophenolate mofetil to azathioprine"
            },
            {
                "label": "E.",
                "text": "Discontinue immunosuppression"
            }
        ],
        "correct_answer": "Change mycophenolate mofetil to azathioprine",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with SLE nephritis who wants to conceive, mycophenolate should be switched to azathioprine, an alternate antimetabolite that is safer in pregnancy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SLE during pregnancy is associated with significant maternal and neonatal morbidity and mortality. Risk factors for SLE flare during pregnancy include active disease within 6 months of conception, history of multiple flares, and abrupt withdrawal of hydroxychloroquine. Maternal complications from SLE include hypertensive disorders (including preeclampsia) and progressive worsening of kidney function. Fetal complications include preterm birth, intrauterine growth retardation, and fetal death. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, history of lupus nephritis and long-term steroid use are risk factors for adverse pregnancy outcomes. Preconception counseling and management must include the following:</p>\n<ol>\n<li style=\"margin-bottom: 15px;\">Maintain optimal BP. </li>\n<li style=\"margin-bottom: 15px;\">Change mycophenolate mofetil, which is teratogenic, to azathioprine.</li>\n<li style=\"margin-bottom: 15px;\">Continue low-dose prednisone (&lt;10 mg/day). Adrenal insufficiency and thymic hyperplasia in the fetus are rare with low-dose prednisone. </li>\n<li style=\"margin-bottom: 15px;\">Continue hydroxychloroquine to reduce risk of SLE flare. </li>\n<li style=\"margin-bottom: 15px;\">Monitor urine protein, kidney function, anti-phospholipid antibodies, and SLE serology during pregnancy.</li>\n</ol>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with SLE do not need to wait until proteinuria resolves to conceive, although patients with clinical remission of nephritis &lt;18 months, those with anti-C1q or anti-phospholipid positivity, and those taking high doses of corticosteroids have a higher risk of fetal loss and premature birth.</p>\n</div>",
        "references": [
            "Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT: Update on the diagnosis and management of systemic lupus erythematosus.Ann Rheum Dis80: 14–25, 2021",
            "Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Boumpas D: EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphosphospholipid syndrome.Ann Rheum Dis76: 476–485, 2017",
            "Stanhope TJ, White WM, Moder KG: Obstetric nephrology: lupus and lupus nephritis in pregnancy.Clin J Am Soc Nephrol7(12): 2089–2099, 2012",
            "Chen Y, Li K, Zhang H, et al: Good pregnancy outcomes in lupus nephritis patients with complete renal remission [published online ahead of print October 5, 2021].Nephrol Dial Transplantdoi:10.1093/ndt/gfab289."
        ]
    },
    "35": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man is admitted to the ICU for worsening hypoxemia and volume overload. His past medical history is notable for congestive heart failure with ejection fraction 15%–20% and CKD stage 3. One month ago, he had gained 5 kg, and his outpatient physician increased his dose of furosemide to 80 mg PO twice daily. During this admission his weight has increased another 5 kg. His furosemide dose has been titrated to 120 mg IV twice daily without a change in his weight. Urine output is 1000 mL/24 h.</p>\n<p>BP is 124/68 mm Hg, heart rate is 100/min, respiratory rate is 22/min, and oxygen saturation is 96% while receiving 40% oxygen via Venturi mask. Physical examination is notable for jugular venous distention, bilateral lung crackles, and pitting edema to both thighs. </p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>On Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Hospital Day 5 </strong>\n</td>\n<td \"=\" \" style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Sodium\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                136 mEq/L\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                138\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Potassium\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                4.3 mEq/L\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                3.9\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Chloride\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                103 mEq/L\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                100\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Total CO<sub>2</sub> \n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                28 mEq/L\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                35\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                BUN \n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                36 mg/dL\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                45\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Creatinine\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                1.8 mg/dL\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                2.4\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                Albumin\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                3.2 g/dL\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                2.9\n            </td>\n<td style=\" border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; \">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe metolazone 10 mg PO daily"
            },
            {
                "label": "B.",
                "text": "Prescribe acetazolamide 500 mg PO daily"
            },
            {
                "label": "C.",
                "text": "Change furosemide dosing to 10 mg/h IV"
            },
            {
                "label": "D.",
                "text": "Prescribe isolated ultrafiltration"
            },
            {
                "label": "E.",
                "text": "Prescribe albumin 25% IV twice daily"
            }
        ],
        "correct_answer": "Prescribe metolazone 10 mg PO daily",
        "abim_content_category": "Sodium and water abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step in this patient’s management should be to add metolazone to the diuretic regimen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diuretic resistance is defined as the failure to effect fluid excretion in moderate to severe congestive heart failure despite escalating doses of loop diuretic. The potential mechanisms of diuretic resistance include high daily sodium intake, inadequate dose and frequency of diuretics, reduced urinary diuretic secretion due to decreased kidney function, renal sodium avidity due to activation of the renin-angiotensin-aldosterone system, and distal tubule epithelial cell hypertrophy, leading to an increase in sodium reabsorption. Strategies for managing diuretic resistance include restricting sodium intake, optimizing the dose and frequency of loop diuretic, combination diuretic therapy, and ultrafiltration. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best option for this patient would be initiating a thiazide diuretic in addition to high-dose IV loop diuretics. Thiazide diuretics, although less effective as a monotherapy, act at the distal tubule and lead to sequential blocking of sodium reabsorption when combined with the action of loop diuretics at the ascending loop of Henle and thus allow for enhanced natriuresis. A recent randomized controlled trial comparing the diuretic effects of metolazone, hydrochlorothiazide, and tolvaptan when added to a loop diuretic showed a cumulative urine output of 4.2, 4.3 and 4.2 L respectively over 24 hours compared with 1.2 L using the loop diuretic alone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acetazolamide may be prescribed to counteract the metabolic alkalosis produced by most other diuretics, and in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial, patients who received acetazolamide and IV loop diuretics had an average of 500 mL of additional urine output daily compared to patients who received IV loop diuretics alone. Patients in this trial did not receive thiazide diuretics, so a direct comparison is not possible.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The results of the Diuretic Optimization Strategies Evaluation (DOSE) trial showed no significant difference in symptoms, weight loss, or change in kidney function when IV loop diuretic was administered as a bolus compared with continuous infusion among patients with acute decompensated heart failure. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isolated ultrafiltration (IUF) involves performing ultrafiltration via peripheral IV. Although IUF has been used to treat acute decompensated heart failure and cardiorenal syndrome, the Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial did not demonstrate superiority of IUF over step-wise diuretic titration. IUF was actually associated with worse outcomes. This patient should be optimized with medical management prior to starting more invasive therapies.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics are highly protein-bound, so hypoalbuminemia will decrease the delivery of these drugs to the kidneys. However, albumin infusions have not been shown to effectively augment diuresis in combination with loop diuretics in adult, critically ill patients. </p>\n</div>",
        "references": [
            "De Bruyne LKM: Mechanisms and management of diuretic resistance in congestive heart failure.Postgrad Med J79(931): 268–271, 2003",
            "Wilcox CS, Testani JM, Pitt B: Pathophysiology of diuretic resistance and its implication for the management of chronic heart failure.Hypertension76(4): 1045–1054, 2020",
            "Felker GM, Lee KL, Bull DA, et al: Diuretic strategies in patients with acute decompensated heart failure.N Engl J Med364(9): 797–805, 2011",
            "Bart BA, Goldsmith SR, Lee KL, et al; Heart Failure Clinical Research Network: Ultrafiltration in decompensated heart failure with cardiorenal syndrome.N Engl J Med367(24): 2296–2304, 2012",
            "Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.JACC Heart Fail8(3):157-168, 2020",
            "Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.N Engl J Med387(13):1185-1195, 2022"
        ]
    },
    "36": {
        "question": "<div class=\"qtext\"><p>A 37-year-old man with recently diagnosed HIV presents to the hospital with altered mental status and headache. Prior to admission, he was prescribed abacavir, dolutegravir, and lamivudine. In the emergency department, he is empirically treated with ceftriaxone, ampicillin, vancomycin, and acyclovir. MRI of the brain on hospital day 4 shows toxoplasmosis, at which point inpatient medications are changed to sulfadiazine and pyrimethamine. Mental status and headache have since improved, but the patient currently reports poor appetite.</p>\n<p>BP is 108/66 mm Hg, and heart rate is 92/min. Physical examination reveals cachexia. Heart, lungs, and abdomen are normal. The patient is alert to directed questioning and displays no focal neurologic deficits. </p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Hospital Day 7</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span><strong>Serum</strong></span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  CD4 T-lymphocyte count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                51/μL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                530–1570 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.3 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span><strong><span style=\"\">Urine</span> \n                </strong></span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Blood \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Nitrite \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Leukocyte esterase \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  pH \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Protein \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Trace \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative \n            </td>\n</tr>\n</tbody>\n</table>\n<p>Spun urine sediment is notable for many of the elements seen below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b1q34.png\" width=\"60%\"/><br/>\n<figcaption><em>Light microscopy, 400×magnification. Image courtesy of Kenneth Ralto, MD. University of Massachusetts Medical School.</em></figcaption>\n</figure>\n<p><strong>Which of the following is the MOST likely cause of increased creatinine?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Vancomycin"
            },
            {
                "label": "B.",
                "text": "Acyclovir"
            },
            {
                "label": "C.",
                "text": "HIV-associated nephropathy"
            },
            {
                "label": "D.",
                "text": "Dolutegravir"
            },
            {
                "label": "E.",
                "text": "Sulfadiazine"
            }
        ],
        "correct_answer": "Sulfadiazine",
        "abim_content_category": "Acute Kidney Disease and ICU nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sulfadiazine toxicity causing crystal-induced AKI is the most likely etiology of this patient’s AKI. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has evidence of sulfa crystals in his urine sediment and has crystal-induced AKI from sulfadiazine. Sulfa crystals can take different forms, including needle-shaped crystals or crystals resembling a “shock of wheat,” as in this case. Although most sulfonamide antibiotics can form crystals, sulfadiazine has a particularly low solubility in acidic urine and is associated with a high rate of AKI due to precipitation in the acidic environment of the distal tubule, causing intratubular obstruction. AKI has also been attributed to tubule cytotoxicity caused by crystal-mediated inflammation. Patients with volume depletion are particularly at risk. Treatment involves sodium bicarbonate infusion to increase urine flow rate and to alkalinize the urine to achieve urine pH ≥7.5. If AKI does not resolve with urinary alkalinization and IV fluids, then the drug should be discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acyclovir can also cause crystal-induced AKI, but acyclovir crystals are needle-shaped. The solubility of acyclovir is not pH-dependent, and initial therapy for acyclovir crystal-induced AKI is isotonic IV fluids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vancomycin toxicity is unlikely with only 4 days of vancomycin exposure and typically presents as acute tubular necrosis with granular casts on urine sediment examination, which are not seen here. Alternatively, acute interstitial nephritis has been implicated in some cases.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HIV-associated nephropathy (HIVAN) is a podocytopathy that affects patients with undiagnosed or poorly controlled HIV and is characterized by high-grade proteinuria, which was not seen in this patient. Kidney biopsy findings include podocyte hypertrophy with de-differentiation (“pseudocrescents”), collapsing glomerulopathy, and tubulocystic dilation. HIVAN is no longer common in most countries with access to antiretroviral therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Some medications commonly used in patients with HIV, notably dolutegravir and trimethoprim, may increase serum creatinine without a decrease in GFR due to inhibition of tubular creatinine secretion through organic cation transporters. This effect would typically lead to a 10%–30% rise in creatinine but would not explain the stage 3 AKI seen in this patient.</p>\n</div>",
        "references": [
            "Daudon M, Frochot V, Bazin D, Jungers P: Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment.Drugs78(2): 163–201, 2018",
            "Perazella MA, Herlitz LC: The crystalline nephropathies.Kidney Int Rep2021, 6(12): 2942–2957, 2021",
            "Gameiro J, Jorge S, Lopes JA: HIV and renal disease: a contemporary review.Int J STD AIDS29(7): 714–719, 2018"
        ]
    },
    "37": {
        "question": "<div class=\"qtext\"><p>A 71-year-old man with a history of ESRD secondary to diabetes and hypertension presents for follow-up 6 months after a deceased donor kidney transplant. He received immunosuppression induction with thymoglobulin and had immediate graft function, with a nadir serum creatinine level of 1.1 mg/dL and nadir urine protein-to-creatinine ratio of 0.1 mg/mg (reference range, &lt;0.2). Medications include tacrolimus 3 mg twice daily, mycophenolate mofetil 1 g twice daily, prednisone 5 mg daily, amlodipine 10 mg daily, and carvedilol 12.5 mg twice daily. The patient is adherent to medications and a 2 g/day sodium diet but reports his home BP has averaged 160/94 mm Hg for the last several weeks. </p>\n<p>On physical examination, BP is 164/96 mm Hg, which is confirmed with a repeat measurement after several minutes of resting in a quiet place. Cardiac and respiratory examinations are unremarkable. He has a well-healed surgical incision and a nontender allograft in the right lower quadrant. He has 1–2+ edema of his lower extremities bilaterally. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                139 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                103 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Tacrolimus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5–15, &gt;3 months after transplantation\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for protein, WBCs, and RBCs.</p>\n<p><strong>In addition to optimization of his BP regimen, which ONE of the following is the MOST appropriate next step in diagnosis or management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Duplex Doppler kidney ultrasound"
            },
            {
                "label": "B.",
                "text": "Prescribe IV methylprednisolone"
            },
            {
                "label": "C.",
                "text": "Kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Increase tacrolimus to 4 mg twice daily"
            },
            {
                "label": "E.",
                "text": "Prescribe 24-hour ambulatory blood pressure monitoring"
            }
        ],
        "correct_answer": "Duplex Doppler kidney ultrasound",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in this patient with post-transplant hypertension, hypokalemia, and elevated total CO<sub>2</sub> would be transplant kidney ultrasound with duplex Doppler study.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertension after kidney transplantation is common, with overall prevalence, defined as use of antihypertensive agents, as high as 85%. Risk factors for post-transplant hypertension include pretransplant hypertension, elevated body mass index, male sex, African-American race, and older donor age. Transplant-specific risk factors include delayed graft function, calcineurin inhibitor and steroid use, acute rejection, recurrent kidney disease, and post-transplant proteinuria. Transplant renal artery stenosis (TRAS) is the most common and potentially curable cause of secondary hypertension after kidney transplantation, accounting for 1%–5% of post-transplant hypertension and affecting up to 23% of kidney transplant recipients in total.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TRAS usually occurs between 3 months and 2 years after transplant but can present at any time. It typically presents as worsening hypertension with increased renin, angiotensin II, and aldosterone production and manifesting with hypokalemia, metabolic alkalosis, and decreased kidney function with reduced perfusion pressure, especially in the setting of ACEI or ARB use. Although arterial bruit may suggest TRAS, it is neither a sensitive nor a specific finding. TRAS can be diagnosed by Doppler ultrasound of the kidney or with CT or MR angiography. Definitive diagnosis and treatment can be attempted with renal angiography. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with a therapeutic tacrolimus level and benign urinalysis, suspicion for acute rejection is not high enough to warrant empiric IV steroids. Similarly, although allograft biopsy is generally warranted for the evaluation of allograft dysfunction, the presence of worsening hypertension, hypokalemia, metabolic alkalosis, and a mild increase in the serum creatinine suggest TRAS as the most likely diagnosis. This patient’s tacrolimus trough level is within the goal range for his allograft vintage, so increasing the tacrolimus dose is not indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although ambulatory BP monitoring can be a useful tool if white coat or masked hypertension are suspected, this patient’s home and clinic BP readings are concordant, so this technique would not be expected to advance his diagnosis or management.</p>\n</div>",
        "references": [
            "Weir MR, Burgess ED, Cooper JE, et al: Assessment and management of hypertension in transplant patients.J Am Soc Nephrol26(6): 1248–1260, 2015",
            "Aziz F, Clark D, Garg N, et al: Hypertension guidelines: how do they apply to kidney transplant recipients?Transplant Rev (Orlando)32(4): 225–233, 2018",
            "Chen W, Kayler LK, Zand MS, et al: Transplant renal artery stenosis: clinical manifestations, diagnosis and therapy.Clin Kidney J8(1): 71–78, 2015",
            "Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis.J Am Soc Nephrol15(1): 134–141, 2004"
        ]
    },
    "38": {
        "question": "<div class=\"qtext\"><p>A 31-year-old woman with ESRD due to lupus nephritis presents to the transplant clinic with a rash and diffuse body aches 2 weeks after her second kidney transplant.</p>\n<p>Three years ago, her first kidney transplant was complicated by severe, early acute cellular rejection. She was treated with pulse glucocorticoids and anti-thymocyte globulin, but had minimal recovery of kidney function, and 4 months after transplant, restarted HD. </p>\n<p>Two weeks ago, she received her second kidney transplant. Pre-transplant calculated panel of reactive antibodies (cPRA) was 98%. The donor was positive for CMV immunoglobulin G (IgG), whereas the recipient was negative (CMV D+R-). Induction immunosuppression included anti-thymocyte globulin, followed by maintenance immunosuppression with tacrolimus, mycophenolate, and prednisone. She was discharged with a serum creatinine of 0.9 mg/dL.</p>\n<p>Two weeks later, she presents with pruritic rash of the trunk and extremities and diffuse arthralgias of the shoulders, hips, and jaw. </p>\n<p>On examination, temperature is 38.5°C, and BP is 123/68 mm Hg. She appears uncomfortable, with tenderness to palpation and decreased range of motion in both shoulders and hips, but no redness or warmth over the affected joints. A diffuse maculopapular rash is present. The transplant incision is healing appropriately.</p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12,400/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>414,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>102 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>32 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  eGFR</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>52 mL/min/1.73 m<sup>2</sup></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≥60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Erythrocyte sedimentation rate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>48 mm/h</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Tacrolimus trough </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11.2 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.0–15.0 (0–3 months after transplantation)</p>\n<p> </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows 1+ protein, trace blood, negative glucose, negative leukocyte esterase, and negative nitrite. </p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s symptoms?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cytomegalovirus infection"
            },
            {
                "label": "B.",
                "text": "Acute allograft rejection"
            },
            {
                "label": "C.",
                "text": "Serum sickness"
            },
            {
                "label": "D.",
                "text": "Graft-versus-host disease"
            },
            {
                "label": "E.",
                "text": "Systemic lupus erythematosus"
            }
        ],
        "correct_answer": "Serum sickness",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has serum sickness, a type III hypersensitivity reaction caused by deposition of preformed antigen-antibody immune complexes.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Serum sickness induced by antibodies to specific epitopes of anti-thymocyte globulin (ATG) is an important side effect of ATG, affecting up to 10% of ATG-treated kidney transplant recipients. ATG-induced serum sickness typically manifests days to a few weeks following ATG exposure and commonly presents with fever, joint pain (including jaw pain), and a pruritic rash. Hypocomplementemia is seen in some cases. This patient’s prior exposure to ATG, temporal association with recent ATG treatment, and clinical manifestations are all consistent with a diagnosis of serum sickness. Treatment includes supportive care, and in severe cases, glucocorticoids and/or plasma exchange.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because donor CMV serology is positive and recipient CMV serology is negative, this patient is at  increased risk for primary CMV infection. Transplant recipients at risk for CMV should receive either antiviral prophylaxis or preemptive CMV screening. It is uncommon for CMV infection to develop in the first few weeks after transplant and typically occurs several months after transplant, often after prophylaxis is completed. Although CMV can cause disease of any organ system, common clinical manifestations include fever, fatigue, diarrhea, and leukopenia. The timing and manifestations in the case here is more consistent with serum sickness than CMV infection. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has AKI, and acute rejection is part of the differential diagnosis of graft dysfunction in the early post-transplant period, particularly in this patient who is highly sensitized and has a history of rejection in the past. However, although rejection may cause graft dysfunction, it is not likely to manifest with a diffuse rash and joint pains.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Graft-versus-host disease can present with rash, kidney and liver dysfunction, diarrhea, and cytopenias. However, early acute graft-versus-host disease is a very rare complication in kidney transplantation and much less likely than serum sickness. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recurrence of systemic lupus erythematosus (SLE) could present with skin, joint, and kidney manifestations, including hypocomplementemia. However, the character of the rash and the timing of the presentation shortly after exposure to anti-thymocyte globulin is less suggestive of SLE than serum sickness.</p>\n</div>",
        "references": [
            "Bamoulid J, Staeck O, Crepin T, et al: Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.Nephrol Dial Transplant32: 1601–1608, 2017",
            "Couvrat-Desvergnes G, Salama A, Le Berre L, et al: Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival.J Clin Invest125(12): 4655–4665, 2015"
        ]
    },
    "39": {
        "question": "<div class=\"qtext\"><p>A 20-year-old man presents to clinic with AKI and weight loss following his second kidney transplant. He has a history of vesicoureteral reflux and received his first kidney transplant at age 5. He developed chronic antibody-mediated rejection and progressive graft dysfunction and received a second living donor kidney transplant 10 months ago. Calculated panel of reactive antibodies was 94% prior to transplant, and he received induction immunosuppression with anti-thymocyte globulin. The donor was seropositive for EBV and CMV, whereas the recipient was seronegative for EBV and seropositive for CMV. He had immediate graft function, with baseline serum creatinine level of 0.9 mg/dL. His current medications include tacrolimus, mycophenolate, and prednisone.   </p>\n<p>Today, he notes an unintentional 7-kg weight loss over the last 6 weeks despite maintaining stable oral intake. Additional symptoms include low-grade fever and fatigue. </p>\n<p>On examination, temperature is 37.6°C, heart rate is 90/min, and BP is 115/75 mm Hg. His allograft is nontender. The remainder of the examination is unremarkable. </p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15,300/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>398,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Tacrolimus trough</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.5 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.0–15.0 (0–3 months after transplantation)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  CMV DNA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  EBV DNA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Positive</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis demonstrates 1+ protein, 1+ blood, and negative glucose. Urine microscopy shows 10–15 WBCs/HPF and 3–5 RBCs/HPF. </p>\n<p>A CT scan of the chest shows mediastinal and axillary lymphadenopathy.</p>\n<p>Kidney biopsy (see image) demonstrates a marked lymphocytic infiltrate of B-cell lineage with monomorphic appearance, with positive lymphocytic staining for EBV early RNA. C4d staining is negative.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b1q40.png\" width=\"75%\"/><br/>\n<figcaption><em>Image courtesy of Kirk Foster, MD. University of Nebraska Medical Center.</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Reduce immunosuppression"
            },
            {
                "label": "B.",
                "text": "Prescribe nivolumab"
            },
            {
                "label": "C.",
                "text": "Prescribe valganciclovir"
            },
            {
                "label": "D.",
                "text": "Prescribe methylprednisolone"
            },
            {
                "label": "E.",
                "text": "Initiate plasmapheresis and IV immunoglobulin"
            }
        ],
        "correct_answer": "Reduce immunosuppression",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has post-transplant lymphoproliferative disease (PTLD), which is initially treated with a reduction of immunosuppression.   </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PTLD is a lymphoproliferative disorder that is variable in presentation, ranging from a mild lymphocytic infiltrate to lymphoma, most commonly diffuse large B-cell lymphoma. PTLD can be polymorphic or monomorphic and is commonly provoked by EBV-infected B cells that can proliferate unchecked due to immunosuppression. EBV-seronegative recipients who receive a kidney from an EBV-seropositive donor are at higher risk of PTLD. Clinical manifestations may include nonspecific B symptoms (weight loss, fever, night sweats) with lymphadenopathy and organ dysfunction (e.g., brain, kidney, gastrointestinal tract), depending on the site involved. Initial treatment involves significant immunosuppression reduction, which in many cases leads to resolution of the infiltrates. Subsequent therapy includes rituximab and other chemotherapy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Immune checkpoint inhibitors, such as nivolumab, are used to treat a variety of malignancies. When used in the post-transplant setting, they significantly increase the risk of acute rejection. Checkpoint inhibitors are not used in the management of PTLD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Valganciclovir is an antiviral agent routinely used in the post-transplant setting for both prophylaxis and treatment of CMV. This patient does not have detectable serum CMV DNA, and the kidney biopsy findings are not consistent with CMV nephritis. Therefore, valganciclovir is not likely to be useful in this context.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glucocorticoids are used to treat acute rejection and other kidney inflammatory conditions (e.g., acute interstitial nephritis, vasculitis). Although this patient has an extensive interstitial lymphocytic infiltrate, the appearance is characteristic of PTLD rather than acute rejection. As a result, the mainstay of therapy is reducing immunosuppression and not intensifying immunosuppression with steroids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasmapheresis and IV immunoglobulin (IVIG) are routinely used to treat antibody-mediated rejection (ABMR), which is a common cause of acute allograft dysfunction. Although this patient is highly sensitized, the biopsy findings do not support a diagnosis of ABMR. Characteristic findings of ABMR include glomerulitis, peritubular capillaritis, and positive C4d staining, none of which is seen here. Plasmapheresis and IVIG are not used to treat PTLD.</p>\n</div>",
        "references": [
            "Al-Adra D, Al-Qaoud T, Fowler K, Wong G:De novomalignancies after kidney transplantation.Clin J Am Soc Nephrol17(3): 434–443, 2022",
            "Dharnidharka V, Araya CE: Post-transplant lymphoproliferative disease.Pediatr Nephrol24(4): 731–736, 2009"
        ]
    },
    "40": {
        "question": "<div class=\"qtext\"><p>A 55-year-old man with ESRD treated with thrice weekly in-center HD via a right internal jugular tunneled dialysis catheter presents to the HD unit with 1 day of fever and chills. His past medical history includes type 2 diabetes and hypertension.</p>\n<p>On examination, his BP is 132/84 mm Hg, heart rate is 86/min, and temperature is 39.1°C. There is no erythema, purulence, or tenderness at the catheter exit site or along the tunnel. The rest of the physical examination is unremarkable.  </p>\n<p>Two sets of blood cultures are obtained from the HD circuit. Empiric antibiotic therapy with vancomycin IV is begun after obtaining blood cultures. Within 24 hours, both culture bottles grow coagulase-negative <em>Staphylococcus</em>. At 48 hours, he returns for his next dialysis session. His BP is 140/83 mm Hg, heart rate is 75/min, and temperature is 37.5°C. He reports he feels well and hasn’t been febrile in 24 hours.</p>\n<p><strong>In addition to continuing vancomycin IV, which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Exchange catheter over guidewire"
            },
            {
                "label": "B.",
                "text": "Remove catheter and replace after 2-3 days"
            },
            {
                "label": "C.",
                "text": "Prescribe mupirocin at the exit site"
            },
            {
                "label": "D.",
                "text": "Change catheter insertion site"
            },
            {
                "label": "E.",
                "text": "No additional management"
            }
        ],
        "correct_answer": "Exchange catheter over guidewire",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with coagulase-negative <em>Staphylococcus</em> bacteremia and no signs of a tunnel infection, the most appropriate next step is catheter exchange over a guidewire and continuation of antibiotics.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Central line–associated bloodstream infections (CLABSI) are a frequently encountered complication for patients receiving HD via a tunneled dialysis catheter. Management includes source control and antibiotic therapy directed against the offending pathogen. In hemodynamically stable patients with coagulase-negative <em>Staphylococcus</em> who are afebrile after 48 hours, catheter exchange over a guidewire is an appropriate strategy to achieve source control. This treatment strategy aims to balance the risks of persistent infection with the risks of obtaining a new vascular access.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Immediate removal of the catheter is indicated if a patient has severe sepsis, suspected metastatic seeding (i.e., endocarditis), or purulence from the exit site. Catheter removal is also indicated in patients with <em>Staphylococcus aureus</em>, <em>Candida</em>, or <em>Pseudomonas</em> bloodstream infection, as salvaging the catheter without infection recurrence is unlikely. Optimally, patients infected with these organisms also receive a “line holiday” of 2–3 days between catheter removal and replacement, such that the biofilm containing the pathogen is allowed to dissolve, increasing the likelihood of pathogen clearance. Such a delay is usually not required for patients with asymptomatic <em>Staphylococcus epidermidis</em> bacteremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">With either guidewire exchange or removal, the crux of treatment concerns the bacterial biofilm that coats the catheter. This is the major source of CLABSI, and without removal, the risk of metastatic seeding such as infective endocarditis rises. Thus, administration of systemic antibiotics alone would not be an appropriate course of action, as source control is needed in all cases of CLABSI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Antibiotic locks combined with systemic antibiotics are an alternative approach for biofilm eradication and catheter salvage. The effectiveness of this strategy varies with the pathogen. In a retrospective study examining antibiotic lock and systemic antibiotic administration in 98 patients with CLABSI, therapeutic failure was more likely with <em>Staphylococcus aureus</em> than with Gram-negative organisms or coagulase-negative <em>Staphylococcus.</em></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Changing the catheter insertion site to a different anatomic location or using the same vessel with a different exit site is not typically required in the absence of a local tunnel infection.</p>\n<p>Mupirocin ointment may be applied to the exit site in cases of uncomplicated exit site infections without bacteremia but would not allow source control in cases of CLABSI such as this patient.</p>\n</div>",
        "references": [
            "Allon M: Dialysis catheter-related bacteremia: treatment and prophylaxis.Am J Kidney Dis44(5): 779–791, 2004",
            "Fernandez-Hidalgo N, Almirante B, Calleja R, et al: Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.J Antimicrob Chemother57(6): 1172–1180, 2006",
            "Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.Clin Infect Dis49(1): 1–45, 2009",
            "Lok CE, Mokrzycki MH: Prevention and management of catheter-related infection in hemodialysis patients.Kidney Int79(6): 587–598, 2011"
        ]
    },
    "41": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man with a past medical history of diet-controlled diabetes and alcohol use disorder presents to the emergency department with 3 days of abdominal pain, nausea, and vomiting. He has been unable to eat anything during this time. He states that he has not consumed alcohol for several years. He takes no medications. </p>\n<p>He is treated with oxygen 2 L/min via nasal cannula and 0.9% saline 2 L IV.</p>\n<p>On examination, he is an ill-appearing man in moderate distress. His BP is 100/54 mm Hg, and his pulse is 105/min. His abdomen is diffusely tender with decreased bowel sounds without rebound tenderness. The remainder of his examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>132 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.3 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.2 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Arterial blood gas </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.21</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   PCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>19 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the BEST description of his acid-base disorder?</strong>  </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Anion gap metabolic acidosis and metabolic alkalosis"
            },
            {
                "label": "B.",
                "text": "Anion gap metabolic acidosis and non-anion gap metabolic acidosis"
            },
            {
                "label": "C.",
                "text": "Anion gap metabolic acidosis and respiratory alkalosis"
            },
            {
                "label": "D.",
                "text": "Anion gap metabolic acidosis and respiratory acidosis"
            },
            {
                "label": "E.",
                "text": "Anion gap metabolic acidosis"
            }
        ],
        "correct_answer": "Anion gap metabolic acidosis and non-anion gap metabolic acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a combined metabolic anion gap and non-anion gap metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In a patient with an acid-base disorder, the first step is to determine whether the patient has an acidemia or an alkalemia. The pH is 7.21, indicating acidemia. His anion gap is Na – (HCO<sub>3</sub> + Cl) = 132 – (110 + 6) = 16 mEq/L, so he has an anion gap metabolic acidosis. Note that in this discussion, serum bicarbonate (HCO<sub>3</sub>) is used interchangeably with serum total CO<sub>2</sub>.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step is to determine whether respiratory compensation is appropriate, using Winter’s formula:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Expected PCO<sub>2</sub> = (1.5 × total CO<sub>2</sub>) + 8 ± 2 = (1.5 × 6) + 8 ± 2 = 17 ± 2 mm Hg</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because his measured pCO<sub>2 </sub>is equal to his expected pCO<sub>2</sub>, his respiratory compensation is appropriate, and he does not have a concomitant respiratory acid-base disorder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The final step is to determine whether there is a secondary metabolic process occurring that may be obscured by the metabolic anion gap acidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The delta-delta (or delta gap) calculation is used to make this determination, as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A normal anion gap is 6‒10 mEq/L, or approximately twice the albumin in mEq/L; this patient’s measured anion gap is 16 mEq/L. His expected anion gap based on the serum albumin is 8‒9 mEq/L. Thus, he has ~8 mEq/L of unmeasured anions, which should be matched by an equivalent decrease in his total CO<sub>2</sub>. The total CO<sub>2</sub> actually decreased from 24 to 6 = 18 mEq/L. The ratio of the change in anion gap (∆AG) to the change in bicarbonate (∆HCO<sub>3</sub>) in a simple anion gap metabolic acidosis should be 0.7‒1.7. In this case, the ∆AG/∆HCO<sub>3</sub> ratio is 8/18 = 0.4.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The interpretation of this low ratio is that the serum total CO<sub>2</sub> decreased much more than expected from a single, simple anion gap metabolic acidosis. This decrease could be caused by either an additional, normal or non-anion gap (hyperchloremic) metabolic acidosis or a respiratory alkalosis. The initial calculation of expected pCO<sub>2</sub> based on Winter’s formula excluded a concomitant respiratory disorder, so a non-anion gap metabolic acidosis must coexist with the anion gap metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The etiology of his anion gap metabolic acidosis is likely starvation ketoacidosis, which can occur in patients who have been fasting. Volume resuscitation with a fluid that does not contain bicarbonate, such as 0.9% saline, can cause a concomitant hyperchloremic acidosis, primarily by dilution of serum bicarbonate.</p>\n</div>",
        "references": [
            "Rewers A, Kuppermann N, Stoner MJ, et al: Effects of fluid rehydration strategy on correction of acidosis and electrolyte abnormalities in children with diabetic ketoacidosis.Diabetes Care44(9): 2061‒2068, 2021",
            "Palmer BF, Clegg DJ: Starvation ketosis and the kidney.Am J Nephrol52(6): 467-478, 2021",
            "Palmer BF, Clegg DJ: Electrolyte and acid-base disturbances in patients with diabetes mellitus. N Engl J Med373(6): 548-559, 2015",
            "Kraut JA, Madias NE: Differential diagnosis of nongap metabolic acidosis: value of a systematic approach.Clin J Am Soc Nephrol7(4): 671-679, 2012",
            "Palmer BF, Clegg DJ: Hyperchloremic normal gap metabolic acidosis.Minerva Endocrinol44(4): 363-377, 2019"
        ]
    },
    "42": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man with CKD stage G3b/A1 and Child-Turcotte-Pugh class B cirrhosis is admitted to the hospital for management of an 8-cm unresectable hepatocellular carcinoma. On hospital day 2, he successfully undergoes a trans-arterial chemoembolization (TACE) procedure using doxorubicin drug-eluting beads. During the procedure, he received 107 mL of intra-arterial iohexol. His procedural and postprocedural course were unremarkable. On hospital day 4, he feels well, and his vital signs and examination are unchanged from baseline. Urine output is 1 L/24 h.</p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<p><strong>Before Procedure</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<p><strong>36 Hours After Procedure</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>36 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>47</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–1.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>142 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>177</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Prothrombin time</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27 s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11–13 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.9 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.8</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>A representative phase-contrast photomicrograph of the postprocedure urine sediment is provided below:</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q7.png\" width=\"50%\"/><br/>\n<figcaption><em>Image courtesy of Giovanni Fogazzi, MD</em>\n</figcaption>\n</figure>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hepatorenal syndrome"
            },
            {
                "label": "B.",
                "text": "Contrast-associated AKI"
            },
            {
                "label": "C.",
                "text": "Doxorubicin nephrotoxicity"
            },
            {
                "label": "D.",
                "text": "Atheroembolic disease"
            },
            {
                "label": "E.",
                "text": "Volume depletion"
            }
        ],
        "correct_answer": "Contrast-associated AKI",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s AKI is contrast-associated AKI (CA-AKI).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Intravascular administration of iodinated contrast agents may be associated with nephrotoxicity, primarily attributed to acute tubular necrosis (ATN). Mechanisms of tubular injury are incompletely understood and may include renal vasoconstriction, leading to medullary hypoxemia and dysregulation of nitric oxide, prostaglandin, endothelin, and adenosine. Iodinated contrast agents may also be directly toxic to tubular cells. In most cases, serum creatinine increases within 48 hours of exposure to contrast and typically stabilizes and improves within 3‒7 days. Most cases are nonoliguric. Urine sediment is often consistent with ATN, showing renal tubular epithelial (RTE) cells (arrows in image), RTE casts (arrowhead in image), or “muddy brown” granular casts. The RTE cells can be distinguished by their large central nuclei and cytoplasmic granules. Risk factors for CA-AKI include CKD (particularly eGFR &lt;30 mL/min/1.73 m<sup>2</sup> and diabetic nephropathy), proteinuria, higher contrast volumes, and prerenal azotemia (cirrhosis, hypovolemia, NSAIDs, hypotension, sepsis, etc.). Intra-arterial administration, compared with IV, appears to increase the risk of AKI. Low-osmolal (iohexol, ioversal, iopamidol) and iso-osmolal agents (iodixanol) are preferable to older hyper-osmolal agents that are rarely used today. CA-AKI is often associated with fractional excretion of sodium &lt;1%, attributed to renal arteriolar vasoconstriction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hepatorenal syndrome is unlikely. The patient is nonoliguric, and although mild hepatic injury after TACE is relatively common, severe decline in liver function with immediate consequences for renal hemodynamics is rare.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Doxorubicin nephrotoxicity is rare, usually manifesting as minimal change disease or collapsing focal segmental glomerulosclerosis. Serum levels of doxorubicin are substantially lower when deposited directly in tissues as intra-arterial drug-eluting beads.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Atheroembolic disease usually manifests as a subacute decline in kidney function, often weeks after arterial catheterization, in a “step-wise” pattern. Severe atheroembolization may present with cutaneous manifestations such as livedo reticularis and necrotic digits from digital arterial atheroembolism, as well as mesenteric ischemia, acute pancreatitis, and central scotoma from retinal artery occlusion. Some cases can be accompanied by peripheral eosinophilia or hypocomplementemia. The tempo of AKI and lack of other systemic manifestations in this patient are inconsistent with atheroembolic disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Volume depletion as a cause of prerenal AKI is not supported by the clinical history or the urine sediment findings.</p>\n</div>",
        "references": [
            "Heyman SN, Rosenberger C, Rosen S: Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy.Nephrol Dial Transplant20(Suppl 1): i6‒i11, 2005",
            "Novak JE, Handa R: Contrast nephropathy associated with percutaneous coronary angiography and intervention.Cardiol Clin37(3): 287‒296, 2019",
            "Heinrich MC, Häberle L, Müller V, Bautz, W, Uder M: Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.Radiology250(1): 68‒86, 2009",
            "Facciorusso A: Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art.World J Gastroenterol24(2): 161‒169, 2018",
            "Mohammed N, Goldstein J, Schiff J, John R: Collapsing glomerulopathy following anthracycline therapy.Am J Kidney Dis61(5): 778‒781, 2013",
            "Scolari F, Tardanico R, Zani R, Pola A, et al: Cholesterol crystal embolism: a recognizable cause of renal disease.Am J Kidney Dis36(6): 1089‒1109, 2000"
        ]
    },
    "43": {
        "question": "<div class=\"qtext\"><p>A 59-year-old woman with CKD stage G3b, atrial fibrillation, prior cardioembolic stroke, hypertension, and type 2 diabetes is admitted to the hospital with AKI. Her baseline creatinine has been 1.3 mg/dL (reference range, 0.5–1.1) for several years and is now 3.6 mg/dL. Urinalysis reveals 3+ blood and 1+ protein, and urine microscopy shows &gt;50 isomorphic RBCs/hpf, no WBCs, and no cellular casts. Serologic evaluation, including ANA, ANCA, anti-GBM antibodies, anti-double-stranded DNA antibodies, and C3 and C4 complement, is negative or normal.</p>\n<p>A kidney biopsy is performed after being delayed several days because of anticoagulation (international normalized ratio [INR] on admission 6.1, target 2–3). The biopsy reveals numerous RBC casts obstructing tubular lumens and no other major abnormalities by light microscopy or IF.</p>\n<p><strong>Which ONE of the following is the BEST next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe cyclophosphamide"
            },
            {
                "label": "B.",
                "text": "Resume warfarin with goal INR of 1.5-2.5"
            },
            {
                "label": "C.",
                "text": "Change warfarin to rivaroxaban"
            },
            {
                "label": "D.",
                "text": "Discontinue anticoagulation"
            },
            {
                "label": "E.",
                "text": "Prescribe mycophenolate"
            }
        ],
        "correct_answer": "Change warfarin to rivaroxaban",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with anticoagulant-related nephropathy (ARN), the most appropriate next step is to change warfarin to rivaroxaban.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ARN is diagnosed in patients receiving therapeutic anticoagulation, leading to glomerular hemorrhage and obstruction of renal tubules by RBCs, and is most often seen in the setting of supratherapeutic INR. Warfarin is the anticoagulant most commonly associated with this condition, but this observation is likely biased by the longer history of warfarin use. Additional risk factors for ARN include underlying CKD, diabetes, and conditions that can interfere with the integrity of the GBM, including thin basement membrane disease, glomerulonephritis, and nephrotic syndrome.</p>\n<p>The most appropriate next step in management would be to change this patient to a direct-acting oral anticoagulant such as rivaroxaban, as ongoing anticoagulation is required, and anticoagulation intensity may be more stable with these agents. It is worth emphasizing, however, that ARN has been observed with most anticoagulants, and clinical evidence and guidelines are still evolving on the appropriate management of this condition. Discontinuing anticoagulation or resuming warfarin with a lower INR goal would not be appropriate, as this patient is at high risk for recurrent cardioembolic stroke. Depending on the patient’s goals for therapy and ability to comply with dietary restrictions and regular monitoring, another option could be to resume warfarin to keep INR in the therapeutic range. A recent randomized trial found that patients with ESRD receiving HD who had atrial fibrillation experienced fewer major adverse cardiovascular events and less major bleeding when prescribed rivaroxaban compared with warfarin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ARN would not be expected to respond to immunosuppression, so initiating cyclophosphamide or mycophenolate would not be the next best step in management.</p>\n</div>",
        "references": [
            "Brodsky S, Eikelboom J, Hebert LA: Anticoagulant-related nephropathy.J Am Soc Nephrol29(12): 2787–2793, 2018",
            "Borinelli de Aquino Moura K, Prates Behrens PM, Pirolli R, et al: Anticoagulant-related nephropathy: systematic review and meta-analysis.Clin Kidney J12(3): 400–407, 2019",
            "Harel Z, McArthur E, Jeyakumar N, et al: The risk of acute kidney injury with oral anticoagulants in elderly adults with atrial fibrillation.Clin J Am Soc Nephrol16(10): 1470–1479, 2021",
            "De Vriese AS, Caluwe R, van Der Meersch H, de Boeck K, de Bacquer D: Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial.J Am Soc Nephrol32(6): 1474–1483, 2021"
        ]
    },
    "44": {
        "question": "<div class=\"qtext\"><p>A 54-year-old woman is evaluated for progressive cramping of her posterior legs with ambulation. The pain resolves with rest. Her past medical history includes hypertension, which was diagnosed at age 23. Family history is negative for hypertension. She does not smoke, and her medications include hydrochlorothiazide and lisinopril. </p>\n<p>On examination, her BP is 102/64 mm Hg in the left arm and 168/98 mm Hg in the right arm. Her height is 142 cm. She is in no distress, and appearance is normal other than short stature. She has a 4/6 systolic ejection murmur over her aortic valve and a continuous murmur over her abdomen. Her femoral and pedal pulses are diminished. No ulceration is appreciated over the lower extremities, and her digits appear normal. Strength in her quadriceps and hamstrings are 5/5 bilaterally, and there is no tenderness to palpation.</p>\n<p>Her ankle-brachial index is 0.60 on the right and 0.53 on the left (reference range, 1–1.4). Chest x-ray is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q11.png\" width=\"48%\"/>\n<p><em>Image courtesy of Mark S. Parker MD FACR, Virginia Commonwealth University Department of Radiology, Thoracic Imaging Case of the Week July 23–July 30, 2010.</em></p>\n<p><strong> </strong></p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></figure></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Supravalvular aortic stenosis"
            },
            {
                "label": "B.",
                "text": "Coarctation of the aorta"
            },
            {
                "label": "C.",
                "text": "Thromboangiitis obliterans"
            },
            {
                "label": "D.",
                "text": "Aortic dissection"
            },
            {
                "label": "E.",
                "text": "Renal artery stenosis"
            }
        ],
        "correct_answer": "Coarctation of the aorta",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has coarctation of the aorta.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although coarctation of the aorta is congenital and usually diagnosed in childhood, and even prenatally, patients may occasionally go undiagnosed into adulthood. Adults most commonly present with hypertension and “bounding pulses” proximal to the coarctation (the right arm) and hypotension and diminished pulses distal to the coarctation (the left arm and legs), and even leg claudication if ischemia ensues. Coarctation can be diagnosed by the classic radiographic findings of rib notching, which occurs when collateral circulation erodes the inferior surface of the third through the eighth posterior ribs. Also visible is the “sign of 3,” which refers to the indentation of the aortic wall at the site of the coarctation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertension of the upper limbs in coarctation of the aorta is multifactorial, due to both obstruction of flow and increased renin-angiotensin-aldosterone activity from relative renal hypoperfusion. Pressures in the lower extremities are low or difficult to obtain. There may be a delayed pulse in the femoral artery compared with the radial arteries. Most commonly, the coarctation arises distal to the left subclavian artery, and BP in the upper extremities will be symmetric; in a minority of cases, the coarctation is more proximal, and asymmetric upper extremity BPs (left less than right) are found. Patients may also experience claudication symptoms, which are typically bilateral. Coarctation has a strong association with Turner syndrome and should be considered in any hypertensive female of short stature. Other manifestations of Turner syndrome, such as reproductive abnormalities, may not be present due to mosaicism. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thromboangiitis obliterans (TAO) or Buerger disease is an inflammatory disease of medium and small vessels, usually in the extremities, and should also be considered in (usually male) patients experiencing claudication symptoms but who otherwise lack traditional risk factors for atherosclerotic disease. This condition typically presents with digital abnormalities (ulceration or Raynaud phenomena) and has a strong association with tobacco use, both of which are absent in this case. Hypertension is common, but aortic involvement is rare. In older patients with TAO, there may be considerable overlap with atherosclerotic peripheral vascular disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Supravalvular aortic stenosis may present in childhood with a systolic aortic ejection murmur, but upper extremity hypertension would not be expected. Chest x-ray may show cardiomegaly and a dilated ascending aorta but not rib notching. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aortic dissection may be associated with coarctation but presents acutely, usually with “tearing” chest pain that radiates to the back. Chest radiographs most often demonstrate a widened mediastinum. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Abdominal bruits may suggest renal artery stenosis, such as fibromuscular dysplasia, especially in relatively young female patients. Isolated renovascular disease would not be associated with rib notching.</p>\n</div>",
        "references": [
            "Kim YY, Andrade L, Cook SC: Aortic coarctation.Cardiol Clin38(3): 337–351, 2020",
            "Torok RD, Campbell MJ, Fleming GA, Hill KD: Coarctation of the aorta: management from infancy to adulthood.World J Cardiol7(11): 765–775, 2015",
            "Puechal X, Fiessinger J-N: Thromboangiitis obliterans or Buerger’s disease: challenges for the rheumatologist.Rheumatology (Oxford)46(2): 192–199, 2007",
            "Turnbull JM: The rational clinical examination. Is listening for abdominal bruits useful in the evaluation of hypertension?JAMA274(16): 1299–1301, 1995",
            "Pape LA, Awais M, Woznicki EM, et al: Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from the International Registry of Acute Aortic Dissection.J Am Coll Cardiol66(4): 350–358, 2015"
        ]
    },
    "45": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man is evaluated for hypertension and hypokalemia. Hypertension was diagnosed at age 48 years. Past medical history includes peripheral vascular disease, a 60% left renal artery stenosis, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension, with an estimated pulmonary artery systolic pressure of 82 mm Hg (reference range, 8–20 mm Hg). One month ago, he was hospitalized for a COPD exacerbation; a CT scan performed at the time revealed a 1-cm left adrenal nodule and confirmed left renal artery stenosis near the ostium. His medications include lisinopril, amlodipine, labetalol, hydrochlorothiazide, potassium chloride, and inhaled albuterol, ipratropium, and iloprost. </p>\n<p>On examination, BP is 175/76 mm Hg, and heart rate is 84/min. He is a thin man in no distress. Breath sounds are distant, and soft expiratory wheezes are present. Mid-abdominal and femoral bruits are audible on auscultation. There is no peripheral edema.</p>\n<p>Laboratory data measured on the morning of evaluation are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>142 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>97 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.91 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Aldosterone, plasma, supine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27 ng/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤10</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Renin, plasma, supine, normal diet</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.1 ng/mL/h</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–2.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Spironolactone"
            },
            {
                "label": "B.",
                "text": "Eplerenone"
            },
            {
                "label": "C.",
                "text": "Left adrenalectomy"
            },
            {
                "label": "D.",
                "text": "Left renal artery revascularization"
            },
            {
                "label": "E.",
                "text": "Discontinue hydrochlorothiazide"
            }
        ],
        "correct_answer": "Spironolactone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with evidence of long-standing primary aldosteronism (PA) should be treated with spironolactone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PA is suggested by resistant hypertension, especially if accompanied by spontaneous or provoked hypokalemia. Patients with adrenal incidentalomas should also be screened for hormone overproduction including cortisol, catecholamines, and aldosterone as appropriate. Screening is usually done by morning plasma aldosterone concentration-to-renin activity ratio, in which a ratio &gt;20 predicts primary hyperaldosteronism (some experts require absolute aldosterone levels to be &gt;15 ng/dL). Unfortunately, many laboratories have changed from measuring renin activity to renin concentration, which has created confusion in the interpretation of these ratios, with no easy means of translating these previously established values. Moreover, at least one study found that these screening plasma laboratory values are insensitive and recommended a 24-hour urinary aldosterone concentration after sodium loading for more accurate diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Once hyperaldosteronism is confirmed, adrenal vein sampling may be performed in appropriate patients to distinguish between bilateral adrenal hyperplasia and unilateral disease, which is often due to an adrenal adenoma. The specificity of adrenal vein sampling can be improved by performing with cosyntropin infusion and normalizing the aldosterone-to-cortisol ratio. A lateralization ratio &gt;4 suggests a unilateral source, and a ratio &gt;18 suggests an aldosterone-producing adenoma. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If a unilateral source is confirmed, management options include medical and surgical approaches. Surgical management is preferred for patients who are younger and good surgical candidates, in whom marked improvement of BP and cure can be expected with acceptable operative morbidity and mortality risks. Older patients and those with a high operative risk, such as this patient, are managed medically with mineralocorticoid receptor antagonists (MRA). These drugs can reverse findings of end-organ damage, such as albuminuria and cardiac myofibrosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although eplerenone has been associated with less frequent secondary sexual side effects than spironolactone, it has a lower affinity for the mineralocorticoid receptor and therefore is less effective as sole therapy for hypertension in patients with primary hyperaldosteronism. Although eplerenone now has a generic formulation, it remains considerably more expensive than spironolactone. For these reasons, eplerenone should be reserved for patients intolerant of spironolactone. Finerenone, a nonsteroidal MRA effective in patients with diabetes and CKD, has not been adequately studied in patients with PA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has both radiographic and physical examination evidence of anatomic renal artery stenosis (RAS), the suppressed renin level argues against a physiologic contribution. Revascularization is reserved for patients with features such as fibromuscular dysplasia, pulmonary edema, rapidly declining kidney function without an alternative explanation, uncontrolled hypertension, or inability to tolerate medications.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypokalemia is a common side effect of diuretic therapy and may unmask or worsen hypokalemia in PA. Although discontinuation of hydrochlorothiazide may reduce the need for potassium supplementation, the best therapy for this patient is the addition of an MRA.</p>\n</div>",
        "references": [
            "Morimoto R, Omata K, Ito S, Satoh F: Progress in the management of primary aldosteronism.Am J Hypertens31(5): 522–531, 2018",
            "Funder JW, Carey RM, Mantero F et al: The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab101(5): 1889–1916, 2016",
            "Amar L, Lorthioir A, Azizi M, Plouin P-F: Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.Eur J Endocrinol172(3): R125–R129, 2015",
            "Parthasarathy HK, Menard J, White WB, et al: A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.J Hypertens29(5): 980–990, 2011",
            "Cooper CJ, Murphy TP, Cutlip DE, et al: Stenting and medical therapy for atherosclerotic renal-artery stenosis.N Engl J Med370(1): 13–22, 2014",
            "Lai H-C, Lai H-C, Wang K-Y, et al: Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery.Br J Anaesth99(2): 184–190, 2007",
            "Young WF, Stanson AW, Thompson GB, et al: Role for adrenal venous sampling in primary aldosteronism.Surgery136(6): 1227–1235, 2004",
            "Brown JM, Siddiqui M, Calhoun DA, Carey RM, et al: The unrecognized prevalence of primary aldosteronism: a cross-sectional study.Ann Intern Med173(1): 10–20, 2020"
        ]
    },
    "46": {
        "question": "<div class=\"qtext\"><p>A 26-year-old man with a history of minimal change disease (MCD) diagnosed by biopsy 6 months ago presents to clinic for a routine follow-up appointment. </p>\n<p>He was prescribed prednisone 60 mg daily at the time of MCD diagnosis and achieved complete resolution of proteinuria and edema within 2 weeks. He was then given instructions to gradually taper the steroid dosage. At his last clinic visit 1 month ago, he was found to have relapse of proteinuria while taking prednisone 10 mg daily, and his dose was increased back to 60 mg daily.</p>\n<p>He feels well and has no peripheral edema on examination.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.01 mg/mg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Continue prednisone 60 mg daily and reassess in 3 months"
            },
            {
                "label": "B.",
                "text": "Whole exome sequencing"
            },
            {
                "label": "C.",
                "text": "Taper prednisone to 20 mg daily"
            },
            {
                "label": "D.",
                "text": "Repeat kidney biopsy"
            },
            {
                "label": "E.",
                "text": "Rituximab and taper off prednisone"
            }
        ],
        "correct_answer": "Rituximab and taper off prednisone",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in the management of this patient’s steroid-dependent nephrotic syndrome (SDNS) is prescribing rituximab followed by tapering prednisone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis of SDNS is made when relapse of nephrotic syndrome occurs during or within 2 weeks of completing glucocorticoid therapy in a patient who previously achieved remission with high-dose steroids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Often, the next step taken by clinicians in managing SDNS patients is to resume high-dose steroids to achieve remission again. If a repeat prednisone taper is attempted, it is highly likely that another relapse will occur. There are several medication options that are effective in SDNS and may allow reduced exposure to or elimination of glucocorticoids, including rituximab, cyclophosphamide, calcineurin inhibitors, and mycophenolate mofetil.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rituximab has been shown to be effective in SDNS with evidence of reduction in the number of immunosuppressive medications and reduction in the number of relapses. Other alternatives include cyclophosphamide, calcineurin inhibitors, and mycophenolate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Continuing high-dose prednisone for 3 months is not the next best step, as the patient has proven to be steroid sensitive with a rapid improvement in proteinuria at 2 weeks. The added duration of high-dose steroid exposure is unnecessary and associated with many adverse effects including insomnia, mood changes, weight gain, glucose intolerance, and hypertension. For similar reasons, a maintenance dose of 20 mg is also not ideal, as it would expose him to long-term adverse effects such as cataracts and osteoporosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because this patient’s MCD was responsive to steroids, genetic testing is not the next best step, as this option is usually reserved for children with steroid-resistant MCD or nephritic syndrome in whom monogenic causes of disease are suspected. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A repeat kidney biopsy is unlikely to add diagnostic value and would not change management.</p>\n</div>",
        "references": [
            "Ruggenenti P, Ruggiero B, Cravedi P, et al: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.J Am Soc Nephrol25(4): 850–863, 2014",
            "Guitard J, Hebral AL, Fakhouri F, et al: Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.Nephrol Dial Transplant29(11): 2084–2091, 2014",
            "Munyentwali H, Bouachi K, Audard V, et al: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.Kidney Int83(3): 511–516, 2013",
            "Hogan J, Radhakrishnan J: The treatment of minimal change disease in adults.J Am Soc Nephrol24(5): 702–711, 2013",
            "Xiao H, Hildebrandt F: Whole exome sequencing identifies monogenic forms of nephritis in a previously unsolved cohort of children with steroid-resistant nephrotic syndrome and hematuria.Pediatr Nephrol37(7): 1567–1574, 2022",
            "Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.Kidney Int100(4S): S1–S276, 2021"
        ]
    },
    "47": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman presented to the hospital 5 days ago with severe lower extremity weakness and poor PO intake. She has a past medical history of hypertension and hypothyroidism. As part of her evaluation, she was noted to have significant lower extremity weakness, sensory loss, and hyporeflexia. Nerve conduction studies showed demyelinating polyneuropathy. Based on her constellation of symptoms, she was diagnosed with Guillain-Barre syndrome. She was prescribed IV immunoglobulin (IVIG) 40 g daily for 5 days. Her other medications include levothyroxine and lisinopril.</p>\n<p>Currently, her BP is 140/90 mm Hg. She has no murmurs. Lungs are clear to auscultation in all fields. Her abdomen is soft and nontender. She has normal bowel sounds. She has 1+ lower extremity edema. </p>\n<p>Laboratory data on day 5 are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>119 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>111 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.96 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>85 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.0 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>302 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>275–295</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Thyroid-stimulating hormone</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3 μU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–4.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine, random</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>32 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>366 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis: specific gravity 1.011, no blood, no protein.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of the patient’s hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Syndrome of inappropriate antidiuretic hormone"
            },
            {
                "label": "B.",
                "text": "IV immunoglobulin"
            },
            {
                "label": "C.",
                "text": "Poor solute intake"
            },
            {
                "label": "D.",
                "text": "Hypothyroidism"
            },
            {
                "label": "E.",
                "text": "Hypovolemia"
            }
        ],
        "correct_answer": "IV immunoglobulin",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s hyponatremia and with normal serum osmolality is most likely attributable to IV immunoglobulin (IVIG). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A decrease in plasma sodium concentration associated with a normal or elevated serum osmolality rather than with hypoosmolality may be due to pseudohyponatremia. This case highlights the importance of measuring serum osmolality in patients with hyponatremia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohyponatremia is an artifact of measuring sodium using indirect ion-selective potentiometry in the presence of a decreased fraction of plasma water, usually because of an increased fraction of solid phase (protein or lipid). In this case, the excess solid phase is attributable to IVIG. Pseudohyponatremia is a separate entity from translocational hyponatremia, which is true hyponatremia due to the accumulation of unmeasured solute, such as glucose in severe hyperglycemia, glycine after transurethral prostate resection, and mannitol in patients with cerebral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypothyroidism only causes hyponatremia in severe cases, such as myxedema coma, and some experts doubt even this association. Hypothyroidism, the syndrome of inappropriate antidiuretic hormone, poor solute intake (“tea and toast” diet or beer potomania), and hypovolemia all cause true (hypotonic) hyponatremia. </p>\n</div>",
        "references": [
            "Rose BD:Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed. New York: McGraw Hill; 2001.",
            "Hoorn EJ, Zietse R: Diagnosis and treatment of hyponatremia: compilation of the guidelines.J Am Soc Nephrol28(5):1340–1349, 2017"
        ]
    },
    "48": {
        "question": "<div class=\"qtext\"><p>A 66-year-old man with nonalcoholic steatohepatitis (NASH) cirrhosis, adenocarcinoma of the liver, hypertension, and type 2 diabetes is referred to the emergency department for hypotension and abnormal laboratory data. He reports lightheadedness, fatigue, decreased appetite, low urine output, melena, and a metallic taste in his mouth. He has not had an infection or a large volume paracentesis in the past 2 months. </p>\n<p>His medications include hydrochlorothiazide, insulin glargine, lisinopril, metformin, and pantoprazole. He does not take NSAIDs or over-the-counter medications.</p>\n<p>On examination, BP is 90/42 mm Hg, and heart rate is 99/min. His lungs are clear. He has right upper quadrant tenderness to palpation and a protuberant abdomen with shifting dullness and a fluid wave. He has 1+ lower extremity edema bilaterally to his knees and bilateral asterixis.</p>\n<p>He is admitted to the ICU, and metformin, hydrochlorothiazide, and lisinopril are discontinued.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>1 Month Ago</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Today</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9300/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>31,100</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>124</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.7 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>103 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>18</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.11 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>106 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>250 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.5 mg/ dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.8</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–1.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Direct bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.1–0.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Indirect bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.2–0.7</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Prothrombin time</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12.4 s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15.6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11–13</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows no blood, nitrite, or leukocyte esterase, and microscopy reveals no RBC or WBC. Urine electrolytes obtained on a random sample on presentation are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>205 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>43 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>602 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound shows no hydronephrosis or shadowing renal calculi.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Albumin and norepinephrine"
            },
            {
                "label": "B.",
                "text": "Furosemide"
            },
            {
                "label": "C.",
                "text": "Isotonic saline IV"
            },
            {
                "label": "D.",
                "text": "Hemodialysis"
            },
            {
                "label": "E.",
                "text": "Sodium chloride PO"
            }
        ],
        "correct_answer": "Albumin and norepinephrine",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management in this patient with hepatorenal syndrome (HRS) is to prescribe albumin and norepinephrine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s clinical situation is concerning for HRS. HRS occurs in the setting of portal hypertension and/or portal vein thrombosis and is in part attributable to splanchnic vasodilation, leading to decreased total peripheral resistance, with increased sympathetic outflow and resulting vasoconstriction of the renal circulation, including afferent and efferent arterioles. The reduced perfusion of the kidney leads to AKI with avid sodium reabsorption. The hallmarks of HRS are a rise in serum creatinine, a bland urine sediment, little proteinuria, and minimal sodium excretion. HRS is often precipitated by a gastrointestinal bleed or an infection. It can often be difficult to distinguish HRS from other causes of AKI, such as acute tubular necrosis, as the fractional excretion of sodium in patients with cirrhosis is often &lt;1%, and patients with cirrhosis can develop granular or bile casts from bilirubinuria. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The recommended treatment of HRS is volume expansion with albumin and a vasopressor, such as norepinephrine, vasopressin, or terlipressin. Midodrine and octreotide have also been used in non-critically ill patients. The choice of vasopressor may be dictated by the availability of specific agents and the location of the patient in the hospital (ICU versus non-ICU setting). Although prior guidelines for HRS required 2 days of volume expansion with albumin before initiating vasopressors, newer guidelines encourage earlier use of HRS therapy to prevent delays in definitive treatment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has evidence of volume overload, he is likely intravascularly volume depleted. However, administration of isotonic saline alone would be unlikely to reverse renal hemodynamic dysregulation and improve AKI. Similarly, furosemide would not be indicated without a trial of albumin and a vasoconstrictor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has AKI and asterixis, attempts to reverse HRS should be undertaken prior to initiating HD. The asterixis may be attributed to his liver failure. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium chloride tablets, in this patient with AKI and volume overload, will not improve his AKI and will potentially worsen his volume overload.</p>\n</div>",
        "references": [
            "Ojeda-Yuren AS, Cerda-Reyes E, Herrero-Maceda MR, et al: An integrated review of the hepatorenal syndrome.Ann Hepatol22: 100236, 2021",
            "Francoz C, Durand F, Kahn JA, et al: Hepatorenal syndrome.Clin J Am Soc Nephrol14(5): 774–781, 2019",
            "Israelsen M, Krag A, Allegretti AS, et al: Terlipressin versus other vasoactive drugs for hepatorenal syndrome.Cochrane Database Syst Rev9(9): CD011532, 2017",
            "Best LM, Freeman SC, Sutton AJ, et al: Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev9(9): CD013103, 2019",
            "Acevedo JG, Cramp ME: Hepatorenal syndrome: update on diagnosis and therapy.World J Hepatol9(6): 293–299, 2017"
        ]
    },
    "49": {
        "question": "<div class=\"qtext\"><p>A 36-year-old woman is referred to nephrology clinic for elevated serum creatinine and hypertension. Two weeks ago, she established care with a primary doctor after many years without medical evaluation. She is asymptomatic except for occasional dull lower back pain and reports she has been in good health, without a history of kidney stones, hematuria, or trauma. She is adopted and does not know her family history. Her medications include hydrochlorothiazide, which was prescribed 2 weeks ago. She does not take over-the-counter medications, NSAIDs, or supplements. </p>\n<p>Her BP is 161/94 mm Hg, and her heart rate is 70/min. The remainder of her physical examination is unremarkable. Her serum creatinine is 1.8 mg/dL (reference range, 0.5–1.1). Prior values are not available.</p>\n<p>A point-of-care ultrasound (POCUS) examination of the kidneys is performed. Representative images are shown below.</p>\n<p> </p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ea16e4da_1-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ea16e4da_1\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"ksapv8m1b2q19Koratala-Q1R%20Figure.mp4\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ea16e4da_1_html5_api\" role=\"application\" tabindex=\"-1\" title=\"ksapv8m1b2q19Koratala-Q1R%20Figure.mp4\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q19Koratala-Q1R%20Figure.mp4\" type=\"video/mp4\"/>\n        https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q19Koratala-Q1R%20Figure.mp4\n    </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-27\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-28\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:05\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 47.92%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">47.92%</span></span><div data-end=\"2.404\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ea16e4da_1_component_285\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ea16e4da_1_component_285\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ea16e4da_1_component_589_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ea16e4da_1_component_589_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ea16e4da_1_component_595_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ea16e4da_1_component_595_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_622\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_622\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-White\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Black\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Red\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Green\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_627\" id=\"captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_627\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ea16e4da_1_component_595\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_637\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_637\"><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Black\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-White\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Red\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Green\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595 captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" id=\"captions-background-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_642\" id=\"captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_642\"><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ea16e4da_1_component_595-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ea16e4da_1_component_595\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_652\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_652\"><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Black\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-White\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Red\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Green\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595 captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" id=\"captions-window-color-id_videojs_68a28ea16e4da_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_657\" id=\"captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_657\"><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595 captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ea16e4da_1_component_595-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_672\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-673-50\" id=\"vjs-track-option-673-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-674-75\" id=\"vjs-track-option-674-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-675-100\" id=\"vjs-track-option-675-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-676-125\" id=\"vjs-track-option-676-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-677-150\" id=\"vjs-track-option-677-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-678-175\" id=\"vjs-track-option-678-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-679-200\" id=\"vjs-track-option-679-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-680-300\" id=\"vjs-track-option-680-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-681-400\" id=\"vjs-track-option-681-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_691\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-692-None\" id=\"vjs-track-option-692-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-693-Raised\" id=\"vjs-track-option-693-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-694-Depressed\" id=\"vjs-track-option-694-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-695-Uniform\" id=\"vjs-track-option-695-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-696-Dropshadow\" id=\"vjs-track-option-696-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595\" id=\"vjs_select_706\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-707-ProportionalSansSerif\" id=\"vjs-track-option-707-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-708-MonospaceSansSerif\" id=\"vjs-track-option-708-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-709-ProportionalSerif\" id=\"vjs-track-option-709-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-710-MonospaceSerif\" id=\"vjs-track-option-710-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-711-Casual\" id=\"vjs-track-option-711-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-712-Script\" id=\"vjs-track-option-712-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ea16e4da_1_component_595 vjs-track-option-713-SmallCaps\" id=\"vjs-track-option-713-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div> <em style=\"font-size: 0.9375rem; font-weight: 400;\">Image courtesy of Dr. Abhilash Koratala Medical College of Wisconsin.</em><p></p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Bilateral hydronephrosis"
            },
            {
                "label": "B.",
                "text": "Acquired cystic kidney disease"
            },
            {
                "label": "C.",
                "text": "Medullary sponge kidney"
            },
            {
                "label": "D.",
                "text": "Autosomal dominant polycystic kidney disease"
            },
            {
                "label": "E.",
                "text": "Medullary cystic kidney disease"
            }
        ],
        "correct_answer": "Autosomal dominant polycystic kidney disease",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with enlarged kidneys and numerous cortical cysts is ADPKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The POCUS images demonstrate large kidneys filled with numerous cysts of varying sizes bilaterally, consistent with ADPKD. On ultrasound, cysts appear as anechoic (black), well-circumscribed lesions. In patients with a positive family history of ADPKD, the presence of a total of ≥3 kidney cysts at age 15–39 years and ≥2 cysts in each kidney at age 40–59 years is sufficient to diagnose ADPKD. Although these criteria do not apply to patients without a family history, ADPKD is still likely in the presence of bilaterally enlarged kidneys and &gt;10 cysts in each kidney. In addition, the presence of cysts in other organs such as the liver, as seen here, supports the diagnosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hydronephrosis appears as an anechoic, dilated, interconnected area in the renal pelvis branching into the calyces of the kidney. Although parapelvic cyst(s) may occasionally be confused with hydronephrosis, the anechoic structures in the images shown here are well separated from each other without the branching pattern, consistent with individual cysts.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In contrast to ADPKD, patients with acquired cystic disease have smaller or normal-sized kidneys with fewer cysts compared with the images shown. The age at diagnosis is usually older, and prior diagnosis of severe CKD is a frequent accompaniment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Medullary sponge kidney (MSK) is a congenital, but not necessarily genetic, disorder characterized by cystic dilation of the collecting tubules. MSK presents with hematuria, nephrolithiasis, nephrocalcinosis, urinary tract infections, and partial distal renal tubular acidosis. Kidney function is usually normal. Imaging demonstrates calcification and microcystic dilation of the papillae and hypo- and hyperechoic areas within medullary pyramids, which acquire a “blush,” “paintbrush,” or “bouquet of flowers” appearance on contrast imaging.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Medullary cystic kidney disease is one of the autosomal dominant tubulointerstitial kidney diseases (ADTKD), typically characterized by small, corticomedullary cysts on imaging (cysts may be too small to visualize). ADTKD is caused by mutations in the genes encoding uromodulin, renin, mucin-1, and other proteins and presents as early-onset, familial CKD with bland urinalysis and nonspecific kidney biopsy findings, as well as gout and anemia in some cases. Kidneys are usually small and echogenic.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q19.png\" width=\"75%\"/></figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><em>Images courtesy of Dr. Abhilash Koratala Medical College of Wisconsin.</em></p>\n</div>",
        "references": [
            "Chebib FT, Torres VE: Autosomal dominant polycystic kidney disease: core curriculum 2016.Am J Kidney Dis67(5): 792-810, 2016",
            "Cornec-Le Gall E, Alam A, Perrone RD: Autosomal dominant polycystic kidney disease.Lancet393(10174): 919-935, 2019",
            "Koratala A, Bhattacharya D, Kazory A: Point of care renal ultrasonography for the busy nephrologist: a pictorial review.World J Nephrol8(3): 44-58, 2019",
            "Reisinger N, Koratal A, Goral S: Use of point-of-care ultrasound to assess CKD. Am J Kidney Dis77(1): A16-A19, 2021",
            "Pisani I, Giacosa R, Giuliotti S, et al: Ultrasound to address medullary sponge kidney: a retrospective study.BMC Nephrol21(1): 430, 2020",
            "Whang G, Tchelepi H: Ultrasound, computed tomography, and magnetic resonance imagining in a patient with medullary cystic kidney disease.Ultrasound Q34(4): 288-291, 2018"
        ]
    },
    "50": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man is admitted to the emergency department after a motor vehicle collision. He had been intubated in the field for hypoxemia and inability to protect the airway.  </p>\n<p>On examination, he is initially afebrile with BP 150/87 mm Hg, heart rate is 90/min, and oxygen saturation is 99% with the ventilator set to a respiratory rate of 16/min and a fraction of inspired oxygen of 60%. His Glasgow coma score is 7 without sedation. Pupillary reflexes are sluggish but equal. Lung fields are clear, and he has no edema.</p>\n<p>A CT scan of the head without contrast reports moderate, right-sided intraparenchymal hemorrhage without associated edema and no midline shift or herniation.</p>\n<p>He is admitted to the trauma ICU, and propofol is infused. Four hours into his hospital admission, his BP is 190/42 mm Hg, and heart rate is 52/min. His Glasgow coma score is now 4. Laboratory data, including electrolytes and kidney function, are within normal limits.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Mannitol"
            },
            {
                "label": "B.",
                "text": "Nicardipine"
            },
            {
                "label": "C.",
                "text": "Hydralazine"
            },
            {
                "label": "D.",
                "text": "Repeat CT scan of the brain"
            },
            {
                "label": "E.",
                "text": "Change propofol to dexmedetomidine"
            }
        ],
        "correct_answer": "Mannitol",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with suspected intracranial edema is the administration of mannitol.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed increased intracranial pressure (ICP) as evidenced by bradycardia and hypertension with increased pulse pressure in the setting of a known intraparenchymal hemorrhage. High ICP leads to increased resistance within cerebral blood vessels and a concomitant increase in systolic BP to maintain perfusion. The mechanism underlying the bradycardia is not understood. The differential diagnosis of wide pulse pressure includes Cushing reflex, hyperthyroidism, distributive shock, wet beriberi, arteriovenous fistula, aortic insufficiency, severe peripheral atherosclerosis, pregnancy, and normal aging.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Initial management includes maintaining head position at 30° of elevation with normal arterial pCO<sub>2</sub> 35–40 mm Hg and normal body temperature. Sedation, analgesia, and ICP monitoring with cerebrospinal fluid drainage may also be required. Subsequent management may include hypothermia, paralysis, medically-induced coma, and decompressive craniotomy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mannitol is used to increase intravascular tonicity, resulting in an osmotic gradient to draw water into the vascular space and decrease cellular swelling in the central nervous system. Hypertonic saline is an alternative treatment, with a 2022 meta-analysis suggesting that hypertonic saline led to increased treatment success, lower ICP, and improved cerebral perfusion after infusion termination, but no effect on outcome, mortality, ICP and cerebral perfusion pressure &gt;90 minutes after infusion, or duration of response. A Cochrane review in 2020 did not find data to preferentially support mannitol versus hypertonic saline treatment, although most trials were of poor quality.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Decreasing the systemic BP with hydralazine or nicardipine would worsen intracranial hypoperfusion. Restoration of perfusion by decreasing the ICP is the preferred treatment strategy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeat CT scan of the brain would likely show evidence of increased ICP but would not be the appropriate next step when urgent treatment is required.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Propofol infusion syndrome is characterized by cardiogenic shock, rhabdomyolysis, AKI, and acidosis and would not be expected in this patient with hypertension and a widened pulse pressure.</p>\n</div>",
        "references": [
            "Jha RM, Kochanek PM: A precision medicine approach to cerebral edema and intracranial hypertension after severe traumatic brain injury: quo vadis?Curr Neurol Neurosci Rep18(12): 105, 2018",
            "Fodstad H, Kelly PJ, Buchfelder M: History of the Cushing reflex.Neurosurgery59(5): 1132–1137, 2006",
            "Chen H, Song Z, Dennis JA: Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury.Cochrane Database Syst Rev1(1): CD010904, 2020",
            "Han C, Yang F, Guo S, Zhang J: Hypertonic saline compared to mannitol for the management of elevated intracranial pressure in traumatic brain injury: a meta-analysis.Front Surg8: 765784, 2022"
        ]
    },
    "51": {
        "question": "<div class=\"qtext\"><p>An 82-year-old woman is evaluated for hyponatremia. One week ago, she was hospitalized for a traumatic subarachnoid hemorrhage that resulted from a fall. She was managed with nimodipine and isotonic saline to reduce the risk of cerebral vasospasm. She complains of a headache and nausea.</p>\n<p>On examination, she appears slightly drowsy but in no acute distress. Her BP is 145/88 mm Hg supine and 115/70 mm Hg seated. Her heart rate is 96/min supine and 106/min seated. By internal jugular catheter, her central venous pressure is 3 cm of water. Her lungs are clear and there is no peripheral edema.</p>\n<p>Laboratory data include the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Hospital Day 8</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                125\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1<strong>.</strong>1 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                260 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Cortisol (8:00 a.m.)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 µg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5–25\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 µU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                52 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Variable\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                450 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–1400\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Fractional excretion of uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Variable\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Fractional excretion of phosphorus</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Variable\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Following the infusion of 1 L of isotonic saline over 4 hours, the serum sodium is 126 mmol/L, urine sodium 55 mmol/L, and urine osmolality 280 mOsm/kg.</p>\n<p><strong>Which of the following is the most likely explanation for hyponatremia in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Adrenal insufficiency"
            },
            {
                "label": "B.",
                "text": "Hypothyroidism"
            },
            {
                "label": "C.",
                "text": "Hypovolemia"
            },
            {
                "label": "D.",
                "text": "Cerebral salt wasting"
            },
            {
                "label": "E.",
                "text": "Syndrome of inappropriate antidiuretic hormone"
            }
        ],
        "correct_answer": "Cerebral salt wasting",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s hyponatremia is best explained by cerebral salt wasting (CSW), also referred to as renal salt wasting.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyponatremia is very common after subarachnoid hemorrhage, occurring in more than 50% of cases, and severe hyponatremia (plasma sodium &lt;130 mEq/L) is identified in up to 20%. In those with severe hyponatremia, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common etiology, established in approximately 60% of cases, compared with CSW in approximately 6%. Hypovolemia and mixed features account for the remaining cases. The existence of CSW remains controversial, and a definite pathophysiology has not been established. Nonetheless, there appear to be features that allow distinction between SIADH and CSW.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both SIADH and CSW are associated with hypo-osmolar hyponatremia, manifested by excretion of an inappropriately concentrated urine with respect to plasma osmolality. Hyperosmolal urine, hypouricemia, and high (&gt;10%) fractional excretion of urate (FE uric acid) are features common to both disorders. Both syndromes are characterized by elevated levels of antidiuretic hormone. Volume status can be the most important means of distinguishing these disorders, as patients with SIADH are, by definition, clinically euvolemic, whereas those with CSW appear to be hypovolemic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Other potentially distinguishing features include resolution of the high FE uric acid with resolution of hyponatremia in SIADH, but a persistently high FE uric acid in CSW. In the setting of hypophosphatemia, a high FE phosphorus (&gt;20%) is reported to be a feature of CSW but not of SIADH. Furthermore, patients with CSW demonstrate improvement in plasma sodium and dilution of urine after correction of volume contraction, whereas those with SIADH do not improve. This divergent response is the basis for treatment of CSW with isotonic volume expansion, a strategy that typically results in progressive hyponatremia in SIADH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the presentation is compatible with either diagnosis because the postural fall in BP could be explained by nimodipine and does not necessarily imply volume depletion. The baseline laboratory data are likewise nondiagnostic, although the relatively high FE phosphorus in the face of hypophosphatemia favors CSW. The increase in plasma sodium after a 4-hour infusion is nondiagnostic; not enough time has elapsed for a steady state to be achieved. Conversely, the decrease in urine osmolality after infusion of isotonic saline favors a diagnosis of CSW, because a fall in urine osmolality would not be expected after isotonic saline infusion in SIADH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hypothyroidism and hypoadrenalism have not been excluded, additional testing would be required before establishing either of these as the most likely diagnosis. The pathophysiology of both of these disorders in generating hyponatremia is thought to be similar to that of SIADH, although the role of hypothyroidism in causing hyponatremia is questionable. The relatively high urine sodium in the presence of intact kidney function argues against primary hypovolemia as the cause of hyponatremia.</p>\n</div>",
        "references": [
            "Maesaka JK, Miyawaki N, Palaia T, Fishbane S, Durham JH: Renal salt wasting without cerebral disease: Diagnostic value of urate determinations in hyponatremia.Kidney Int71(8): 822–826, 2007",
            "Bitew S, Imbriano L, Miyawaki N, Fishbane S, Maesaka JK: More on renal salt wasting without cerebral disease: Response to saline infusion.Clin J Am Soc Nephrol4(2): 309–315, 2009",
            "Cerdà-Esteve M, Cuadrado-Godia E, Chillaron JJ, Pont-Sunyer C, et al: Cerebral salt wasting syndrome: Review.Eur J Intern Med19(4): 249–254, 2008"
        ]
    },
    "52": {
        "question": "<div class=\"qtext\"><p>A 55-year-old woman is evaluated for CKD. Her medical history includes osteoporosis and obesity. Body mass index (BMI) was previously 55.8 kg/m<sup>2</sup>, so 15 years ago, the patient underwent biliopancreatic diversion with duodenal switch and has since lost 79 kg. She was found to have a persistently elevated creatinine of 1.5 mg/dL during evaluation by an endocrinologist for osteoporosis therapy. Medications include calcium carbonate, iron sulfate, vitamin D, vitamin B12, and a multivitamin. She currently feels well except for mild fatigue, loose stools, and generalized joint pain.</p>\n<p>BP is 110/70 mm Hg, heart rate is 78/min, and body mass index (BMI) is 24.8 kg/m<sup>2</sup>. Physical examination is unremarkable, with normal heart, lung, abdomen, and skin findings, except for evidence of her weight loss. There is no edema.</p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the next BEST STEP to establish the cause of CKD?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "24-Hour urine collection for oxalate"
            },
            {
                "label": "B.",
                "text": "Serum PTH"
            },
            {
                "label": "C.",
                "text": "Serum protein electrophoresis and free light chain ratio"
            },
            {
                "label": "D.",
                "text": "Fractional excretion of calcium"
            },
            {
                "label": "E.",
                "text": "Urine protein-to-creatinine ratio"
            }
        ],
        "correct_answer": "24-Hour urine collection for oxalate",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with CKD, history of bariatric surgery, and loose stools, enteric hyperoxaluria with nephrocalcinosis is the most likely diagnosis, and 24-hour urine collection for oxalate would be the next step in evaluation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyperoxaluria, with calcium oxalate deposition in the renal parenchyma (nephrocalcinosis) or tubules (nephrolithiasis), is a recognized complication of gastrointestinal malabsorption, including some types of bariatric surgery. Normally, oxalate in the gut binds to dietary calcium in the intestinal lumen and is excreted in the stool. Any condition that decreases absorption of free fatty acids or bile acids will result in calcium binding to these acids (saponification) and increase the absorption of unbound, free oxalate into the circulation and subsequent excretion in the urine (hyperoxaluria). The incidence of oxalate-associated CKD is related to the type of bariatric surgery undertaken, with restrictive procedures (lap band and gastric sleeve) associated with less risk than malabsorptive procedures (Roux-en-Y and duodenal switch). A 24-hour urine collection would establish the diagnosis of hyperoxaluria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the serum calcium is borderline high and the patient is taking calcium carbonate and vitamin D supplements, primary or secondary hyperparathyroidism is a less likely diagnosis in this case. Serum protein electrophoresis with immunofixation and serum free light chain ratio are recommended to evaluate for multiple myeloma, which is not the most likely diagnosis in this patient without significant hypercalcemia or anemia. Fractional excretion of calcium on a random or 24-hour urine sample may be done to evaluate for hypercalciuria, for example, to distinguish between primary hyperparathyroidism and familial hypocalciuric hypercalcemia, but would not be useful in this case, where hyperoxaluria is the primary disorder. Finally, although urinalysis is an important component of CKD evaluation, proteinuria is not a prominent feature of hyperoxaluria and nephrocalcinosis.</p>\n</div>",
        "references": [
            "Sethi M, Chau E, Youn A, et al: Long-term outcomes after biliopancreatic diversion with and without duodenal switch: 2-, 5-, and 10-year data.Surg Obes Relat Dis12(9): 1697–1705, 2016",
            "Patel BN, Passman CM, Fernandez A, et al: Prevalence of hyperoxaluria after bariatric surgery.J Urol181: 161–166, 2009",
            "Ritz E: Bariatric surgery and the kidney—much benefit, but also potential harm.Clin Kidney J6(4): 368–372, 2013",
            "Nazzal L, Puri S, Goldfarb DS: Enteric hyperoxaluria: an important cause of end-stage kidney disease.Nephrol Dial Transplant31(3): 375–382, 2016"
        ]
    },
    "53": {
        "question": "<div class=\"qtext\"><p>A 23-year-old man presents to the emergency department with increasing weakness after eating a large bag of red licorice. His serum potassium is 2.9 mEq/L, his symptoms improve with oral potassium supplementation, and he is discharged. He returns the next day with recurrent weakness, once again after consumption of red licorice. He has no relevant past medical or surgical history and takes no medications, either prescribed or over-the-counter. He reports minimal alcohol intake and no use of recreational drugs.</p>\n<p>His BP is 110/68 mm Hg and heart rate 99/min. On physical examination, he appears thin and has diffuse muscle weakness with hyporeflexia. The abdomen is nontender with hypoactive bowel sounds. The remainder of the examination is normal.</p>\n<p>Laboratory data reveal the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                144 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                111 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.74 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                113 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine (random)</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                84 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                146 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                112 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the MOST LIKELY cause of hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Renal tubular acidosis"
            },
            {
                "label": "B.",
                "text": "Glycyrrhetinic acid"
            },
            {
                "label": "C.",
                "text": "Insulin"
            },
            {
                "label": "D.",
                "text": "Hyperthyroidism"
            },
            {
                "label": "E.",
                "text": "Inadequate potassium intake"
            }
        ],
        "correct_answer": "Hyperthyroidism",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has thyrotoxic periodic paralysis mediated by transcellular shift of potassium in the setting of hyperthyroidism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The evaluation of hypokalemia begins with an assessment of renal K handling, which may include spot or 24-hour urine K determination or the urine K-to-creatinine ratio. Calculation of the transtubular potassium gradient (TTKG) is no longer recommended because the assumptions underlying its use were found to be invalid. Although spot urine K concentrations may vary with urine volume, their measurement is a convenient strategy, and the accuracy is improved when normalized to creatinine concentration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the urine K-to-creatinine ratio is 14 mEq/L ÷ 1.12 g/L = 12.5 mEq/g. Appropriate renal K conservation in the presence of hypokalemia is indicated by a ratio &lt;15 mEq/g. Thus, this patient has appropriate K conservation. A spot urine K &lt;20–25 mEq/L or a 24-hour K excretion of &lt;25mEq/L also suggests K conservation in response to hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recurrent hypokalemia after a carbohydrate load is consistent with thyrotoxic periodic paralysis, which occurs more frequently in men of Asian ethnicity. Hyperthyroidism should be confirmed by measuring thyroid stimulating hormone and thyroid function. The mechanism for this disorder is unknown, but it is thought to be caused by increased activity of the Na-K-ATPase from hyperthyroidism-mediated sympathetic activation. Episodes of skeletal muscle weakness may be precipitated by factors that increase the activity of the Na-K-ATPase, including exercise and carbohydrate consumption. This disorder has been described in patients with primary and secondary causes of hyperthyroidism, including exogenous sources of thyroid hormone. A similar disorder, hypokalemic periodic paralysis, is caused by an autosomal dominant defect in skeletal muscle sodium or calcium channels but has the same precipitants and clinical presentation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Red licorice is not technically licorice at all, but some varieties of black licorice derived from the root of <em>Glycyrrhiza glabra</em> inhibit the 11β-hydroxysteroid dehydrogenase type 2 enzyme in the principal cell, which detoxifies cortisol to cortisone. Inhibition by glycyrrhetinic acid causes intracellular cortisol to accumulate and activates the mineralocorticoid receptor, causing the syndrome of apparent mineralocorticoid excess. In this condition, patients are hypertensive, with hypokalemia and metabolic alkalosis from urinary losses of potassium and hydrogen, respectively. This patient does not have renal K loss, metabolic alkalosis, or hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Insulin can cause transcellular potassium shift, and the recent carbohydrate load might suggest this mechanism, but hypokalemia is rarely so profound. Indeed, intracellular K transport with insulin release is thought to prevent hyperkalemia after a meal. The absence of hypoglycemia argues against hyperinsulinemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reduced dietary intake of potassium is rarely the sole cause of hypokalemia, particularly of this severity.</p>\n</div>",
        "references": [
            "Takahashi K, Yoshino T, Maki Y, et al: Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: A multi-centre cross-sectional study.Arch Toxicol93(11): 3111–3119, 2019",
            "Fialho D, Griggs RC, Matthews E: Periodic paralysis.Handb Clin Neurol148: 505–520, 2018",
            "Chaudhry MA, Wayangankar S: Thyrotoxic periodic paralysis: A concise review of the literature.Curr Rheumatol Rev12(3): 190–194, 2016",
            "Cheema MA, Zain MA, Cheema K, et al: Thyroxine-induced periodic paralysis: A rare complication of nutritional supplements.BMJ Case Rep11: e227946, 2018",
            "Kamel KS, Halperin ML: Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: An hypothesis with clinical implications.Curr Opin Nephrol Hypertens20(5): 547–554, 2011"
        ]
    },
    "54": {
        "question": "<div class=\"qtext\"><p>A 33-year-old man with a history of HIV and chronic hepatitis B is referred for evaluation. He was diagnosed with HIV infection 8 months ago and prescribed tenofovir disoproxil fumarate (TDF), emtricitabine, indinavir, and ritonavir at the time of diagnosis. Previously, he took TDF alone for chronic hepatitis B. He denies taking any other medications currently but was previously prescribed potassium tablets. He reports generalized weakness and fatigue. He has had a poor appetite and chronic loose stools but has been eating regularly. His HIV has been well controlled with undetectable viral load and a CD4 T-lymphocyte count of 490/μL (reference range, 530–1570).  </p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                139 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                111 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 mg/dL (6 months ago, 0.6)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                87 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine (random)</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                39 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                72 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.38 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows a specific gravity of 1.017, pH 5.3, glucose 2+, protein 1+, and no ketones, nitrites, or leukocyte esterase.</p>\n<p><strong>Which of the following is the MOST LIKELY explanation for the observed laboratory abnormalities?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Multiple myeloma"
            },
            {
                "label": "B.",
                "text": "Antiretroviral therapy"
            },
            {
                "label": "C.",
                "text": "HIV"
            },
            {
                "label": "D.",
                "text": "Diarrhea"
            },
            {
                "label": "E.",
                "text": "Diabetes"
            }
        ],
        "correct_answer": "Antiretroviral therapy",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s laboratory abnormalities are most consistent with a proximal (type 2) renal tubular acidosis (RTA) attributed to TDF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proximal RTA occurs due to impaired ability to reabsorb bicarbonate at the proximal tubule and is characterized hyperchloremic (normal anion gap) metabolic acidosis. Proximal RTA is often a component of Fanconi syndrome, which is generalized proximal tubule dysfunction, accompanied by impaired absorption of potassium, phosphorus, glucose, uric acid, and amino acids, as well as low-grade proteinuria, many of which are present here. As the proximal tubule is essential for ammonium production, urine ammonium is often inappropriately low in proximal RTA and may now be measured directly in some laboratories. The urine anion gap correlates poorly with urine ammonium and may also vary depending on the duration of proximal RTA; in early disease, excess urine bicarbonate may increase the urine anion gap even with appropriate urine ammonium production. Urine pH is often &lt;5.5 as distal tubular acidification is intact, although this finding is also variable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Drug-induced proximal RTA is encountered with carbonic anhydrase (CA) inhibitors such as acetazolamide, which inhibits the luminal, membrane-anchored isoform CA-IV, as well as the antiseizure/migraine prophylaxis drug topiramate, which inhibits the cytosolic isoform CA-II. As CA-II is also present in the distal tubule, topiramate has been reported to cause both proximal and distal RTA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of proximal tubulopathy in this patient is TDF, especially in the presence of the protease inhibitor ritonavir. TDF enters the proximal renal tubule epithelial cell (RTEC) via the basolateral organic anion transporters (OAT1) and is excreted into the lumen via the multidrug resistance-associated protein (MRP4). Concomitant use of ritonavir, which exits via MRP2, or the nucleoside reverse transcriptase inhibitor didanosine, which also uses OAT1 for entry into the proximal RTECs, has been shown to cause decreased tubular secretion of tenofovir and resultant intracellular retention with evidence of mitochondrial DNA depletion and mitochondrial structural abnormalities. Single nucleotide polymorphisms in <em>ABCC2, </em>a gene that encodes MRP2, have been reported in HIV-positive patients with tenofovir proximal tubulopathy. Proximal RTECs have limited capacity for anaerobic ATP generation, making them susceptible to injury by drugs that cause mitochondrial dysfunction.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TDF can cause proximal RTA with or without other features of proximal tubulopathy, which is often reversible after cessation of the drug, and is rarely encountered with the newer formulation tenofovir alafenamide, which does not enter tubule cells.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Multiple myeloma with light chain mediated Fanconi syndrome would present with proximal RTA, but the low-grade proteinuria, mild AKI, and younger age of the patient makes this diagnosis less likely. HIV infection of the kidney itself would not be expected to cause a proximal RTA. Gastrointestinal bicarbonate losses from diarrhea would present with normal anion gap metabolic acidosis but would not explain the other electrolyte abnormalities, including inappropriately high urine phosphorus excretion in the setting of hypophosphatemia (fractional excretion of phosphorus, 26%). Diabetes can be associated with type IV RTA from hyporeninemic hypoaldosteronism but would typically present with hyperkalemia.</p>\n</div>",
        "references": [
            "Kashoor I, Batlle D: Proximal renal tubular acidosis with and without Fanconi syndrome.Kidney Res Clin Pract38(3): 267–281, 2019",
            "Boron WF: Acid-base transport by the renal proximal tubule.J Am Soc Nephrol17(9): 2368–2382, 2006",
            "Haque SK, Ariceta G, Batlle D: Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.Nephrol Dial Transplant27(12): 4273–4287, 2012",
            "Hall AM, Hendry BM, Nitsch D, Connolly JO: Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.Am J Kidney Dis57(5): 773–780, 2011",
            "Perazella MA: Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.Kidney Int78(11): 1060–1063, 2010"
        ]
    },
    "55": {
        "question": "<div class=\"qtext\"><p>A 75-year-old man with bipolar disorder is sent to the emergency department to evaluate abnormal serum creatinine found during his annual physical. His medications are tamsulosin, valproic acid, and lithium, which was prescribed 1 week ago by his psychiatrist. </p>\n<p>On physical examination, he is alert. His BP is 105/60 mm Hg, and pulse is 67/min. Cardio-pulmonary examination is within normal limits. There is no pedal edema. The remainder of the examination is unremarkable.</p>\n<p>Laboratory values are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum/plasma</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                145 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136‒145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                103 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98‒106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8‒20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 (baseline 0.8 mg/dL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7‒1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                85 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70‒99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Lithium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5‒1.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                41 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                406 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38‒1400\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis with microscopy shows a specific gravity of 1.016, pH 7, negative protein, and 2‒5 granular casts/HPF.</p>\n<p>A urinary catheter is inserted, and 1 L of 0.9% normal saline is administered. Over the next 24 hours, the patient produces 3.5 L of urine.</p>\n<p><strong>Which of the following is the MOST LIKELY cause of this patient’s diuresis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Post-obstructive diuresis"
            },
            {
                "label": "B.",
                "text": "Post-acute tubular necrosis (ATN) diuresis"
            },
            {
                "label": "C.",
                "text": "Partial nephrogenic diabetes insipidus (DI)"
            },
            {
                "label": "D.",
                "text": "Central DI"
            },
            {
                "label": "E.",
                "text": "IV fluid administration"
            }
        ],
        "correct_answer": "Post-obstructive diuresis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has polyuria from post-obstructive solute diuresis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Polyuria is generally defined as urine output greater than 3–3.5 L/d. Optimally, the diagnosis of polyuria requires discontinuing IV fluids and then measuring the urine osmolality (U<sub>osm</sub>). U<sub>osm</sub> &lt;150 mOsm/kg H<sub>2</sub>O indicates a water diuresis, whereas U<sub>osm</sub> &gt;300 mOsm/kg H<sub>2</sub>O indicates a solute diuresis in a patient with polyuria. Values of 150‒300 mOsm/kg H<sub>2</sub>O suggest a mixed diuresis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine osmole excretion is typically 600‒750 mOsm/day in subjects eating a typical Western diet. A daily urine osmole excretion of &gt;1000 mOsm is consistent with solute diuresis. In this case, if extrapolated to a 24-hour period, the urine osmole excretion would be (406 mOsm/kg H<sub>2</sub>O × 3.5 L/day =) 1421 mOsm/day. Thus, both the 24-hour urine osmole excretion and the spot U<sub>osm</sub> indicate a solute diuresis. The patient most likely has chronic urinary retention from benign prostate hypertrophy. When the obstruction is relieved, there is an appropriate attempt by the kidney to excrete excess solutes and water retained during the period of obstruction. Urine volume is directly proportional to daily osmole excretion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Given the history of 3.5 L urine output during the 24 hours following urinary catheter insertion, obstruction is a more likely cause of AKI than ATN. Additionally, in the recovery phase of ATN, the tubules have diminished concentrating ability, leading to loss of solutes and water that may result in mixed polyuria. In this case, the urine osmolality is usually 150‒300 mOsm/kg H<sub>2</sub>O, and the daily urine osmole excretion is &lt;1000 mOsm/day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">DI, whether central or nephrogenic, would present with a water diuresis, with U<sub>osm</sub> &lt;150 mOsm/kg H<sub>2</sub>O; additionally, the daily urine osmole excretion would not be elevated, as in this case. Nephrogenic DI may be associated with chronic lithium use; however, in this case, lithium was initiated recently, and the lithium level is therapeutic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Administration of IV fluids can induce diuresis due to the expansion of intravascular volume. The amount of diuresis is dependent on the patient’s volume status and their antidiuretic hormone activity. This patient seems euvolemic, and there is no evidence of a concentrating defect. Therefore, it is not plausible that 1 L normal saline would result in 3.5 L of urine output. </p>\n</div>",
        "references": [
            "Berl T: Impact of solute intake on urine flow and water excretion.J Am Soc Nephrol19(6): 1076‒1078, 2008",
            "Bhasin B, Velez JCQ: Evaluation of polyuria: the roles of solute loading and water diuresis.Am J Kidney Dis67(3): 507‒511, 2016"
        ]
    },
    "56": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man with bipolar disorder presents for follow-up of CKD. He was first seen 3 years ago to evaluate a serum creatinine level of 1.6 mg/dL (reference range, 0.7–1.3). Several family members had developed ESRD, prompting genetic testing that demonstrated a pathogenic variant in <em>UMOD</em>, the gene encoding uromodulin (Tamm-Horsfall protein). Bipolar disorder has been well controlled on lithium for the last 20 years. Lithium levels have been therapeutic without supratherapeutic excursions for &gt;10 years. He has not initiated any new medications or supplements. He denies tremors, thirst, or arthralgia. He has a long-standing history of polyuria, predating the start of lithium therapy.</p>\n<p>Vital signs and physical examination are within normal limits. His urinalysis is bland without blood, albumin, or cellular elements. </p>\n<p>Over the last year, his serum creatinine level has increased from 1.6 to 2.0 mg/dL (reference range, 0.7‒1.3). </p>\n<p>CT imaging with IV contrast (done for evaluation of abdominal pain) shows symmetric kidneys without obstruction or stones, as shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1q56.png\" width=\"75%\"/>\n<figcaption><em>Image courtesy of Neera Dahl, MD, Yale University School of Medicine.</em></figcaption>\n</figure>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Prescribe amiloride"
            },
            {
                "label": "C.",
                "text": "Prescribe allopurinol"
            },
            {
                "label": "D.",
                "text": "Prescribe lisinopril"
            },
            {
                "label": "E.",
                "text": "Change lithium to divalproex"
            }
        ],
        "correct_answer": "Change lithium to divalproex",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with progressive CKD and history of autosomal dominant tubulointerstitial kidney disease due to <em>UMOD</em> mutation (ADTKD-UMOD) and chronic lithium use should have lithium discontinued or replaced to retard progression of CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ADTKD and lithium-induced nephropathy are both associated with slowly progressive CKD that typically presents without significant electrolyte abnormalities or proteinuria and with bland sediment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ADTKD, previously called medullary cystic kidney disease, is caused by mutations in at least 5 different genes (<em>UMOD, MUC1, REN, HNF1B, </em>and<em> SEC61A1</em>) that lead to accumulation of misfolded proteins, endoplasmic reticulum stress, necrosis, and apoptosis with subsequent inflammatory infiltration and interstitial fibrosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lithium is a monovalent cation that is reabsorbed similarly to sodium in both the proximal and distal tubule. Toxic intracellular accumulation interferes with cell signaling pathways and cell cycle progression. Duration of treatment and total cumulative dose are associated with CKD, with at least a 20-year latency period before the development of ESRD. Chronic tubulointerstitial disease with fibrosis and tubular dilation is seen on kidney biopsy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lithium can be an effective treatment for bipolar disorder, but one study showed increased time to symptom recurrence with divalproex, thus providing a viable option for some patients. Because stopping lithium treatment may slow the progression of CKD, it is worthwhile to pursue this option when possible. Because chronic interstitial changes may be seen in both ADTKD and lithium nephropathy, kidney biopsy would not be useful to distinguish between these causes of CKD, nor would it assist with management. The corticomedullary microcysts seen on this patient’s CT scan are thought to be more characteristic of lithium nephropathy than ADTKD, but both conditions may be associated with cysts. Amiloride prevents lithium reabsorption in the collecting duct and may potentially reduce polyuria if lithium is continued, but amiloride would not be expected to slow the progression of CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with ADTKD-UMOD may have concentrating and salt-wasting defects, causing water and salt loss, which leads to increased proximal tubule reabsorption of urate, hyperuricemia, and gout. However, this patient does not have any signs or symptoms of gout and does not require treatment with allopurinol. The patient is without hypertension or proteinuria, so lisinopril would not confer any clear benefit.</p>\n</div>",
        "references": [
            "Devuyst O, Olinger E, Weber S, et al: Autosomal dominant tubulointerstitial kidney disease.Nat Rev Dis Primers5: 60, 2019",
            "Grünfeld JP, Rossier BC: Lithium nephrotoxicity revisited.Nat Rev Nephrol5(5): 270–276, 2009",
            "Davis J, Desmond M, Berk M: Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification.BMC Nephrol19: 305, 2018"
        ]
    },
    "57": {
        "question": "<div class=\"qtext\"><p>A 62-year-old man with a history of hyperlipidemia and monoclonal gammopathy of undetermined significance (MGUS) presents with new-onset lower extremity edema and a 5-kg weight gain over the last month. He does not report any shortness of breath, chest pain, lightheadedness, or fatigue. The MGUS was previously evaluated by laboratory tests and bone marrow biopsy, which were nondiagnostic. His only medication is atorvastatin.</p>\n<p>On examination, BP is 105/70 mm Hg, heart rate is 94/min, and weight is 80 kg. He has 2+ lower extremity edema. The remainder of his examination is unremarkable.  </p>\n<p>Laboratory evaluation reveals the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Today</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>12 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;60 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;60\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Troponin I\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.01 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.02\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<u>&lt;</u>0.04 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum free kappa-to-free lambda light chain ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.10\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.52\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.26–1.65\n            </td>\n</tr>\n</tbody>\n</table>\n<p>The patient undergoes a repeat bone marrow biopsy, which demonstrates 3% plasma cell clonal population (unchanged from prior bone marrow biopsy) and a fat pad biopsy, which demonstrates deposits that stain with Congo red and are comprised of lambda light chains by spectrophotometric analysis. </p>\n<p><strong>Which of the following is the MOST APPROPRIATE next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Bortezomib and dexamethasone"
            },
            {
                "label": "C.",
                "text": "Lisinopril"
            },
            {
                "label": "D.",
                "text": "Furosemide"
            },
            {
                "label": "E.",
                "text": "Repeat serum free light chain ratio in 3 months"
            }
        ],
        "correct_answer": "Bortezomib and dexamethasone",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management for this patient with amyloid light chain (AL) amyloidosis would be to start therapy with bortezomib and dexamethasone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a history of MGUS is at risk for development of both multiple myeloma and AL amyloidosis. He now presents with weight gain, edema, and nephrotic syndrome, with an abnormal free light chain ratio suspicious for AL amyloidosis, which is confirmed by fat pad biopsy. He does not, however, meet the criteria for multiple myeloma. Early diagnosis and initiation of chemotherapy and/or stem cell transplantation in eligible patients has been shown to significantly improve survival in those with AL amyloidosis. The prototypical chemotherapy regimen for AL amyloidosis was melphalan and prednisone, but this has been supplanted by more effective bortezomib-based regimens.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney biopsy would not be necessary for further investigation of nephrotic range proteinuria, as fat pad biopsy has confirmed amyloidosis. When there is high suspicion for amyloidosis, bone marrow and/or fat pad biopsy are preferred as less invasive than kidney, liver, or myocardial biopsy and less likely to be complicated by serious bleeding. Kidney biopsy may be done if the diagnosis remains unclear, but in this case would be unlikely to change management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lisinopril often decreases proteinuria nonspecifically but would not be the best therapy for AL amyloidosis, which would be expected to respond to chemotherapy. His current BP may also preclude lisinopril initiation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient may ultimately require diuresis, but furosemide would not be the best choice for initial therapy. Diuresis may be challenging in patients with amyloidosis due to hypoalbuminemia with decreased intravascular volume or reduced ability to mobilize edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because early diagnosis and initiation of chemotherapy has been shown to improve survival in patients with AL amyloidosis even in the absence of multiple myeloma, monitoring the trend in serum free light chains in 3 months would lead to an unnecessary delay in therapy.</p>\n</div>",
        "references": [
            "Gertz MA: Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.Am J Hematol95(7): 848–860, 2020",
            "van Gameren II, Hazenberg BPC, Bijzet J, van Rijswijk MH: Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice.Arthritis Rheum54(6): 2015–2021, 2006",
            "Rysava R: AL amyloidosis: advances in diagnostics and treatment.Nephrol Dial Transplant34(9): 1460–1466, 2019"
        ]
    },
    "58": {
        "question": "<div class=\"qtext\"><p>A 59-year-old man with ESRD who receives HD via a left arm arteriovenous fistula (AVF) is evaluated for prolonged bleeding from needle cannulation sites after HD. For the last 2 weeks, bleeding has continued from both arterial and venous sites after needles are removed despite holding pressure for at least 15 minutes. Past medical history includes atrial fibrillation and non-ST elevation myocardial infarction. Medications include apixaban and aspirin.</p>\n<p>The patient is referred for angiography to evaluate the AVF.</p>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Bridge apixaban to heparin and hold before angiogram"
            },
            {
                "label": "B.",
                "text": "Proceed with angiogram"
            },
            {
                "label": "C.",
                "text": "Discontinue apixaban"
            },
            {
                "label": "D.",
                "text": "Hold apixaban 2 days before angiogram"
            },
            {
                "label": "E.",
                "text": "Hold apixaban and aspirin 2 days before angiogram"
            }
        ],
        "correct_answer": "Hold apixaban 2 days before angiogram",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, who requires angiography to evaluate and manage AVF dysfunction but receives chronic anticoagulation, should hold apixaban for 2 days before the angiogram and resume 2 days afterward. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prolonged bleeding following the removal of dialysis needles is most likely caused by an outflow obstruction of the AVF, usually manifested by increased venous pressure during HD with a pulsatile AVF. An angiogram is essential to diagnose the culprit lesion, and angioplasty will likely be needed. The continuation of systemic anticoagulation increases the risk of significant bleeding. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Familiarity with direct oral anticoagulants (DOACs) will be increasingly important for nephrologists as their use in patients with ESRD and atrial fibrillation is expanding. Among the DOACs, apixaban is considered one the safest to use in patients with ESRD, as pharmacokinetic data reveal minimal renal metabolism or elimination. However, dose adjustment is required in patients with ESRD. Apixaban has a half-life of 8–11 hours and should be held for 24 hours before low-risk procedures and for 36–48 hours before high-risk procedures. Angiography of an AVF with anticipated intervention is considered high risk. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no need to bridge apixaban to heparin, discontinue heparin, and bridge back to apixaban in this patient, in whom anticoagulation has been prescribed for stroke prophylaxis in atrial fibrillation. Continuous anticoagulation with a heparin bridge is required for patients who cannot safely discontinue anticoagulation because of high risk of acute thrombosis, such as those with mechanical heart valves or those being treated for an active thrombotic event. Although outpatient bridging might be possible with enoxaparin in certain circumstances, enoxaparin is difficult to administer effectively for patients with advanced kidney disease. These patients generally require hospitalization for heparin IV. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proceeding with angiography and angioplasty without temporarily discontinuing apixaban is not recommended, because these procedures would confer a high risk of bleeding during systemic anticoagulation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no reason to permanently discontinue apixaban in a patient with atrial fibrillation at risk for thromboembolism. The prolonged bleeding after HD is most likely caused by high intra-access pressure caused by an anatomical obstruction rather than the apixaban itself. If angiography fails to identify an anatomic explanation for the bleeding, the risk versus benefit of ongoing systemic anticoagulation would require additional discussion with the patient. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no need to discontinue aspirin before angiography or angioplasty because aspirin is not associated with excess bleeding risk.</p>\n</div>",
        "references": [
            "Crockett MT, Moynagh MR, Kavanagh EC: The novel oral anticoagulants: an update for the interventional radiologist.Am J Roentgenol199(3): W376–W379, 2012",
            "Van den Bosch I, Bouillon T, Verhamme P, et al: Apixaban in patients on hemodialysis: a single dose pharmacokinetics study.Nephrol Dial Transplant356(5): 884–889, 2021",
            "De Vriese AS, Caluwé R, Van Der Meersch H,et al: Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: A multicenter randomized controlled trial.J Am Soc Nephrol 32(6): 1474–1483, 2021"
        ]
    },
    "59": {
        "question": "<div class=\"qtext\"><p>A 60-year-old woman with a history of kidney transplantation presents to clinic with worsening orthopnea and dyspnea on exertion. She received a kidney transplant from her brother 2 years ago, and her clinical course has been stable with no episodes of rejection and a creatinine level of 1.1 mg/dL (reference range, 0.5–1.1). Her medical history includes ESRD attributed to hypertension. Her medications include tacrolimus, mycophenolate mofetil, lisinopril, and prednisone.</p>\n<p>On examination, her BP is 130/70 mm Hg, and heart rate is 94/min. Bibasilar crackles are present, and the jugular venous pressure is elevated. Her rhythm is regular. A continuous murmur is audible throughout the left precordium. She has hepatomegaly and 2+ pitting edema of her lower extremities bilaterally. Her left arm brachiocephalic arteriovenous fistula (AVF) has a loud bruit and vigorous thrill and only partially collapses with elevation. Manual compression of the AVF is accompanied by a fall in heart rate and disappearance of the precordial murmur.</p>\n<p>US of her fistula shows a flow rate of 1800 mL/min. </p>\n<p><strong>Which of the following is the MOST APPROPRIATE management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe furosemide"
            },
            {
                "label": "B.",
                "text": "Increase lisinopril dose"
            },
            {
                "label": "C.",
                "text": "Perform AVF ligation"
            },
            {
                "label": "D.",
                "text": "Refer for cardiac rehabilitation"
            },
            {
                "label": "E.",
                "text": "Perform AVF flow-limiting procedure (banding)"
            }
        ],
        "correct_answer": "Perform AVF ligation",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with a well-functioning kidney transplant, high-flow AVF, and probable high-output heart failure, fistula ligation is the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with high-flow fistulas (&gt;1500 mL/min) are at risk for developing high-output heart failure, pulmonary hypertension, and right heart remodeling. Ligation of the fistula can improve cardiac parameters. In two recent randomized controlled trials, patients who had prophylactic ligation of high-flow fistulas had regression of their high-output state and MRI or echocardiographic improvement in their cardiac anatomy and function. In one study, 38% of patients in the control group developed right heart failure over 24 months compared with 0% of patients in the intervention group. A fall in heart rate and an increase in BP with occlusion of the AVF, known as the Nicoladoni-Branham sign, is a bedside observation that can suggest significant hemodynamic effect of an AVF. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both medical management of congestive heart failure, such as titration of diuretics and afterload reduction, and cardiac rehabilitation may provide symptomatic benefit and functional improvement in patients with heart failure but would not address the underlying etiology. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A flow-limiting or banding procedure is used to treat dialysis access–related steal syndrome. It can also be used in a patient with a high-flow fistula and evidence of high-output heart failure who requires HD access. However, in this patient with a stable allograft and new-onset right heart failure, ligation would be the better option.</p>\n</div>",
        "references": [
            "Rao NN, Stokes MB, Rajwani A, et al: Effects of arteriovenous fistula ligation on cardiac structure and function in kidney transplant recipients.Circulation139(25): 2809–2818, 2019",
            "Hetz P, Pirklbauer M, Muller S, et al: Prophylactic ligature of AV fistula prevents high output heart failure after kidney transplantation.Am J Nephrol51(7): 511–519, 2020",
            "Zheng H, Bu S, Song Y, et al: To ligate or not to ligate: a meta-analysis of cardiac effects and allograft function following arteriovenous fistula closure in renal transplant recipients.Ann Vasc Surg63: 287–292, 2020",
            "Velez-Roa S, Neubauer J, Wissing M, et al: Acute arterio-venous fistula occlusion decreases sympathetic activity and improves baroreflex control in kidney transplanted patients.Nephrol Dial Transplant19(6):1606-1612, 2004"
        ]
    },
    "60": {
        "question": "<div class=\"qtext\"><p>A 75-year-old woman with CKD stage 4 from diabetic nephropathy presents for her 6-month follow-up. She reports increasing fatigue and poor appetite, associated with a 5-kg weight loss over the last year. She lives with her daughter and reports that she spends most days on the couch because she is too exhausted to cook or clean as she had previously. Her medications include lisinopril, sevelamer, furosemide, and weekly erythropoietin.</p>\n<p>BP is 130/70 mm Hg, and pulse is 70/min. Physical examination reveals temporal wasting and sarcopenia. There are no rubs or rales appreciated on heart or lung examination, respectively. Grip strength is reduced bilaterally. She does not have asterixis.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>6 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                110 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the next BEST STEP in the management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discuss patient’s goals of care"
            },
            {
                "label": "B.",
                "text": "Obtain CT scan of the chest, abdomen, and pelvis"
            },
            {
                "label": "C.",
                "text": "Initiate HD via tunneled dialysis catheter"
            },
            {
                "label": "D.",
                "text": "Admit to hospital for failure to thrive"
            },
            {
                "label": "E.",
                "text": "Refer to surgeon to place PD catheter"
            }
        ],
        "correct_answer": "Discuss patient’s goals of care",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with advanced CKD and frailty, the next best step in management would be to discuss her goals of care. Frailty is common in patients with ESRD and CKD, with a prevalence of 50%–80% in ESRD and a twofold increased risk in late-stage CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Frailty, along with malnutrition, advanced age, and other comorbidities, are all predictors of mortality and hospitalizations in patients with ESRD. Because there is no uniform way of measuring frailty in patients receiving dialysis, studies have shown various associations of frailty with mortality. The Fried Frailty Index defines frailty as three or more of the following: weight loss (&gt;10 pounds in 12 months), self-reported exhaustion, weak grip, low physical activity, and slow walking speed. This patient exhibits at least four of these criteria and would be classified as frail. Frail patients are also shown to have a higher rate of GFR decline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Given this patient’s risk factors for progressive CKD and high mortality with starting dialysis, it is imperative to engage in shared decision-making to explore her goals and priorities. Discussion should include the risks of initiating renal replacement therapy in a frail elderly woman and options for conservative management of her CKD, which has been shown to produce similar mortality outcomes with less hospitalization in an elderly and frail population.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">At this time, she does not have any indication to start renal replacement therapy by HD or PD. She does not have an indication for hospitalization, as her symptoms are consistent with frailty. Although it is reasonable to consider potentially identifiable and treatable conditions that could contribute to failure to thrive, hunting for an occult malignancy with a CT scan would not substitute for a goals-of-care discussion and is of low yield in the absence of specific indicators. </p>\n</div>",
        "references": [
            "van Loon IN, Wouters TR, Boereboom FT, et al: The relevance of geriatric impairments in patients starting dialysis: a systematic review.Clin J Am Soc Nephrol11(7): 1245–1259, 2016",
            "Koncicki HM, Schell JO: Communication skills and decision making for elderly patients with advanced kidney disease: a guide for nephrologists.Am J Kidney Dis67(4): 688–695, 2016",
            "Smith C, Da Silva-Gane M, Chandna S, et al: Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure.Nephron Clin Pract95(2): c40–c46, 2003",
            "Verberne WR, Geers AB, Jellema WT, et al: Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis.Clin J Am Soc Nephrol11(4): 633–640, 2016"
        ]
    },
    "61": {
        "question": "<div class=\"qtext\"><p>An 82-year-old man presents to the emergency department with 1 week of left knee pain and redness. He has a medical history of osteoarthritis of the knees, diabetes, hypertension, gastrointestinal bleed, obesity, and CKD stage 5. He notes 1 week of fevers, chills, and poor appetite but denies trauma to the knee. His medications include furosemide, labetalol, and sevelamer hydrochloride. </p>\n<p>BP is 160/80 mm Hg, pulse is 105/min, and temperature is 39.0°C. His body mass index (BMI) is 32 kg/m<sup>2</sup>. He appears unwell. His left knee is swollen, erythematous, warm, and tender to palpation. The rest of his joints are unremarkable, and his skin is without rashes. His heart, lung, and abdominal examinations are all within normal limits.</p>\n<p><strong>In addition to prescribing broad-spectrum antibiotics, which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe naproxen"
            },
            {
                "label": "B.",
                "text": "Administer intra-articular glucocorticoids"
            },
            {
                "label": "C.",
                "text": "Perform radiographs of the knee"
            },
            {
                "label": "D.",
                "text": "Obtain blood cultures"
            },
            {
                "label": "E.",
                "text": "Examine the synovial fluid"
            }
        ],
        "correct_answer": "Examine the synovial fluid",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with acute, inflammatory knee pain, the next step in management should be examination of the synovial fluid. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The differential diagnosis includes gout and acute calcium pyrophosphate crystal arthritis (acute CPP crystal arthritis, formerly known as pseudogout). Patients with either gout or acute CPP crystal arthritis typically have an acute presentation of swelling, redness, and tenderness of the affected joint, which is commonly the knee. Systemic symptoms including fever and chills are also common. The link between CKD, diuretics, hyperuricemia, and gout is well recognized. Loop diuretic use and CKD stage 5 are also associated with CPP crystal arthritis (odds ratio of 1.35 and 2.3, respectively) and can predispose to its development. The diagnosis of acute CPP crystal arthritis requires the presence of positively birefringent CPP crystals in the synovial fluid and chondrocalcinosis of the affected joint. Negatively birefringent, needle-shaped crystals, especially within WBCs, are diagnostic of gout. Radiographic findings of chondrocalcinosis can be support a diagnosis of CPP crystal arthritis but lack sufficient specificity for diagnosis. Furthermore, the presence of chondrocalcinosis does not exclude the presence of infection. Only synovial fluid analysis is sufficiently accurate to guide management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Blood cultures may be helpful, but definitive diagnosis of monoarticular joint inflammation requires examining the synovial fluid. If septic arthritis is suggested by synovial fluid analysis, antibiotic therapy should not wait for blood cultures to result.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If this patient has acute CPP crystal arthritis, the main treatment per the European League Against Rheumatism is intra-articular glucocorticoids. However, until septic arthritis is ruled out or acute CPP crystal arthritis is ruled in, steroids should not be administered empirically. Intra-articular steroids are similarly effective for acute gout and should be followed by urate-lowering therapy. Naproxen can be used in the treatment of an acute gout or CPP attack, but would not be best first line therapy in a patient with a history of a gastrointestinal bleed.</p>\n</div>",
        "references": [
            "Rosenthal AK, Ryan LM: Calcium pyrophosphate deposition disease.N Engl J Med374(26): 2575–2584, 2016",
            "Zhang W, Doherty M, Bardin T, et al: European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.Ann Rheum Dis70(4): 563–570, 2011",
            "Rho YH, Zhu Y, Zhang Y, et al: Risk factors for pseudogout in the general population.Rheumatology (Oxford)51(11): 2070–2074, 2012",
            "Vargas-Santos AB, Neogi T: Management of gout and hyperuricemia in CKD.Am J Kidney Dis70(3): 422–439, 2017"
        ]
    },
    "62": {
        "question": "<div class=\"qtext\"><p>A 40-year-old man is evaluated for impaired kidney function. He has a history of hypertension, for which he takes hydrochlorothiazide. For the last 3 months, he had been trying to “get healthy” by switching to a plant-based diet, increasing his consumption of nuts and seeds, exercising more, and taking twice-daily supplements containing vitamin C 2000 mg, cholecalciferol 1600 IU, and calcium carbonate 500 mg. He has no symptoms other than decreased urine output. </p>\n<p>On physical examination, he is an obese, well-appearing man. BP is 155/85 mm Hg, pulse is 80/min, and he has 1+ edema of his lower extremities bilaterally. There is no costovertebral angle tenderness.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1800 mg/24 h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;100\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urine microscopy shows 25–50 RBCs/HPF and 10–15 WBCs/HPF. </p>\n<p>US shows normal-sized kidneys with increased echogenicity.</p>\n<p>A kidney biopsy is performed. Histopathology is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1q62.png\" width=\"75%\"/>\n</figure>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1q62b.png\" width=\"75%\"/>\n</figure>\n<p><em>Hematoxylin and eosin stain, 20× magnification [top panel] and 4× magnification with polarized light [bottom panel]. Images courtesy of Jeremy Leventhal, MD, and Daniel Schwartz, MD. </em></p>\n<p><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Myeloma cast nephropathy"
            },
            {
                "label": "B.",
                "text": "Oxalate nephropathy"
            },
            {
                "label": "C.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "D.",
                "text": "Hypertensive nephrosclerosis"
            },
            {
                "label": "E.",
                "text": "Amyloidosis"
            }
        ],
        "correct_answer": "Oxalate nephropathy",
        "abim_content_category": "Calcium, Phosphorus, Magnesium Disorders, and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis is oxalate nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The kidney biopsy images demonstrate amorphous crystalline material in multiple tubular lumens that is brightly birefringent under polarized light. The glomeruli are uninvolved, and there is no evidence of an inflammatory infiltrate in the glomeruli or interstitial compartments.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oxalate nephropathy is defined as progressive kidney disease with demonstration of calcium oxalate crystals associated with tubular injury on kidney biopsy in the absence of another identifiable cause. It is an underdiagnosed condition, appearing in ~1% of biopsies performed for AKI, acute kidney disease, or CKD in a recent case series. Most cases are attributable to fat malabsorption causing enhanced oxalate absorption, but ~15% of cases are thought to be caused by either overconsumption of dietary oxalate or oxalate precursors. Oxalate is found in spinach, nuts, and seeds, among other foods. Vitamin C (ascorbic acid) is metabolized to oxalate. Ingestion of more than 2 g/d has been postulated as a risk threshold, but some case reports document a much lower exposure. Oxalate is excreted by the kidney, and therefore increased absorption or intake may cause hyperoxaluria, intratubular deposition of crystals, and AKI. Patients will often have microscopic hematuria, leukocyturia, and non-nephrotic range proteinuria. Calcium oxalate crystals can be seen on kidney biopsy, appearing as amorphous material in the tubule and demonstrating positive birefringence under polarized light. Often, a careful dietary history, including attention to supplements, is needed to make this diagnosis. Kidney injury may be irreversible, and treatment is directed at reducing or eliminating any ongoing hyperoxaluria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cast nephropathy is seen in patients with multiple myeloma and other monoclonal gammopathies and may present with other features of a plasma cell dyscrasia such as hypercalcemia and/or anemia, in addition to AKI. The cast lesions appear on biopsy as a light pink or polychromatic material within the tubules. The casts may appear brittle and fractured and are often associated with an adjacent inflammatory infiltrate that may include giant cells. These casts are not birefringent under polarized light. Acute interstitial nephritis would be expected to show interstitial infiltrates of WBCs on biopsy. Hypertensive nephrosclerosis appears as scarred glomeruli on biopsy; no foreign material is expected. Amyloidosis typically presents with more proteinuria, often nephrotic range, and predominantly albumin. The diagnosis is based on identification of salmon-pink deposits on light microscopy and apple-green birefringence on Congo red stain. The deposits are typically found within the glomeruli but may also affect tubules and vessel walls.</p>\n</div>",
        "references": [
            "Buysschaert B, Aydin S, Morelle J, et al: Etiologies, clinical features, and outcome of oxalate nephropathy.Kidney Int Rep5(9): 1503–1509, 2020",
            "Clark B, Baqdunes MW, Kunkel GM: Diet-induced oxalate nephropathy.BMJ Case Rep12(9): e231284, 2019",
            "Lumlertgul N, Siribamrungwong M, Jaber BL, Susantitaphong P: Secondary oxalate nephropathy: a systematic review. Kidney Int Rep3(6): 1363–1372, 2018",
            "Poulin LD, Riopel J, Castonguay V, Mac-Way F: Acute oxalate nephropathy induced by oral high-dose vitamin C alternative treatment.Clin Kidney J7(2): 218, 2014",
            "Lin WV, Turin CG, McCormick DW, et al: Ascorbic acid-induced oxalate nephropathy: a case report and discussion of pathologic mechanisms.CEN Case Rep. 8: 67–70, 2019"
        ]
    },
    "63": {
        "question": "<div class=\"qtext\"><p>A 25-year-old previously healthy female veterinary student presents for worsening malaise, fever, myalgias, headache, and skin discoloration over the last 2 weeks. Medications include as-needed ibuprofen, which she has used sparingly, and a multivitamin. Social history is significant for two alcoholic drinks weekly; she does not use tobacco, inhaled nicotine, or recreational drugs.</p>\n<p>On examination, BP is 98/46 mm Hg, heart rate is 110/min, and temperature is 39°C. Eye examination is significant for scleral icterus and subconjunctival hemorrhages without purulent exudate. Abdominal examination reveals splenomegaly. Musculoskeletal examination reveals tenderness to palpation of the lower back and both calves. She is jaundiced, but there is no rash.</p>\n<p>Laboratory data:</p>\n<table>\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Bilirubin, total\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Bilirubin, direct\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.1–0.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                300 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Peripheral blood smear shows rare schistocytes. Urinalysis shows dark yellow urine with 1+ blood, 8–10 isomorphic RBCs/HPF, and 1–2 granular casts/LPF.</p>\n<p><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "NSAID-associated AKI"
            },
            {
                "label": "B.",
                "text": "Thrombotic thrombocytopenic purpura"
            },
            {
                "label": "C.",
                "text": "Antiphospholipid syndrome"
            },
            {
                "label": "D.",
                "text": "Leptospirosis"
            },
            {
                "label": "E.",
                "text": "Hepatorenal syndrome"
            }
        ],
        "correct_answer": "Leptospirosis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with AKI, acute liver injury, and hypokalemia is leptospirosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Leptospirosis is a zoonotic disease caused by the spirochete <em>Leptospira interrogans</em> via an infected reservoir, which includes the brown rat, <em>Rattus norvegicus</em>. Infection leads to nonoliguric AKI and acute liver injury. Pathogenic <em>Leptospira</em> are shed from host urine and may contaminate water and soil, leading to environmental spread. This patient is at risk because of her veterinary exposure to rats; other exposure would be those living in hot, urban, unsanitary conditions. Hematogenous spread with accumulation in the tubulointerstitium leads to AKI, which appears as acute tubular necrosis (ATN) or acute interstitial nephritis (AIN) on kidney biopsy. Leptospirosis is also associated with potassium wasting caused by impaired sodium and potassium absorption in the thick ascending limb of the loop of Henle. Muscle pain and tenderness are common and characteristically involve the calves and lower back. Ophthalmologic findings include conjunctival suffusion, dilation of conjunctival vessels without purulent exudate, and subconjunctival hemorrhages and icterus. Hemorrhagic complications are also common and may include life-threatening alveolar hemorrhage associated with coagulation abnormalities.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NSAID-associated AKI, including prerenal AKI, ATN, and glomerular disease, is unlikely, as ibuprofen use was minimal. ATN may be a concurrent finding with leptospirosis in patients with prolonged hypovolemia from diarrhea, and NSAIDs might exacerbate this situation. In this case, NSAID toxicity would not explain the myriad findings.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although thrombotic thrombocytopenic purpura (TTP) must be considered in the presence of fever, thrombocytopenia, AKI, and anemia, it is not the most likely diagnosis in this case, as features of microangiopathic hemolysis are limited on the peripheral smear, and most of the bilirubin is conjugated, reflecting (with the elevated liver enzymes) hepatocellular injury and biliary stasis rather than intravascular hemolysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Catastrophic antiphospholipid antibody syndrome may cause simultaneous liver and kidney disease as a consequence of diffuse thrombosis but would not explain the clinical manifestations present in this case, including eye findings and hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hepatorenal syndrome would be unlikely in the absence of cirrhosis or severe acute liver failure and would not explain the other clinical and laboratory features of this case</p>\n</div>",
        "references": [
            "Haake DA, Levett PN: Leptospirosis in humans.Curr Top Microbiol Immunol387: 65–97, 2015",
            "Cippà PE, Auinger K, Wüthrich RP, Segerer S: An infectious cause of acute kidney injury with low serum potassium.BMJ Case Rep2015: bcr2015209910, 2015",
            "de Francesco Daher E, de Abreu KLS, da Silva Jr GB: Leptospirosis-associated acute kidney injury.J Bras Nefrol32(4): 400–407, 2010"
        ]
    },
    "64": {
        "question": "<div class=\"qtext\"><p>A 34-year-old woman who had a living-unrelated kidney transplant 4 years ago presents with diarrhea, vomiting, and anorexia. She has ESRD due to lupus nephritis but has had an unremarkable post-transplant course without infections, rejection, or evidence of active lupus.</p>\n<p>Six days before presentation, she developed liquid bowel movements (approximately eight times per day) associated with a decreased appetite. She denies any abdominal pain, blood in the stool, or melena. She also denies any sick contacts, ingestion of unpasteurized dairy products or raw or undercooked meat or fish, recent travel, or recent antibiotic exposure.  </p>\n<p>Her immunosuppression consists of tacrolimus and mycophenolate mofetil.</p>\n<p>On physical examination, her temperature is 37.7°C, BP is 125/70 mm Hg sitting and 100/60 mm Hg standing, and pulse is 95/min. Mucosa is dry, and jugular veins are not distended. Abdominal examination reveals increased bowel sounds but no tenderness or rebound. Lower extremities have no edema.</p>\n<p>An ultrasound of the kidney allograft and bladder demonstrates mild pelvicaliectasis and a postvoid residual bladder volume of 30 mL.</p>\n<p>Laboratory data show the following: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                250,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 mg/dL (baseline, 1.5)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for cells or albumin.</p>\n<p><strong>Which of the following is the MOST important diagnostic study to evaluate this patient’s allograft dysfunction?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CMV serology"
            },
            {
                "label": "B.",
                "text": "Fractional excretion of sodium"
            },
            {
                "label": "C.",
                "text": "Stool culture"
            },
            {
                "label": "D.",
                "text": "Tacrolimus trough level"
            },
            {
                "label": "E.",
                "text": "BK viral load"
            }
        ],
        "correct_answer": "Tacrolimus trough level",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most important diagnostic study to evaluate this patient’s allograft dysfunction is a tacrolimus trough level. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diarrhea is a frequent complication after kidney transplantation, and common etiologies include medication side effects (especially mycophenolate) and infections (viral, bacterial, or protozoal). Some pathogens, such as Shiga toxin–producing <em>Escherichia coli</em>, can cause AKI due to hemolytic uremic syndrome (HUS). Patients may present with bloody diarrhea and have an exposure history. Microangiopathic hemolytic anemia and thrombocytopenia are hallmarks. Although investigation for an infectious cause of the diarrhea is important, HUS is not the most likely etiology of this patient’s AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bowel inflammation of any cause may significantly affect the metabolism of tacrolimus and lead to elevated serum tacrolimus levels. Although reduced tacrolimus levels might be expected in the setting of diarrhea from decreased drug absorption, an elevated level is more commonly the case. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Under normal conditions, tacrolimus has a low bioavailability (~20%); it has poor PO absorption, is partially metabolized by enzymes in gut mucosa, and undergoes first-pass metabolism by the liver. In the setting of diarrheal illness and bowel inflammation, there may be decreased gut metabolism and increased drug absorption. Possible mechanisms to explain this phenomenon include reduced expression or function of enterocyte proteins such as P-glycoprotein, which is responsible for the transport of drugs back into the intestinal lumen, and CYP3A4 enzyme, which is responsible for metabolism of tacrolimus. An elevation in tacrolimus levels may lead to AKI mainly by vasoconstriction of the afferent arteriole. Therefore, measurement of the tacrolimus trough level should be performed for this patient with ongoing diarrhea and elevated creatinine. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CMV infection may occur in at-risk individuals 1–4 months following solid organ transplant if patients do not receive prophylaxis or 1–3 months following discontinuation of prophylaxis. Because this patient is now 4 years after transplant, this diagnosis would be less likely. The diagnosis of CMV-related disease is typically established by evidence of viral replication in plasma or histopathologic evidence of disease rather than serology, because immunosuppressed patients may have a defective antibody response in the setting of infections. Other clues to CMV infection may include fever and leukopenia, both of which are absent here.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Volume depletion can lead to prerenal azotemia. This patient has a clinical history consistent with hypovolemia, and her physical examination is notable for orthostatic hypotension, dry mucosa, and evidence of decreased peripheral perfusion. If the fractional excretion of sodium (FENa) is low, this would also be consistent with prerenal azotemia, although it is worth noting that this test may be misleading in patients with AKI or CKD. In addition, patients with tacrolimus nephrotoxicity may also have a low FENa. Lastly, patients with kidney transplants do not have sympathetic innervation of their allografts, so they may be less likely to retain sodium in the setting of decreased kidney perfusion compared with those with functioning native kidneys. Instead, isotonic fluid administration is appropriate based on the clinical presentation. Calculation of the FENa may be useful to guide further volume expansion if the patient does not improve after fluid resuscitation and other causes of AKI have been excluded. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BK nephropathy typically presents with asymptomatic AKI and not diarrhea. Microscopic or visible hematuria is also typically seen. BK nephropathy is more common in the first year after transplant and is unlikely to present with this time course in a patient with an unremarkable post-transplant course. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney allograft ultrasound should be obtained in the following cases: (1) unclear etiology of AKI or CKD, in particular, early after transplant due to frequent prevalence of mechanical problems related to vascular and urinary tract abnormalities; (2) in the setting of urinary tract infection in transplant recipients; and (3) in the presence of allograft tenderness. Kidney ultrasound can be obtained if function does not improve after optimizing the tacrolimus level and volume status. Despite a low yield in other circumstances, kidney ultrasound is commonly obtained, as in this case, due to wide availability, relatively low cost, and absence of toxicity.</p>\n</div>",
        "references": [
            "Lemahieu W, Maes B, Verbeke K, et al: Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.Am J Transplant5: 1383–1391, 2005",
            "Maes BD, Lemahieu W, Kuypers D, et al: Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients.Am J Transplant2: 989–992, 2002",
            "Milan Manani S, Virzì GM, Giuliani A, et al: Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature.Nephron136(3): 245–253, 2017"
        ]
    },
    "65": {
        "question": "<div class=\"qtext\"><p>A 78-year-old woman with stage IIIB, high-grade, serous ovarian carcinoma is seen in clinic for evaluation of recent onset edema, hypoalbuminemia, and proteinuria. Five months ago, she underwent surgical debulking of her ovarian cancer, which was followed by 1 cycle of carboplatin and paclitaxel chemotherapy. Her second cycle was held after she developed painful lower extremity edema, dyspnea on exertion, and a 10-kg weight gain. Her past medical history includes hypertension and hypothyroidism. Her medication regimen includes levothyroxine and furosemide, which was recently prescribed due to weight gain. Despite initiating diuretics, her weight has continued to increase. She reports no NSAID or over-the-counter medication use.</p>\n<p>On examination, her BP is 152/74 mm Hg, and heart rate is 73/min. Her oxygen saturation while breathing room air is 96%. Her lungs have dullness to auscultation and percussion at both bases and her abdomen is soft and protuberant, with a fluid wave and shifting dullness. Her lower extremities have 4+ edema to mid-thigh, and she has sacral edema. There is no jaundice or scleral icterus.</p>\n<p>Her laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.32 μU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A CT scan of her chest and abdomen shows bilateral pleural effusions, peritoneal carcinomatosis, ascites, and a small pericardial effusion. Her echocardiogram shows no wall motion or valvular abnormalities and an ejection fraction of 64%.</p>\n<p>A kidney biopsy is obtained. Light microscopy, immunohistochemical staining of the glomeruli for anti-phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) antibodies, and electron microscopy are shown below.</p>\n<p>Light microscopy (periodic acid-Schiff stain; 400× magnification):</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q21a.png\" width=\"50%\"/></figure>\n<p>PLA2R immunofluorescence (IF):</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q21b.png\" width=\"50%\"/></figure>\n<p>THSD7A IF:</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q21c.png\" width=\"50%\"/></figure>\n<p>Electron microscopy (EM; 12,000× magnification):</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q21d.png\" width=\"50%\"/></figure>\n<p><em>Images courtesy of Dr. Surya Seshan, Weill Cornell Medicine</em></p>\n<p><strong>Which ONE of the following is MOST consistent with a diagnosis of paraneoplastic membranous nephropathy? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Positive staining for PLA2R on IF"
            },
            {
                "label": "B.",
                "text": "Subepithelial deposits on EM"
            },
            {
                "label": "C.",
                "text": "Positive staining for THSD7A on IF"
            },
            {
                "label": "D.",
                "text": "Negative staining for NELL-1 on IF"
            },
            {
                "label": "E.",
                "text": "Positive staining for IgG4 on IF"
            }
        ],
        "correct_answer": "Positive staining for THSD7A on IF",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with ovarian carcinoma and new-onset nephrotic syndrome, the biopsy finding most suggestive of paraneoplastic (secondary) membranous nephropathy (MN) is positive immunohistochemical staining for THSD7A on IF. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The reported prevalence of secondary MN in patients with cancer is 6%–22%. MN is considered secondary to malignancy when the clinical and histologic features of the glomerulopathy remit after full remission of the cancer. Biopsy findings suggesting a paraneoplastic phenomenon include positive immunohistochemical staining for THSD7A on IF, with IgG1, IgG2, or IgG3 as the dominant subclass. On EM, findings associated with paraneoplastic MN include subepithelial and intramembranous deposits (much like primary MN), in addition to mesangial deposits and mesangial inflammatory cells. Solid tumors are more frequently associated with paraneoplastic MN, and although the precise etiology of the kidney lesion is not well defined, the hypothesis is that circulating tumor antigens are deposited on the subepithelial side of the GBM, where they induce in situ immune complex formation. Remission of the MN requires appropriate cancer-directed therapy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary MN is associated with autoantibodies to PLA2R, which are positive in up to 80% of cases of primary MN. In primary MN, the dominant IgG subclass found on IF is IgG4. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Autoantibodies to THSD7A account for only 1%–3% of cases of primary MN. Thus, a positive THSD7A with a negative PLA2R stain raises suspicion for paraneoplastic membranous nephropathy, as in this case. Neural epidermal growth factor-like 1 protein (NELL-1)–positive staining is also associated with malignancy.</p>\n</div>",
        "references": [
            "Alsharhan L, Beck LH Jr: Membranous nephropathy: Core Curriculum 2021.Am J Kidney Dis77(3): 440–453, 2021",
            "Bacchetta J, Juillard L, Cochat P, Droz JP: Paraneoplastic glomerular diseases and malignancies.Crit Rev Oncol Hematol70(1): 39–58, 2009",
            "Hoxha E, Beck LH Jr, Wiech T, Tomas NM, et al: An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy.J Am Soc Nephrol28(2): 520–531, 2017"
        ]
    },
    "66": {
        "question": "<div class=\"qtext\"><p>A 73-year-old woman with stage IV renal cell cancer is evaluated for the recent onset of hypertension. Eight months ago, she underwent left nephrectomy for control of the primary lesion but already had metastases, prompting initiation of axitinib. Her BP was normal until 1–2 months ago. She does not specifically restrict sodium intake.</p>\n<p>On examination, her BP is 176/82 mm Hg, and heart rate is 72/min. There is dullness to percussion at the lung bases. Cardiac sounds are normal. There is no appreciable organomegaly, ascites, or edema.</p>\n<p>An echocardiogram demonstrates normal left ventricular contraction. A positron emission tomographic (PET) scan shows improvement in the renal cell carcinoma metastatic burden.</p>\n<p>Laboratory tests yield the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>180,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>135 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.9 mg/dL (baseline)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Lactate dehydrogenase (LDH)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>221 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80–225</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Haptoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>210 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>83–267</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3 mg/mg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the BEST approach to managing this patient’s hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hydrochlorothiazide"
            },
            {
                "label": "B.",
                "text": "Diltiazem"
            },
            {
                "label": "C.",
                "text": "Carvedilol"
            },
            {
                "label": "D.",
                "text": "Amlodipine"
            },
            {
                "label": "E.",
                "text": "Discontinue axitinib"
            }
        ],
        "correct_answer": "Amlodipine",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Amlodipine is among the preferred therapeutic agents for hypertension related to treatment with angiogenesis inhibitors, including axitinib.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Angiogenesis inhibitors include monoclonal antibodies that target the vascular endothelial growth factor (VEGF) receptor, such as bevacizumab, and small molecule tyrosine kinase inhibitors (TKIs), such as axitinib. Hypertension is observed in up to 57% of patients receiving angiogenesis inhibitors. Risk factors for developing hypertension with angiogenesis inhibitors include preexisting hypertension, age &gt;60 years, CKD, and body mass index (BMI) &gt;25 kg/m<sup>2</sup>. Proteinuria can develop in up to 64% of patients taking this class of drugs and is observed more frequently in those who are taking angiogenesis inhibitors for the treatment of metastatic renal cell carcinoma. This finding may be due to hyperfiltration and compensatory renal hypertrophy after nephrectomy. A 2019 retrospective study of patients with renal cell carcinoma treated with anti-VEGF therapy reported that calcium channel blockers and potassium-sparing diuretics were most effective at treating anti-VEGF-induced hypertension, with modest decreases in patients using ACEIs. A different 2019 retrospective study comparing BP in patients who were versus those who were not receiving renin-angiotensin-aldosterone system (RAAS) inhibitors prior to initiation of anti-VEGF therapy showed that those who were taking RAAS inhibitors developed less hypertension. The authors speculated that the mechanism of anti-VEGF–induced hypertension is related to increased RAAS activation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The development of hypertension, edema, and proteinuria with angiogenesis therapy may be related to reduction of VEGF at the glomerular endothelium, which can lead to endothelial dysfunction, capillary rarefaction, and podocyte injury. At the extreme, these processes can manifest clinically as thrombotic microangiopathy (TMA). In addition to edema, hypertension, and proteinuria, TMA is associated with AKI, high LDH, low haptoglobin, and schistocytes in the peripheral blood smear. Patients who develop edema, hypertension, and proteinuria should be closely monitored for the development of TMA, but it is not necessary to discontinue the anti-angiogenesis therapy in the absence of TMA. In this case, there is evidence that axitinib is controlling the cancer, and there is no evidence for TMA, so axitinib can reasonably be continued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">VEGF receptor inhibitors and TKIs are metabolized by the cytochrome CYP3A4 pathway. The non-dihydropyridine calcium channel blockers diltiazem and verapamil inhibit this pathway. Therefore, these agents should be avoided. Nifedipine has been demonstrated to induce VEGF in various tumor models and should also be avoided in this setting. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hydrochlorothiazide, or an alternative diuretic, may be useful to help control hypertension, it would not be the preferred primary agent in this case. Similarly, in the absence of heart failure with reduced ejection fraction, carvedilol would also not be the best agent to control axitinib-mediated hypertension.</p>\n</div>",
        "references": [
            "Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy.N Engl J Med358(11): 1129–1136, 2008",
            "Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K: Nifedipine induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1 NO pathway.Hypertens Res28(2): 147–153, 2005",
            "Sathick I, Seshan S, Glezerman IG: Onco-nephrology highlights: why did my patient get this kidney problem after receiving this new cancer drug?J Onco-Nephrol1: 9–17, 2017",
            "McKay RR, Rodriguez GE, Lin X, et al: Angiotension system inhibition and survival outcomes in patients with metastatic renal cell carcinoma.Clin Cancer Res21(11): 2471–2479, 2015",
            "Bottinor WJ, Shuey MM, Manouchehri A, et al: Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition.JACC CardioOncol1(1): 14–23, 2019",
            "Waliany S, Sainani KL, Park LS, Zhang CA, Srinivas S, Witteles RM: Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor.JACC CardioOncol1(1): 24–36, 2019"
        ]
    },
    "67": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with ESRD due to hypertensive nephropathy returns for his monthly PD clinic visit. One year ago, HD was initiated after the patient presented to the hospital with uremic pericarditis, his first contact with the medical community in nearly 20 years. After missing several treatments per month because of transportation problems, he transitioned to PD 5 months ago. He is adherent to his medications, which include losartan 50 mg daily, sevelamer 2400 mg three times daily, calcitriol 1 μg daily, and cinacalcet 90 mg daily, although he notes some moderate nausea with cinacalcet.</p>\n<p>Last month, after complaining of left hip pain, an x-ray was obtained, which revealed a lytic lesion of the pelvis. A biopsy of the lesion revealed hemosiderin staining, giant cells, and woven osteoid, consistent with osteitis fibrosa cystica.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>PTH, intact</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2377 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>130–585 (dialysis patients)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Kt/V, total weekly</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≥1.7</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase dialysis dose"
            },
            {
                "label": "B.",
                "text": "Parathyroidectomy"
            },
            {
                "label": "C.",
                "text": "Increase calcitriol dose"
            },
            {
                "label": "D.",
                "text": "Increase cinacalcet dose"
            },
            {
                "label": "E.",
                "text": "Oncology referral"
            }
        ],
        "correct_answer": "Parathyroidectomy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with osteitis fibrosa cystica, severe hyperparathyroidism, side effects from cinacalcet, and acceptable serum phosphorus and calcium levels, parathyroidectomy should be performed. The etiology of this patient’s refractory hyperparathyroidism is likely prolonged parathyroid stimulation from years of unmanaged CKD followed by intermittent HD attendance prior to switching to PD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Osteitis fibrosa cystica, or “brown tumor,” is a benign finding caused by a severe form of high bone turnover in the setting of PTH-driven osteoclast activity. The term brown tumor is derived from the gross appearance of the tissue due to hemosiderin deposition. These tumors can form in any bone and may grow rapidly. Radiographically, they appear as lytic lesions, and biopsy reveals multinucleated giant cells, fibroblasts, and hemosiderin-laden macrophages. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The initial management of brown tumors in patients with secondary hyperparathyroidism of renal origin includes aggressive PTH control using vitamin D analogs and calcimimetics, as well as efforts to normalize serum calcium and phosphorus. As in other cases of severe hyperparathyroidism, should medical management fail to improve the PTH, parathyroidectomy should be pursued. Control of PTH should allow for regression of the lesions.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although both calcitriol and cinacalcet are cornerstones in the initial treatment of brown tumors, this patient’s refractory hyperparathyroidism makes increased dosing unlikely to successfully manage his disease. Increasing the dialysis dose will not improve this patient’s hyperparathyroidism. Referral to oncology would be appropriate for multiple myeloma, which can also cause lytic lesions of bone, but would not be indicated for this metabolic bone disease.</p>\n</div>",
        "references": [
            "Wiederkehr M: Brown tumor complicating end-stage kidney disease.Clin Nephrol CaseStud8: 72–79, 2020",
            "Duval-Sabatier A, Gondouin B, Bouvier C, Bataille S, Berland Y, Brunet P: Brown tumor: still an old disease?Kidney Int80(10): 1110, 2011",
            "Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.Clin J Am Soc Nephrol6(4): 913–921, 2011"
        ]
    },
    "68": {
        "question": "<div class=\"qtext\"><p>A 60-year-old woman with ESRD secondary to glomerulonephritis, treated with HD for 8 years, presents to the emergency department with nausea, continuous vomiting, and altered mental status. Her past medical history includes hypertension, obesity, and secondary hyperparathyroidism. Two months ago, she developed bilateral, painful, violaceous ulcerations on her lower extremities. A biopsy of these ulcers showed calcification of the small arteries in the surrounding subcutaneous and adipose tissue. Her medications include low-dose aspirin, lisinopril, metoprolol, cholecalciferol, calcium carbonate, and sodium thiosulfate (STS) thrice weekly after each HD session for the last month. Her family reports poor adherence to her phosphate binders, although she has not missed any HD sessions.</p>\n<p>On examination, she has a BP of 110/80 mm Hg, heart rate of 110/min, temperature of 37.8°C, and oxygen saturation of 95% while breathing room air. Her body mass index (BMI) is 35 kg/m<sup>2</sup>. She is confused and oriented only to self. Her abdomen is soft and nontender to palpation. Her skin has dark ulcerations on the lower extremities (see images below).</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q25a.png\" style=\"vertical-align: text-top;\" width=\"50%\"/><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b2q25b.png\" style=\"vertical-align: text-top;\" width=\"25%\"/></figure>\n<p><em>Images from Clin J Am Soc Nephrol 9(1): 166‒173, 2014.</em></p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.4 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>94 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      PTH, intact</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>960 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>130–585, dialysis</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Lactate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.1 mmol/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–2.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Arterial blood gas</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.2</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      PCO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Sodium thiosulfate toxicity"
            },
            {
                "label": "B.",
                "text": "Inadequate dialysis"
            },
            {
                "label": "C.",
                "text": "Salicylate toxicity"
            },
            {
                "label": "D.",
                "text": "Septic shock"
            },
            {
                "label": "E.",
                "text": "Cardiogenic shock"
            }
        ],
        "correct_answer": "Sodium thiosulfate toxicity",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, who is receiving STS for calciphylaxis or calcific uremic arteriolopathy (CUA), presents with symptoms and laboratory data consistent with STS toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">STS is an inorganic salt that is believed to have antioxidant and vasodilatory properties, with some in vitro studies suggesting it can block the adipocyte-induced calcification of vascular smooth muscle cells that is the hallmark of CUA. Although there are no prospective studies showing benefit of STS in CUA and a 2019 meta-analysis of retrospective studies showed no difference in mortality or wound healing with STS, it has nonetheless become a mainstay of treatment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The main side effects of STS are nausea, vomiting, abdominal pain, and mild metabolic acidosis. In some cases, patients can develop a severe anion gap metabolic acidosis, at least in part attributable to the accumulation of thiosulfate, sulfide, and other anion metabolites of STS. These metabolites are postulated to inhibit mitochondrial function, causing a secondary type B lactic acidosis. Patients who develop severe side effects should have the STS dose reduced; some may need to discontinue the drug entirely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inadequate dialysis can also be associated with a high anion gap metabolic acidosis, but the timing of the presenting symptoms with STS initiation for CUA and the concomitant lactic acidosis make STS toxicity a more likely diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Salicylate toxicity often presents with a combined high anion gap metabolic acidosis and respiratory alkalosis. Additionally, it would be unlikely for low-dose aspirin to cause such significant toxicity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Septic and cardiogenic shock could cause lactic acidosis with a high anion gap metabolic acidosis. Septic shock is less likely given the localized lesions without clear findings to suggest infection. Although this patient has atrial fibrillation and coronary artery disease, the clinical presentation is not consistent with cardiogenic shock. Additionally, it is noteworthy that the anion gap of 30 mEq/L is unaccounted for by the lactate level of only 2.1 mEq/L.</p>\n</div>",
        "references": [
            "Nigwekar SU, Kroshinsky D, Nazarian RM, et al: Calciphylaxis: risk factors, diagnosis, and treatment.Am J Kidney Dis66(1): 133‒146, 2015",
            "Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P: Treatment of calciphylaxis in CKD: a systematic review and meta-analysis.Kidney Int Rep4(2): 231‒244, 2018",
            "Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr: Sodium thiosulfate therapy for calcific uremic arteriolopathy.Clin J Am Soc Nephrol8(7): 1162‒1170, 2013",
            "Sprague SM: Painful skin ulcers in a hemodialysis patient.Clin J Am Soc Nephrol9(1): 166‒173, 2014",
            "Mao M, Lee S, Kashani K, Albright R, Qian Q: Severe anion gap acidosis associated with intravenous sodium thiosulfate administration.J Med Toxicol9(3): 274‒277, 2013",
            "Hunt GM, Ryder HF: Metabolic acidosis after sodium thiosulfate infusion and the role of hydrogen sulfide.Clin Case Rep6(8): 1595‒1599, 2018"
        ]
    },
    "69": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man is admitted to the hospital for acute abdominal and back pain for the past week. He describes his pain as episodic and radiating to the lumbar region bilaterally with no known aggravating factors and associated with vomiting of food and bile. His urinary frequency and quantity are unchanged. His past medical history includes hypertension, and he has a 15-pack-year history of smoking. He uses alcohol weekly and cocaine and marijuana intermittently for the last 10 years, most recently 3 weeks ago. His only prescription medication is hydralazine, but he has been taking ibuprofen twice daily for the last week for his abdominal and back pain.</p>\n<p>On examination, his BP is 200/120 mm Hg, heart rate is 110/min, and body mass index (BMI) is 35 kg/m<sup>2</sup>. His abdominal examination is remarkable only for mild tenderness in his periumbilical region, without peritoneal signs or organomegaly. He has trace edema and a faint, purple, reticular rash on his lower extremities bilaterally. The rest of his examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12,500/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14‒18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>172,000/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>40 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5 mg/dL (baseline 1.3)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>135 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Prothrombin time, plasma</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12 s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11–13</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Activated partial thromboplastin time</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>45 s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25–35</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  ANA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&gt;1:40</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Antibodies to double-stranded DNA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3 IU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–7 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Anticardiolipin antibody IgG</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>40 GPL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>˂20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Anticardiolipin antibody IgM</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>35 MPL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>˂20</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals pH 5.5, specific gravity of 1.015, 1+ protein, and 2+ blood. Urine microscopy shows 8–10 RBC/hpf and 6–8 WBC/hpf.</p>\n<p>A CT scan of the abdomen without contrast shows the right kidney enlarged with perinephric stranding and the left kidney with a lobulated contour. There is no hydronephrosis. Liver and spleen are normal.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney infarction"
            },
            {
                "label": "B.",
                "text": "NSAID toxicity"
            },
            {
                "label": "C.",
                "text": "Cocaine toxicity"
            },
            {
                "label": "D.",
                "text": "Lupus nephritis"
            },
            {
                "label": "E.",
                "text": "Thrombotic microangiopathy"
            }
        ],
        "correct_answer": "Kidney infarction",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of AKI in this patient is acute kidney infarction, attributable to antiphospholipid syndrome (APS).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">APS is a complex, systemic autoimmune disease characterized by circulating antibodies directed against anionic phospholipids and the proteins bound to them. Criteria for diagnosing APS include ≥1 clinical (venous, arterial, or small vessel thrombosis [excluding superficial vessels] or pregnancy morbidity) and ≥1 laboratory criteria (IgG or IgM anticardiolipin or anti-β<sub>2</sub>-glycoprotein antibodies at &gt;99th percentile titer or lupus anticoagulant activity on ≥2 occasions &gt;12 weeks apart).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Besides the clinical criteria above, APS may also present with livedo reticularis, thrombocytopenia, hemolytic anemia, and cardiac valvular disease. Kidney manifestations of APS include acute arterial thrombosis resulting in renal infarction, renal venous thrombosis, thrombotic microangiopathy (TMA), renal artery stenosis, resistant hypertension, and nephritic or nephrotic glomerular disease (most commonly membranous nephropathy).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney infarction usually presents as severe unilateral or bilateral lumbar pain, accompanied by severe hypertension and AKI. Diagnosis is made by documenting the laboratory criteria above, as well as by imaging findings of wedge-shaped cortical infarcts. Chronic thrombotic episodes may lead to atrophic kidneys with lobulated contours.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NSAID and cocaine toxicity could cause AKI and hypertension but would not explain the positive APS serologic findings. TMA remains on the differential diagnosis for this patient in the setting of hypertensive emergency, cocaine use, and APS, but would be expected to cause microangiopathic hemolytic anemia with significant thrombocytopenia, which is not present in this case. Lupus is frequently associated with APS, but lupus nephritis would be expected to present with hypocomplementemia and antibodies against double-stranded DNA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IV anticoagulation is the recommended initial strategy in management of acute kidney infarction secondary to APS. Subsequently, maintenance therapy would include a statin, hydroxychloroquine, and warfarin or aspirin.</p>\n</div>",
        "references": [
            "Sinico RA, Cavazzana I, Nuzzo M, et al: Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients.Clin J Am Soc Nephrol5(7): 1211–1217, 2010",
            "Turrent-Carriles A, Herrera, Felix JP, Amigo MC: Renal involvement in antiphospholipid syndrome.Front Immunol9:1008, 2018",
            "Tektonidou MG: Antiphospholipid syndrome nephropathy: from pathogenesis to treatment.Front Immunol9:1181, 2018",
            "Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).J Thromb Haemost4(2): 295–306, 2006"
        ]
    },
    "70": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man is referred for evaluation of worsening CKD for the last 6 years. Past medical history is significant for long-standing hypertension and an episode of pancreatitis 7 years ago. He has consumed alcohol 4–5 times per week for the last 25 years. Medications include nifedipine and pancreatic enzymes. Review of systems is positive for painless masses that have developed in both cheeks and urinary frequency with a weak, delayed urinary stream.</p>\n<p>On examination, his BP is 150/90 mm Hg, heart rate is 95/min, and body mass index (BMI) is 28 kg/m<sup>2</sup>. Head and neck examination reveals bilateral, painless parotid enlargement, poor dentition, and gingival hyperplasia. Oral mucosa is moist. He has mild tenderness in the epigastric region. The remainder of the examination is normal.</p>\n<p>Laboratory data reveal the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9500/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14‒18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>170,000/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>35 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.2 mg/dL (last year, 1.7)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10‒40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>45 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10‒40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alkaline phosphatase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30‒120</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Immunoglobulins</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   IgA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>210 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90–325</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   IgE</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>420 IU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;380</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   IgG</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2500 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80–1500</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   IgM</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>55 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>45–150</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals pH 6.5, specific gravity of 1.013, 1+ protein, and 1+ blood. Microscopy reveals 1–2 RBC/hpf and 4–8 WBC/hpf. Protein-to-creatinine ratio is 0.4 mg/mg (reference range, &lt;0.2).</p>\n<p>A CT scan of the abdomen shows numerous, wedge-shaped, low-attenuation lesions in both kidneys, without hydronephrosis or hydroureter. There is mild hepatomegaly.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of CKD?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypertension"
            },
            {
                "label": "B.",
                "text": "Urinary tract obstruction"
            },
            {
                "label": "C.",
                "text": "IgG4-related disease"
            },
            {
                "label": "D.",
                "text": "Myeloma cast nephropathy"
            },
            {
                "label": "E.",
                "text": "Sjögren syndrome"
            }
        ],
        "correct_answer": "IgG4-related disease",
        "abim_content_category": "Tubular, Interstitial and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely etiology of CKD in this patient with progressive CKD, a history of pancreatitis, and parotid gland enlargement is IgG4-related disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient likely has IgG4-related CKD based on his age, parotid gland enlargement, episode of pancreatitis, hypodense lesions on kidney imaging, hypocomplementemia, and elevated serum IgG levels. IgG fractionation would likely reveal elevated IgG4 subclass levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IgG4-related disease is a multisystemic, inflammatory disorder that most commonly presents as enlargement and/or mass formation within the lymph nodes, pancreas, kidneys, and salivary or lacrimal glands. Gingival hyperplasia is attributed to infiltration of the gingival epithelium with IgG4-rich plasma cells. Kidney disease, which may affect 7%–24% of patients, often manifests as chronic tubulointerstitial nephritis, with lymphoplasmacytic infiltration and storiform (irregularly whorled) fibrosis on biopsy. IF typically shows IgG4 predominance. The presentation of kidney disease may be nonspecific, with low-grade proteinuria or hematuria in about 50% of patients. Diagnosis is often delayed but may be suspected due to unexplained AKI or CKD in a patient with systemic lymphadenopathy or with classic imaging findings. Other kidney manifestations of IgG4-related disease include membranous nephropathy, retroperitoneal fibrosis, and renal pelvic lesions, which may cause obstruction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has a long history of hypertension, neither hematuria nor depressed complement levels are consistent with hypertensive kidney disease. Lower urinary tract obstruction may occur in IgG4-related disease, as discussed above, but CT findings are inconsistent with obstructive uropathy. Multiple myeloma, with light chain cast nephropathy, may be the underlying diagnosis in some patients with progressive CKD, elevated IgG levels, and anemia, but would not explain the hypocomplementemia or parotid gland enlargement. Sjögren syndrome may cause tubulointerstitial nephritis and parotid gland swelling, but patients with this condition will almost always report dry eyes and mouth (sicca complex, 100% of patients), and IgG4 subclass levels would be expected to be normal. Patients with Sjögren syndrome frequently present with cytopenias as well. Although IgG4-related sialadenitis may occur in some patients with Sjögren syndrome, this condition is much more common in women (15.7:1 female:male ratio).</p>\n</div>",
        "references": [
            "Kawano M, Saeki T, Nakashima H: IgG4-related kidney disease and retroperitoneal fibrosis: an update.Mod Rheumatol29(2): 231–239, 2019",
            "Saeki T, Kawano M: IgG4-related kidney disease.Kidney Int85(2): 251–257, 2014",
            "Saeki T, Kawano M, Nagasawa T, et al. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version.Clin Exp Nephrol25(2): 99–109, 2021",
            "Garcia-Carrasco M, Mendoza-Pinto C, Jimenez-Hernandez C, et al: Serologic features of primary Sjogren’s syndrome: clinical and prognostic correlation.Int J Clin Rheumatol7(6): 651–659, 2012",
            "Hong X, Li W, Xie XY, Zhang ZY, et al: Differential diagnosis of IgG4-related sialadenitis, primary Sjogren syndrome, and chronic obstructive submandibular sialadenitis.Br J Oral Maxillofac Surg55(2): 179–184, 2017"
        ]
    },
    "71": {
        "question": "<div class=\"qtext\"><p>A 52-year-old man with a past history of type 2 diabetes and ESRD treated with CCPD for 3 months presents to the dialysis unit for monthly follow-up. His PD prescription is 7 exchanges of 1.8 L over 8 hours with no mid-day exchange. His average daily ultrafiltration is 1.7 L using a combination of 1.5% and 2.5% dextrose solutions. He reports exertional dyspnea, which has been worsening since starting dialysis. He also describes significant thirst. He otherwise feels well and has not had fever, nausea, abdominal pain, or constipation. His weight has increased by 5 kg since starting PD, which he attributes to an increased appetite.</p>\n<p>On examination, BP is 168/88 mm Hg, heart rate is 66/min, respiratory rate is 18/min, oxygen saturation is 93% breathing room air, and temperature is 37.5°C. He has bibasilar rales and 1+ lower extremity edema to the mid-shin bilaterally. Feet are warm and well perfused. The PD catheter exit site and tunnel are without tenderness, erythema, or exudate. The remainder of the examination is unremarkable. </p>\n<p><strong>Which ONE of the following is the most likely cause of this patient’s hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ultrafiltration failure"
            },
            {
                "label": "B.",
                "text": "Sodium sieving"
            },
            {
                "label": "C.",
                "text": "Congestive heart failure"
            },
            {
                "label": "D.",
                "text": "Excessive water intake"
            },
            {
                "label": "E.",
                "text": "Essential hypertension"
            }
        ],
        "correct_answer": "Sodium sieving",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with very short PD dwell times, the most likely etiology of his hypertension is sodium sieving. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Water and solute transport across the peritoneal membrane occurs via aquaporins, small pores, and large pores. Early in the dwell, transport is dominated by free water movement through aquaporin channels. This results in a reduction in sodium concentration in the dialysate and an increase in the sodium concentration in the blood. After 60–90 minutes, small pore transport predominates, allowing solutes such as sodium to be transported from the blood into the peritoneum via diffusion and convection. Eventually, the concentration of sodium in the blood and dialysate will equilibrate, resulting in net sodium and water loss. However, if the dwell time is too short, as in this patient, there is an imbalance between water and sodium loss, resulting in an increase in the patient’s serum sodium concentration, osmolality, and thirst, which drive PO fluid intake and volume expansion. The net result is sodium and fluid retention despite the appearance of adequate ultrafiltration. The management is to increase dwell time, typically by decreasing the number of overnight exchanges.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ultrafiltration failure may occur due to loss of aquaporins, increase in lymphatic drainage, and membrane scarring. Ultrafiltration failure is diagnosed using the “rule of 4s,” in which a 4-hour dwell of 4.25% dextrose fails to result in 400 mL of ultrafiltration. Chronic ultrafiltration failure may occur after repeated episodes of peritonitis or prolonged use of 4.25% dextrose exchanges and is unlikely in this patient who has received PD for only 3 months.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although fluid balance is often described in terms of water or fluid intake, excessive water intake alone manifests as a reduction in serum tonicity and not as hypertension and hypervolemia. The excessive water intake in this case is a result of increased tonicity from sodium sieving, leading to thirst.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although pulmonary rales, edema, and exertional dyspnea may be seen in acute decompensated heart failure, there is no history of congestive heart failure, and associated physical examination findings such as hypotension, an S3 or S4 gallop on heart examination, or cool extremities are absent.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In patients with ESRD, hypertension is most frequently a manifestation of volume expansion and managed by ultrafiltration and titration of dry weight. In this case, essential hypertension is unlikely in the setting of physical examination findings of hypervolemia.</p>\n</div>",
        "references": [
            "Teitelbaum I: Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach.Blood Purif39(1–3):70–73, 2015",
            "Khanna R: Solute and water transport in peritoneal dialysis: a case-based primer.Am J Kidney Dis69(3): 461–472, 2017",
            "Fischbach M, Schmitt CP, Shroff R, Zaloszyc A, Warady BA: Increasing sodium removal on peritoneal dialysis: applying dialysis mechanics to the peritoneal dialysis prescription.Kidney Int89(4): 761–766, 2016"
        ]
    },
    "72": {
        "question": "<div class=\"qtext\"><p>A 54-year-old kidney transplant recipient presents to clinic with acute allograft dysfunction. Her past medical history includes ESRD attributed to membranous nephropathy. She received her first kidney transplant 4 years ago but developed premature graft failure from BK polyoma virus nephropathy. She received a second transplant 6 months ago. At the time of transplant, calculated panel of reactive antibodies (PRA) was 82% and she received anti-thymocyte globulin induction, followed by tacrolimus, mycophenolate, and prednisone for maintenance immunosuppression.   </p>\n<p>Her serum creatinine has been 0.8–1.1 mg/dL (reference range, 0.5–1.1). However, her kidney function has progressively declined over the last 2 weeks, and serum creatinine is now 2.6 mg/dL. Tacrolimus 12-hour trough level is 6.8 ng/mL (reference range, 5.0–10.0 at &gt;3 months post-transplant). She is afebrile and asymptomatic, with an unremarkable examination. </p>\n<p>Her urinalysis shows 1+ protein, trace blood, negative nitrite, and 1+ leukocyte esterase. Her urine microscopy is notable for 3–5 RBC/hpf and 15–20 WBC/hpf. Her spot urine protein-to-creatinine ratio is 1.1 mg/mg (reference range, &lt;0.2).</p>\n<p>A transplant kidney biopsy demonstrates acute tubular injury, peritubular capillaritis (with both mononuclear cells and neutrophils), and glomerulitis. No interstitial inflammation or tubulitis is seen, and SV40 staining is negative. Immunofluorescence shows linear C4d staining in the peritubular capillaries. Staining for IgA, IgG, and C3 is negative.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in diagnosis? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Donor-specific antibodies"
            },
            {
                "label": "B.",
                "text": "BK polyomavirus PCR"
            },
            {
                "label": "C.",
                "text": "Anti-phospholipase A2 receptor antibody"
            },
            {
                "label": "D.",
                "text": "Urine culture"
            },
            {
                "label": "E.",
                "text": "Biopsy tissue gene transcript expression"
            }
        ],
        "correct_answer": "Donor-specific antibodies",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best next step is to test for the presence of human leukocyte antigen (HLA) donor-specific antibodies (DSAs). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has acute allograft dysfunction and biopsy features highly suggestive of acute antibody-mediated rejection (ABMR). The primary criteria for the diagnosis of ABMR include histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with the endothelium, and presence of circulating DSAs. In this patient’s biopsy, the microvascular inflammation (glomerulitis and peritubular capillaritis) and peritubular capillary C4d staining are suspicious for ABMR. Testing for the serologic presence of DSAs is the appropriate next step to confirm the diagnosis of ABMR.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient’s first transplant failed due to BK virus nephropathy, currently this is a less likely diagnosis. The histologic appearance of BK virus nephropathy typically includes tubulitis, interstitial inflammation, viral inclusion bodies, and positive staining for SV40. The features of this patient’s biopsy are more consistent with ABMR. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anti–phospholipid A2 receptor antibody (anti-PLA2R) is commonly found in patients with primary membranous nephropathy and can be useful in some cases to assess for recurrent disease. Although this patient has a history of membranous nephropathy, the current transplant biopsy and clinical presentation are not consistent with recurrent membranous nephropathy. This patient has only modest proteinuria, and the histologic features are more consistent with ABMR.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If there is concern that acute graft dysfunction is caused by allograft pyelonephritis, a urine culture should be obtained. However, this patient’s clinical presentation is not consistent with pyelonephritis (no fever, pain, or urinary symptoms). The urine WBCs and the neutrophils observed in the peritubular capillaries are most likely caused by ABMR rather than acute infection.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Banff classification of ABMR recognizes the potential utility of validated biopsy tissue gene expression toward the diagnosis of ABMR. Although tissue gene expression may substitute for the presence of DSAs in some cases, particularly in the absence of DSAs, it is strongly recommended that thorough DSA testing be performed in all patients in whom there is suspicion for ABMR. </p>\n</div>",
        "references": [
            "Loupy A, Haas M, Roufosse C, et al: The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.Am J Transplant20(9): 2318–2331, 2020",
            "Aubert O, Loupy A, Hidalgo L, et al: Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients.J Am Soc Nephrol28(6): 1912–1923, 2017"
        ]
    },
    "73": {
        "question": "<div class=\"qtext\"><p>A 21-year-old man with a past medical history of hearing loss detected on audiometry presents to clinic for evaluation of hematuria and proteinuria. He believes his hearing loss has worsened over the last year, especially in situations of moderate background noise. He has headaches almost daily. He notes that his urine has become darker despite drinking 2 L of fluid per day. He denies dysuria, rashes, abdominal pain, or recent illness. There is a family history of kidney disease in his maternal grandfather, who initiated HD at the age of 38. The patient does not take any prescription or over-the-counter medications.</p>\n<p>BP is 152/85 mm Hg, with a heart rate of 90/min. His physical examination is unremarkable.</p>\n<p>Complete blood count is normal. Other laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>35 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.5 mg/dL (1.1 last year)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.0</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Blood</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Moderate </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   RBC</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30–50/hpf</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   WBC</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3–5/hpf</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Albumin-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>600 mg/g</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;30</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Kidney biopsy shows GBM thinning and focal lamellation. </p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform skin biopsy"
            },
            {
                "label": "B.",
                "text": "Prescribe prednisone"
            },
            {
                "label": "C.",
                "text": "Prescribe prednisone and mycophenolate"
            },
            {
                "label": "D.",
                "text": "Perform α-galactosidase activity assay"
            },
            {
                "label": "E.",
                "text": "Prescribe lisinopril"
            }
        ],
        "correct_answer": "Prescribe lisinopril",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step in the management of this patient with Alport syndrome is to prescribe lisinopril.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a classic presentation of Alport syndrome, including hearing loss, progressive CKD, hematuria, proteinuria, and a positive family history. His kidney biopsy findings of a thin GBM with lamellations is confirmatory. This patient most likely has X-linked Alport syndrome (XLAS). XLAS typically shows the skip generation pattern, in which the maternal grandfather is affected but the mother is not, as she is a carrier because of hemizygosity and random inactivation of one X-chromosome in females, leading to varying levels of <em>COL4A5 </em>gene expression and few disease manifestations. Compared with other forms of Alport syndrome, XLAS is the most common, and 90% of patients with this diagnosis will develop ESRD by the age of 40.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Upon diagnosis, in childhood if possible, all patients with Alport syndrome should be started on renin-angiotensin-aldosterone system blockade, as clinical studies have shown a decrease in proteinuria and delayed progression of CKD with these agents. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Skin biopsy may be used as an initial diagnostic test for Alport syndrome, but if equivocal, then kidney biopsy would need to be pursued. This patient has already had a kidney biopsy confirming Alport syndrome, so a skin biopsy is unnecessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Corticosteroids and other immunosuppression such as mycophenolate mofetil and cyclophosphamide are not used to treat Alport syndrome.  </p>\n<p>An α-galactosidase activity assay is used to diagnose Fabry disease, a lysosomal storage disease that may cause systemic or kidney-limited disease. Patients usually present with proteinuria and progressive CKD. Hearing loss would be rare; the nonrenal manifestations of Fabry disease include neuropathic pain, angiokeratomas, and corneal opacities. EM reveals globotriaosylceramide deposits and lamellated membrane structures called myeloid or zebra bodies.</p>\n</div>",
        "references": [
            "Savige J, Gregory M, Gross O, et al: Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.J Am Soc Nephrol24(3): 364–375, 2013",
            "Nozu K, Nakanishi K, Abe Y, et al: A review of clinical characteristics and genetic backgrounds in Alport syndrome.Clin Exp Nephrol23(2): 158–168, 2019",
            "Gross O, Licht C, Anders HJ, et al: Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.Kidney Int81(5): 494–501, 2012",
            "Gross O, Tonshoff B, Weber LT, Pape L, et al: A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome.Kidney Int97(6): 1275–1286, 2020"
        ]
    },
    "74": {
        "question": "<div class=\"qtext\"><p>A 54-year-old woman with CKD stage 3 attributed to type 2 diabetes and hypertension is seen in clinic for a routine follow-up visit. She reports that she fell 3 months ago, fracturing her wrist. Her primary care physician prescribed alendronate 2 months ago for osteoporosis diagnosed by dual-energy x-ray absorptiometry (DEXA) scan.  </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Results</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.7 mg/dL (baseline)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.0 mg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alkaline phosphatase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 IU/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30–120</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Bone-specific alkaline phosphatase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 μg/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.6–18.0, premenopausal women </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>PTH, intact</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70 pg/mL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–65</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue alendronate"
            },
            {
                "label": "B.",
                "text": "Refer for bone biopsy"
            },
            {
                "label": "C.",
                "text": "Prescribe calcitriol"
            },
            {
                "label": "D.",
                "text": "Continue current management"
            },
            {
                "label": "E.",
                "text": "Prescribe calcium carbonate"
            }
        ],
        "correct_answer": "Continue current management",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with osteoporosis and evidence of high bone turnover, current management should be continued. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The use of bisphosphonates to reduce fracture risk in patients with CKD remains controversial. In patients with CKD stage 3, analysis of registration trials and preclinical data suggests that bisphosphonates improve bone strength and reduce fracture risk, as in the general population. Although high-dose bisphosphonate therapy has been associated with glomerular disease and acute tubular injury, studies have not shown a decrease in kidney function with doses used for osteoporosis treatment. Current KDIGO guidelines recommend that patients with CKD G3a–G3b who have PTH in the normal range and who are at high risk of fracture or who have osteoporosis by World Health Organization guidelines be treated with a bisphosphonate. In this patient with osteoporosis by DEXA and a previous fracture, whose PTH is at goal for CKD stage 3, the benefit of preventing future fractures outweighs the potential risks of adynamic bone disease, so alendronate should be continued. One concern with using bisphosphonates in patients with advanced CKD or ESRD is causing or exacerbating adynamic bone disease; in this patient, the relatively high PTH and bone-specific alkaline phosphatase indicate that she does not have low bone turnover.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The 2009 KDIGO guidelines stated “it is reasonable” to perform a bone biopsy prior to starting bisphosphonates in a patient with CKD G3a–G5, but this recommendation was modified in the 2017 guidelines based on growing experience with using bisphosphonates in CKD and the detrimental effect of withholding antiresorptive therapy in patients with high fracture risk. Thus, bone biopsy is not mandatory to initiate or continue bisphosphonate therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcitriol is not indicated because her PTH is at goal for CKD stage 3. Calcium supplementation is not required in this patient with normal serum calcium, especially with concerns for vascular calcification due to increased calcium intake. However, 25-hydroxyvitamin D levels should be checked and supplemented considered if low.</p>\n</div>",
        "references": [
            "Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1): 1–59, 2017",
            "Khairallah P, Nickolas TL: Management of osteoporosis in CKD.Clin J Am Soc Nephrol13(6): 962–969, 2018",
            "Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.J Bone Miner Res20(12): 2105–2115, 2005"
        ]
    },
    "75": {
        "question": "<div class=\"qtext\"><p>A 70-year-old woman with a history of hypertension and metastatic ovarian cancer is evaluated for worsening hypertension. Because of progressive metastatic disease despite paclitaxel and carboplatin, etoposide was initiated 4 months ago and bevacizumab 2 months ago. Her baseline creatinine level 6 months ago was 1.0 mg/dL. Other medications include metoprolol, amlodipine, losartan-hydrochlorothiazide, and fluticasone nasal spray. She reports foamy urine but no visible hematuria.</p>\n<p>On examination, her BP is 160/80 mm Hg, and her heart rate is 64/min. Her examination is unremarkable except for trace lower extremity edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.7 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12‒16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                145,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000‒450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136‒145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7‒1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6‒10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0‒4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0‒7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                265 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80‒225\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24-hour urine protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2400 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;100 mg\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Dipstick urinalysis is notable for clear, yellow urine with trace blood, 2+ protein, and negative nitrites and leukocyte esterase. Kidney US shows no hydronephrosis.</p>\n<p><strong>Which ONE of the following is the most likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Tumor lysis syndrome"
            },
            {
                "label": "B.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "C.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "D.",
                "text": "Acute tubular necrosis"
            },
            {
                "label": "E.",
                "text": "Focal segmental glomerulosclerosis"
            }
        ],
        "correct_answer": "Thrombotic microangiopathy",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Worsening hypertension with AKI and proteinuria in a patient who recently started bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is most concerning for drug-mediated thrombotic microangiopathy (TMA).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TMA is defined as a lesion of arteriolar and capillary vessel wall thickening with intraluminal platelet thrombosis and a partial or complete obstruction of the vessel lumina. Aside from AKI, TMA may present with microangiopathic hemolytic anemia and thrombocytopenia, but these findings may be modest, particularly in the case of renal-limited TMA. Drug-mediated TMA typically occurs over weeks to months in a dose-related manner, and many causative drugs, including immunosuppressive (e.g., calcineurin inhibitors) and chemotherapeutic agents, have been reported. Inhibition of VEGF function in renal endothelial cells and podocytes by bevacizumab, and similar agents, causes progressive development of glomerular TMA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy typically shows widening of the subendothelial space, corrugation of the GBM, and intraluminal platelet thrombi. However, a kidney biopsy is not required to make the diagnosis of drug-induced TMA if clinical features are recognized after exposure to a known cause.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Management of drug-induced TMA is typically supportive but may include drug dose reduction or avoidance. In the case of cancer management, the benefit of discontinuing therapy must be weighed against the potential loss of control of the cancer. With discontinuation of the offending agents, the anemia and thrombocytopenia typically improve, although the proteinuria and kidney injury may persist. There is no defined role for plasmapheresis or eculizumab in drug-induced TMA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although tumor lysis syndrome can cause AKI, it is associated with hyperkalemia, hyperphosphatemia, hyperuricemia, and/or hypocalcemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis has been reported to occur with immune checkpoint inhibitors and even other anti-VEGF drugs like sorafenib, a tyrosine kinase inhibitor. However, this patient’s medications are not typically associated with interstitial nephritis, nor does interstitial nephritis typically cause this degree of proteinuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute tubular necrosis can occur with platinum-based chemotherapeutic agents, although carboplatin is significantly less toxic than cisplatin. In this case, the onset of hypertension and proteinuria with associated thrombocytopenia and hemolytic anemia is most consistent with TMA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Focal segmental glomerulosclerosis has been reported to occur rarely with bevacizumab, but TMA has a higher reported incidence and is the more likely diagnosis in this case. Paclitaxel and etoposide are not typical causes of glomerular disease.</p>\n</div>",
        "references": [
            "George JN, Nester CM: Syndromes of thrombotic microangiopathy.N Engl J Med371(7): 654‒666, 2014",
            "Noris M, Ruggenenti PL, Remuzzi G: Thrombotic microangiopathies, including hemolytic uremic syndrome. In:Comprehensive Clinical Nephrology, 6th Ed., edited by Feehally J, Floege J, Tonelli M, Johnson RJ; New York, Elsevier; 2019, pp 343‒356",
            "Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy.N Engl J Med358 (11): 1129‒1136, 2008",
            "Brocklebank V, Wood KM, Kavanagh D: Thrombotic microangiopathy and the kidney.Clin J Am Soc Nephrol13(2): 300‒317, 2018",
            "Person F, Rinschen MM, Brix SR, et al: Bevacizumab-associated glomerular microangiopathy.Mod Pathol32(5): 684‒700, 2019"
        ]
    }
}